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Abstract 
 
The vast majority of medical devices currently applied in clinics were developed based 
on the classical concepts of biocompatibility and bioinert materials. These implantable 
biomaterials “avoid” natural responses from the host, which may include allergic reactions but 
also lead to tissue healing and repair. However, clinicians and manufacturers have been 
perceiving that this inert behavior has a deleterious effect at long-term since it leads to chronic 
immune responses and encapsulation of the medical device. In this sense, biodegradable 
materials have been developed, preventing foreign body response but presenting limited 
tissue healing and implant integration.  
Inspired by the “lessons from the past”, a new generation of biomaterials have been 
engineered with the aim of providing proper biological clues, to promote the regenerative 
process in the host. In this context, immunomodulatory biomaterials constitute a promising 
strategy for both regenerative medicine and advanced therapies for diseases involving 
immune responses. 
The doctoral dissertation presented herein was based on the paradigm shift from 
“fighting inflammation” to “modulating inflammation”, which is now a hot topic in the 
Biomaterials field. In the following chapters, original work focusing the role of inflammation in 
the response to orthopedic biomaterials will be reported and discussed. The research plan was 
defined to study the drawbacks and biological responses induced by conventional orthopedic 
prostheses and to explore the use of fibrinogen and metals ions as alternative 
immunomodulatory agents. 
We have started by studying the biological response that occurs in the synovial tissues 
of osteoarthritis and aseptic loosening patients. Extensive histological evaluation found a 
particle-induced chronic inflammation driven by macrophages in the tissues retrieved from 
aseptic loosening patients. However, the distinct tissue response observed in osteoarthritis 
and aseptic loosening groups was not accompanied by differences regarding the expression 
of inflammatory mediators, namely the classically pro-inflammatory cytokines such as TNF-a, 
IL-1b and IL-6. In this context, a significant reduction of TGF-b1 mRNA levels with a changed 
expression pattern at protein level was locally detected in aseptic loosening. However, the 
differences observed at synovial tissues were not found in the bloodstream, highlighting the 
confinement of the pathology to the joint region.  
The second part of this doctoral programme was to explore strategies for 
immunomodulation, namely in the context of bone healing. The first strategy consisted in a 
biomimetic approach based on implants of pure fibrinogen to treat femoral bone defects. This 
study demonstrated that fibrinogen, when stabilized in 3D structures (Fg-3D), presents 
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immunomodulatory properties. The in vivo implantation of Fg-3D implants led to early bone 
healing at the defect region, without interfering with the up-regulation of IL-6 and IL-8 induced 
by the bone injury. Moreover, Fg-3D impacted the systemic immune response, inducing 
changes in the proportions of T, B, NK and NKT lymphocytes and myeloid cells in blood, spleen 
and draining lymph nodes. Remarkably, these early changes in immune cell populations 
appear to be later related with complete bone repair at 8 weeks post-injury, and some of the 
altered proportions of B, T and myeloid cells were still detectable at this late timepoint. This 
work highlighted the systemic nature of the immune response to bone injury and biomaterials 
implantation, showing the immunomodulatory effect of fibrinogen implants and their 
consequences for bone healing. 
A second approach based on the potential role of magnesium ions (Mg2+) in the 
macrophage behaviour was also explored. The rational for this study relied on the increasing 
evidence supporting immunoregulatory effects of Mg2+, allied to the importance of 
macrophages in both healing and response to biomaterials. The differentiation and activation 
of primary human macrophages were assessed in presence of supraphysiological 
concentrations of extracellular Mg2+ ions. The tested Mg2+ concentrations exerted a regulatory 
effect on pro-inflammatory M1 macrophages inducing significant decrease of CD86 expression 
and reducing the production of IL-8. The exposure of non-activated and M2 macrophages to 
Mg2+-enriched media did not lead to significant changes in surface molecules and macrophage 
secreted cytokines. The culture of primary human mesenchymal stromal cells (MSC) with 
conditioned media from macrophages revealed that non-activated macrophages and 
macrophages exposed to high extracellular Mg2+ concentrations support MSC osteogenic 
differentiation. Therefore, our findings point out the role of Mg2+ in modulating biological 
responses involving LPS-activated macrophages. 
In summary, the major contributions of this Doctoral thesis are (i) highlighting the central 
role of macrophages and immune mediators in the response against the degradation products 
of orthopedic biomaterials, (ii) in vivo testing of a new fibrinogen-based biomaterial with 
immunomodulatory and pro-regenerative properties, and (iii) providing new insights on the 
therapeutic potential of magnesium ions on M1 pro-inflammatory macrophages.  
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Resumo 
 
A maioria dos dispositivos médicos atualmente utilizados na prática clínica foram 
desenvolvidos tendo por base os conceitos clássicos de materiais biocompatíveis e bioinertes. 
Estes biomateriais implantáveis “evitam” a resposta do hospedeiro, que pode incluir reações 
alérgicas, mas também pode levar à reparação e regeneração dos tecidos. No entanto, 
médicos e fabricantes têm vindo a perceber que este comportamento inerte tem um efeito 
nefasto a longo prazo, uma vez que leva a respostas imunes crónicas e ao encapsulamento 
do dispositivo médico. Neste sentido, têm sido desenvolvidos materiais biodegradáveis, 
prevenindo respostas de corpo estranho, mas apresentando ainda uma performance limitada 
em termos de regeneração de tecidos e integração dos implantes. 
Inspirada pelas “lições do passado”, uma nova geração de biomateriais tem sido 
projetada com o objetivo de fornecer pistas biológicas adequadas para promover o processo 
regenerativo no hospedeiro. Neste contexto, os biomateriais imunomoduladores constituem 
uma estratégia promissora tanto no contexto da Medicina Regenerativa, como em terapias 
avançadas para doenças que envolvam a resposta imune. 
A dissertação de doutoramento aqui apresentada baseia-se na mudança de paradigma 
de “combater” para “modelar” a inflamação, amplamente discutida nos últimos anos, na área 
dos Biomateriais. Nos capítulos seguintes será relatado e discutido trabalho original que foca 
o papel da inflamação na resposta a biomateriais ortopédicos. O plano de investigação foi 
definido tendo em vista o estudo das limitações e das respostas biológicas induzidas pelas 
próteses ortopédicas convencionais e também explorar o uso de fibrinogénio e iões metálicos 
como agentes imunomoduladores. 
Inicialmente estudou-se a resposta biológica que ocorre nos tecidos sinoviais de 
doentes quer com osteoartrite quer com descolamento asséptico. A extensa avaliação 
histológica revelou uma inflamação crónica induzida por partículas, e liderada pelos 
macrófagos, nos tecidos recolhidos nos doentes com descolamento asséptico. Contudo, a 
resposta tecidular distinta observada entre os grupos osteoartrite e descolamento asséptico 
não foi acompanhada por diferenças ao nível da expressão de mediadores inflamatórios, 
nomeadamente das citocinas pró-inflamatórias clássicas TNF- a, IL-1b e IL-6. Neste contexto, 
foi detetada uma redução significativa dos níveis de mRNA de TGF-b1, com um padrão de 
expressão alterado ao nível da proteína, nos doentes com descolamento asséptico. No 
entanto, as diferenças observadas nos tecidos sinoviais não foram encontradas na corrente 
sanguínea, destacando o confinamento da patologia à região articular. 
A segunda parte deste doutoramento procurou explorar estratégias para 
imunomodulação, nomeadamente no contexto da reparação óssea. A primeira estratégia 
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consistiu numa abordagem biomimética baseada em implantes de fibrinogénio puro para 
tratar defeitos ósseos. Este estudo demonstrou que o fibrinogénio, quando estabilizado em 
estruturas 3D (Fg-3D), apresenta propriedades imunomoduladoras. Quando implantados in 
vivo, os implantes Fg-3D levaram a uma regeneração óssea mais rápida na região do defeito, 
sem aumentar a expressão de IL-6 e IL-8 induzida pela lesão óssea. Além disso, o Fg-3D teve 
impacto na resposta imune sistémica, induzindo alterações nas proporções de linfócitos T, B, 
NK e NKT e de células mielóides no sangue, baço e gânglios linfáticos drenantes. 
Notavelmente, estas alterações iniciais nas populações celulares imunes parecem estar 
relacionadas com a completa reparação óssea observada às 8 semanas após a lesão, período 
em que algumas das alterações nas proporções de células B, T e mielóides eram ainda 
detetáveis. Este trabalho destacou a natureza sistémica da resposta imune à lesão óssea e 
aos implantes, mostrando o efeito imunomodulador dos implantes de fibrinogénio e suas 
consequências para a regeneração óssea.  
O potencial dos iões de magnésio (Mg2+) para influenciar o comportamento dos 
macrófagos foi explorado como uma segunda abordagem. O racional para este estudo 
baseou-se na evidência crescente que apoia os efeitos imunorreguladores do Mg2+, aliado à 
importância dos macrófagos, tanto na cicatrização como na resposta a biomateriais. A 
diferenciação e ativação de macrófagos humanos primários, foram avaliadas na presença de 
concentrações extracelulares supra-fisiológicas de iões Mg2+. As concentrações de Mg2+ 
testadas exerceram um efeito regulador sobre os macrófagos pró-inflamatórios M1, induzindo 
uma diminuição significativa da expressão de CD86 e reduzindo a produção de IL-8. A 
exposição de macrófagos não ativados e M2 a meios enriquecidos em Mg2+ não conduziu a 
alterações significativas nas moléculas de superfície e citocinas secretadas por esses 
macrófagos. A cultura de células mesenquimais humanas primárias (MSC) com meios 
condicionados de macrófagos revelou que tanto os macrófagos não ativados como os 
macrófagos expostos a concentrações extracelulares mais elevadas de Mg2+ suportam a 
diferenciação osteogénica das MSC. Desta forma, os nossos resultados suportam o papel dos 
iões Mg2+ na modulação de respostas biológicas envolvendo macrófagos ativados por LPS. 
Em resumo, as principais contribuições desta tese de doutoramento são: (i) destacar o papel 
central dos macrófagos e dos mediadores imunes na resposta contra os produtos de 
degradação dos biomateriais ortopédicos, (ii) o teste in vivo de um novo biomaterial à base 
de fibrinogénio com propriedades imunomoduladoras e pro-regenerativas e (iii) proporcionar 
novos conhecimentos sobre o potencial terapêutico dos iões de magnésio sobre os 
macrófagos pró-inflamatórios M1.  
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TLR Toll-like receptor 
TNF-a Tumor necrosis factor alpha 
TRAP Tartrate resistant acid phosphatase 
TRIF TIR-domain- containing adapter-inducing interferon-b 
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1 Musculoskeletal system 
 
The human musculoskeletal system is composed by specialized supporting tissues that 
include muscle, bone, cartilage, and other connective tissues (Figure 1). Together, those 
tissues provide structural support for the rest of the body, allow motion, protect vital organs 
and constitute a major reservoir of growth factors, cytokines, hormones, minerals and 
progenitor cells [1]. Due to their specialization and distinct functions, connective tissues can 
be categorized in three major subsystems: skeletal, muscular and joints, ligaments and 
synovial bursae. Muscle, bone and cartilage are organized tissues, which structure is 
optimized to lead with distinct mechanical stimuli such as contraction, load and friction [2; 3]. 
 
 
Figure 1 – Anatomical and histological structure of the musculoskeletal system. The lower limb is used as an example of 
the vast network of bones, muscles, tendons, ligaments and joints. The musculoskeletal system is composed by specialized 
tissues as illustrated by the Masson’s Trichrome stained sections of muscle (1), bone (2) and cartilage (3) tissues. Differences 
between the collagen content (blue stain), among other proteins, may be noticed by the variation of blue and red regions (cell 
cytoplasm and muscle fibers). Adapted from [4]. 
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1.1 Skeletal subsystem 
1.1.1 Bone structure and biology 
 
The adult human skeletal system comprises bone and cartilage tissues. Although bone, 
cartilage and muscle share the same progenitor, in embryologic terms, bone and cartilage 
distance from muscle tissue through their autonomous development program and interplay 
along ossification [5]. 
Bone tissue has a composite structure designed to simultaneously withstand high loads 
and present relative flexibility. The mechanical behavior of bone is related with its extracellular 
matrix (ECM), which is structurally organized by bone cells through the selective incorporation 
of organic and inorganic elements [6]. Type I collagen is the major organic component of 
bone’s ECM (up to 95%), combined with other proteins such other collagens, osteocalcin, 
osteopontin, osteonectin, bone sialoprotein and proteoglycans. The inorganic component is 
formed by calcium phosphate, organized in hydroxyapatite crystals, which confer rigidity to 
bones [7]. 
Among the cell populations hosted in bone tissue, osteoblasts and osteoclasts are the 
most important in maintaining bone homeostasis and remodeling. Osteoblasts and osteoclasts 
derive from different cell lineages and present distinct functions with osteoblasts synthetizing 
bone ECM and osteoclasts resorbing bone.  
Osteoblasts derive from mesenchymal stem/stromal cells (MSCs), a multipotent cell 
population originated in the mesoderm, with the potential to differentiate in to osteoblasts, 
chondrocytes, myocites and adipocytes [8]. During osteogenic differentiation, osteoblasts 
undergo metabolic and phenotypic changes regulated by growth factors and cytokines such 
as bone morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), insulin-like growth factor (IGF), transforming growth factors-b (TGF-b), 
interleukins (IL)-1b, IL-5 and tumor necrosis factor-a (TNF-a) [1; 9; 10]. Osteogenic 
differentiation is characterized by a time-dependent up-regulation of both alkaline phosphatase 
(ALP) and the transcription factor RUNX2, accompanied by a decreased activity of SOX9 [11; 
12]. This balance between RUNX2 and SOX9 is critical for cell differentiation as RUNX2 
promotes osteogenesis but it may be damped by SOX9 with induction of chondrogenesis [13]. 
Therefore, ALP, RUNX2 and SOX9 are considered important markers in assessing bone 
ossification. In bone, osteoblasts are organized in connected groups of cells to produce 
collagen, osteocalcin, osteopontin as well as hydroxyapatite. The lifespan of osteoblasts is 
approximately one month, after which suffer apoptosis or differentiate into osteocytes, a type 
of bone cell that is embedded in the ECM, regulates bone remodeling and translate mechanical 
stimuli to chemical signals [14; 15]. 
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The progenitors of osteoclasts are the hematopoietic stem cells (HSC), which are located 
at bone marrow and originate both myeloid and lymphoid lineages [1]. Osteoclasts derive from 
the common myeloid progenitor that is also shared with other cells populations, namely the 
monocytes. In terms of morphology, osteoclasts are large and multinucleated cells, which is 
related to their bone resorption function [16]. This biological process occurs in sealed bone 
resorption bays created by osteoclasts, through re-organizing their actin cytoskeleton, to 
protect the surrounding bone tissue from the aggressive environment that is generated. Then, 
osteoclasts establish an interface with the bone to be resorbed named ruffled border, and 
through this secrete enzymes, cathepsin K and matrix-metalloproteinases (MMPs), reactive 
oxygen species, formed by tartrate-resistant acid phosphatase (TRAP), and HCO3- to 
dissociate hydroxyapatite. The osteoclastic differentiation involves several mediators, 
especially the macrophage colony-stimulating factor (M-CSF), the receptor activator of nuclear 
factor kappa-B ligand (RANKL), and is inhibited by osteoprotegerin (OPG). The presence of 
M-CSF induces the formation of osteoclast precursors through the activation of the cell surface 
receptor c-fms and up-regulation of RANK. Expressing RANK at their surface, osteoclast 
precursors became sensitive to RANKL, a pro-osteoclastogenic factor secreted by osteoblasts 
and other cell populations, and are able to complete their differentiation. The effect of RANKL 
may be inhibited by the presence of OPG, because this protein binds RANKL, blocking 
osteoclast differentiation [17]. Bone formation and resorption are tightly regulated processes, 
so that synchronized bone remodeling occurs and homeostasis is maintained.  
 In mammals, bone tissue has two types of organization: the compact bone and the 
trabecular bone, also denominated as cancellous and spongy bone, respectively [3]. In detail, 
the differences between compact and trabecular bone types go beyond their structure and also 
involve relevant changes in terms of cell composition, vascularization and biologic function, 
which have been previously reviewed in [1; 3]. 
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Figure 2 – Organization and composition of bone. (A) Macroscopic scheme of a long bone, which is characterized by an outer 
layer of compact bone, distal extremities made of spongy bone and the medullary cavity in its core where the bone marrow is 
hosted. (B) Closer view of the compact bone illustrating periosteum, the osteon with osteocytes circumventing nerve fibres and 
blood and lymph vessel and the transition to spongy bone and its porous structure. (C) Major bone cell populations: osteocytes, 
osteoblasts, ostegenic cells and osteoclast. Adapted from [18]. 
 
About 80% of the human skeleton is composed by compact bone, which is the denser 
type of bone tissue [3] As illustrated in Figure 2A, compact bone is mostly found at the external 
layer of bones and has the osteon as its primary functional unit. Osteon comprises osteocytes 
concentrically distributed around harversian canals, containing nerve fibers, blood and 
lymphatic vessels [19]. At the outer layer, compact bone has periosteum at the interface with 
soft tissues, which presents an osteogenic layer and a fibrous layer (Figure 2B). While the 
osteogenic layer homes progenitor cells that may differentiate into osteoblasts and lead to 
bone formation, the fibrous layer is constituted by fibroblasts, providing a proper attachment 
for muscles, bones and aponeurosis (Figure 2C). 
Trabecular bone is highly vascularized and is less dense than compact bone, which 
creates a suitable environment for metabolically active cells. This type of bone can be 
observed in flat bones and at the epiphysis of the long bones. The porous structure of 
trabecular bone is associated with its more flexible mechanical behavior and improved 
deformation recovery in comparison to compact bone [20]. Bone trabeculae are dynamic 
structures that are constantly being remodeled to perform optimal distribution of the 
mechanical loads experienced by bone. Thus, bone ECM and osteocytes are organized along 
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stress lines by osteoblasts and osteoclasts. The inter-trabecular spaces home the red bone 
marrow, rich in hematopoietic progenitors, while the medullary cavities store yellow bone 
marrow, characterized by increased content of adipocytes. Bone marrow constitutes an 
important reservoir of HSCs and MSCs, giving rise to key cell populations such as leukocytes, 
erythrocytes and thrombocytes [1]. 
 
1.1.2 Bone healing 
 
Bone healing may be divided in three stages: inflammation, repair, and remodeling [21], 
as summarized in Figure 3. The first two stages may last 4-8 weeks in rodents and 6-10 weeks 
in humans [22] while bone remodeling is a slower process, taking up months in rats and years 
in humans to be completed [23]. The inflammatory stage initiates after tissue damage, lasts 
about 7 days in healthy rats, and is characterized by acute inflammation with vasodilation, 
exudation of plasma and infiltration of leukocytes. Simultaneously, hematoma is formed at the 
lesion site, through the conversion of fibrinogen into fibrin, by plasmin. This new 
microenvironment is hypoxic, presents low pH, and both pro- and anti-inflammatory mediators 
are locally produced. Fracture hematoma is the primordial matrix in bone healing, housing 
peripheral blood-derived inflammatory cells. Polymorphonucleated cells (PMNs), mostly 
neutrophils migrate to bone injury in the first hours, where they accumulate and secrete CCL2 
and IL-6, factors with a key role in further macrophage recruitment [24]. In bone, resident 
macrophages are located on endosteal and periosteal surfaces, migrating towards the bone 
injury [25]. Together with other innate immune cells, resident macrophages initiate a cascade 
of immune mediators that promote the recruitment of inflammatory immune cells, including 
monocytes that will differentiate into “inflammatory macrophages” at the bone injury [25]. 
Lymphocytes are also recruited to the hematoma/callus, where T and B cells have been 
reported to participate in soft and hard callus formation [26]. Soluble factors are locally 
produced during the inflammatory phase with known roles on the immune response (IL-1, IL-
6, TNF-a, M-CSF-1, IL-10), angiogenesis (angiopoetin-1 and VEGF) and bone repair (RANKL, 
TGF-b1 and BMPs) [22; 27]. 
The orchestration of the complex process of bone healing also involves other cell 
populations such as endothelial cells, fibroblasts and MSCs. The formed hematoma is 
gradually replaced by granulation tissue, which is characterized by its highly cellular content, 
newly formed blood vessels and dense collagen fibers, synthetized by fibroblast. The 
participation of endothelial cells in the local revascularization is a key step in bone healing as 
it restores normoxia and establishes a suitable environment for bone healing [28]. Upon 
granulation tissue invasion, MSCs are attracted to the local where they exert an 
immunomodulatory role and further differentiate into chondrocytes and osteoblasts [21]. 
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Figure 3 – Bone fracture repair. The major biological events regarding bone tissue response and the most important cell 
populations involved in bone healing are illustrated and organized in three main stages: inflammatory, endochondral (repair) and 
remodeling stages. The proportion of tissue area occupied by bone, cartilage and soft tissue along bone healing is presented. 
Adapted from [21] and [22]. 
 
Bone healing can be classified as primary or secondary, depending on the fracture 
stability [29]. Primary cortical bone healing requires almost absolute fracture stabilization (< 
5% interfragmentary strain), so that new bone can be directly repaired in absence of callus 
formation [30]. Under these conditions, intramembranous ossification is initiated with 
osteoclasts resorbing dead bone tissue at fractures edges and creating channels along the 
fracture that support blood vessel ingrowth. With the revascularization of the fractured bone, 
MSCs migrate to the lesion, creating ossification centers, where they proliferate and undergo 
osteogenic differentiation [21]. At this timepoint, osteoblasts form the osteoid, the primary form 
of bone ECM mostly composed by type I collagen and where calcium phosphate crystal will 
be deposited [31]. With the ECM mineralization, bone spicules start to appear and by their 
fusion and reorganization more complex structures such as woven bone, periosteum and 
osteon are created, resembling the original structure of healthy bone [3]. As high fracture 
stability is difficult to achieve, exclusive intramembranous ossification in bone healing is rare. 
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This type of ossification partially occurs in bone healing, contributing for successful fracture 
repair.  
Indirect or secondary bone healing occurs in fractures with low stability (6-20% 
interfragmentary strain) or impaired blood supply and involves the formation of a soft 
cartilaginous callus that is further converted into a bony callus. This process of bone healing 
is classified as endochondral ossification due to the involvement of chondrocytes and is the 
dominant type of bone formation [30]. Callus formation starts at the end of the inflammatory 
phase (3-7 days) at the periosteum. Growing from the periphery to the center of the fracture, 
chondrocytes drives cartilage formation at 7-10 days. At 2 weeks, the fracture gap is now 
bridged by cartilage tissue and chondrocytes become hypertrophic, releasing calcium and 
undergoing apoptosis [22]. With the fracture stabilization, new blood vessels invade the 
calcified cartilage, creating a pathway for monocytes and MSCs to migrate and differentiate in 
to osteoclasts and osteoblasts, respectively. At the end of bone repair stage, new woven bone 
with trabecular structures was formed and fracture stability was highly improved. 
The last stage in bone healing is tissue remodeling, as the newly formed bone is 
structurally and mechanically weaker than mature bone [32]. Thus, during bone remodeling 
woven bone is converted in lamellar bone, which is characterized by collagen fibers aligned in 
sheets and increased structural strength with formation of osteons [3]. The remodeling stage 
is characterized by an overall diminishment of inflammation with decreased levels of TGF-b 
but high concentrations of IL-1, TNF-a and BMP-2 [23]. The callus formed during the early 
stages of bone healing are now reabsorbed, constituting the catabolic phase of the process 
where the tissue volume reduces to the one observed in homeostasis. 
 
1.1.3 Cartilage 
 
Cartilage is an elastic tissue with moderate strength that can be found in some joints, at 
ends of long bones, nose, ears, intervertebral discs, among other anatomical sites. From the 
three kinds of cartilage, the hyaline one is the most common and constitutes the articular 
cartilages while elastic and fibrocartilage are more flexible and observed in ears and in other 
parts of the human body. The ECM of the cartilage tissue is produced and maintained by 
chondrocytes and is mostly composed of collagen, proteoglycans, other noncollagenous 
proteins and water [2]. In articular cartilages, ECM is organized in three different zones with 
different content and organization. The elastic and low-friction behavior of cartilage is 
associated to the collagen network, mostly type II, and proteoglycans, as aggrecan. Without 
blood supply, nutrients reach cartilage by diffusion, namely through the synovial fluid in 
synovial joints. Moreover, healthy cartilage is not innervated, in opposition to other 
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musculoskeletal tissues, presenting very limited and confined innervation of the outer layer of 
articular and meniscus cartilage [33]. 
 
1.2 Joints and associated soft tissues 
 
Bones articulate at complex structures named joints. Among the different kinds of joints 
(fibrous, cartilaginous), synovial joints are the main type found in the body [34]. Knee and hip 
are two examples of synovial joints, which allow freedom of movement in many directions. To 
achieve frictionless and smooth locomotion, bones, cartilage, muscles, ligaments, tendons and 
synovial bursae are perfectly organized in an intricate network that constitutes synovial joints 
(Figure 1). 
Besides movement, muscles, ligaments and tendons are important anatomical 
structures at stabilizing the joint and limiting the extension of the motion to avoid dislocation, 
excessive strain or, ultimately, soft tissues rupture [35]. While ligaments stablish bone-to-bone 
connections (e.g. cruciate ligaments), tendons attach muscles to bone [36] (Figure 4A). 
Synovial bursa delimits the joint cavity, which is externally surrounded by the articular 
capsule and internally contains by the synovial membrane (Figure 4B). Synovial membrane is 
a connective tissue organized in two layers, hosting specialized cells named synoviocytes that 
guarantee nutrients supply and production of synovial fluid to the intra-articular space [34]. 
Those cells are located at the intimal layer, also known as synovial lining, where the synovial 
fluid is produced and secreted to the intra-articular space. Two types of synoviocytes have 
been identified: macrophagic cells (type A) and fibroblast-like cells (type B) [37]. While type A 
synoviocytes are specialized in phagocyting debris and behave as antigen-presenting cells, 
type B synoviocytes are involved in the production of ECM components such as hyaluronic 
acid, collagen and fibronectin. The intimal layer is supported by the outer sublining layer, where 
the blood vessels that supply the synovial membrane are located. The joint cavity is filled with 
synovial fluid, which contributes to friction reduction and shock absorption due to its viscous 
and lubricant properties. The biomechanical properties of synovial fluid are associated to its 
plasma-like composition enriched in hyaluronic acid and lubricin (proteoglycan 4), which is 
altered in pathological conditions [38; 39]. 
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Figure 4 – Anatomy of synovial joints. (A) Lateral view of human knee joint where femur articulates with tibia. Various ligaments 
and tendons are represented and contribute for joint stability and motion. (B) The intra-articular space is filled with synovial fluid 
and is limited by synovium, which is composed by synovial membrane and articular capsule. Adapted from [40]. 
 
1.3 Musculoskeletal disorders 
 
Musculoskeletal disorders (MSD) are a worldwide challenge for patients, healthcare 
systems and societies. The aging of western societies is leading to a shift in medical needs 
with arthritis, bone fractures and low back pain presenting as the most prevalent MSDs and 
leading to work disability and increased utilization of healthcare services [41]. The umbrella 
term MSD encompasses a wide range of diseases, traumatic injuries and syndromes 
characterized by pain and motion reduction. Among other risk factors, age and occupation are 
the major causes of MSD [42; 43]. 
Typically, MSD treatment options involving drugs are limited or ineffective at solving 
mechanical failures such as bone trauma. Although biologic and non-biologic disease-
modifying antirheumatic drugs have been successfully used to reduce pain and control 
exacerbated inflammatory responses, those therapeutics encompass considerable side 
effects and are unable to avoid joint failure [44; 45]. Therefore, the application of biomaterials 
becomes unavoidable in the clinical management of both arthritis and bone defects caused by 
traumatic and non-traumatic events [46]. While metallic nails, plates and screws are applied to 
fix bone fractures, prostheses are implanted to replace failed arthritic joints. These two clinical 
scenarios will be described in the next sections, clarifying the need of using biomaterials for 
bone defects and osteoarthritis management, and addressing current limitations of 
conventional medical devices.  
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1.4 Traumatic and non-traumatic bone defects 
 
Large bone defects are serious complications that are mostly caused by extensive 
trauma or by non-traumatic events such as tumor, infection, or congenital musculoskeletal 
disorders [47]. In the U.S., the 2 million bone fractures that occur annually, cost $17 billion 
dollars [48]. Long-bone fractures are the most common skeletal trauma and present a very 
high success rate of repair. However, non-unions and distal fractures impose a substantial 
clinical challenge in the treatment and management of orthopedic patients [47; 49]. Depending 
on the fractured bone, the rate of non-union, also called delayed union, may be about 5-15% 
[50; 51]. Patients with nonunion fractures present increased risk of additional fractures, require 
more surgical care and physical therapies, which doubles the costs of treating a nonunion 
fracture when compared to patients without nonunion [50]. 
As previously described, bone healing is a complex and finely tuned sequence of 
biological events that can be disturbed by a wide range of factors [52]. Reduction and 
stabilization of the fracture achieved by medical procedures influences the inflammatory phase 
and tissue vascularization. Poor fracture stabilization with high tissue strain and periosteal 
damage may lead to impaired blood supply at the injury site, creating a microenvironment with 
low oxygen tension that is more suitable for cartilage formation than bone repair [53]. 
Moreover, both local and systemic trauma severity may reduce the blood supply to the fracture 
region [54], impairing healing. 
Other factors are not directly related to the bone fracture and highly depend on the 
patient, namely gender [55], age [56], lifestyle habits [57; 58], medication [59], local and 
systemic inflammation and other comorbidities [22; 60]. In detail, an animal study revealed that 
females are more affected by poor fixation than males, presenting newly formed bone with 
lower biomechanical properties [55]. Aging negatively influences vascularization at fracture 
region likely through diminished levels of key angiogenic factors (HIF-1a and VEGF) at the 
early response and unbalanced production of proteases MMP-9 and MMP-13 [56]. Callus 
revascularization may be also impaired by nicotine [58], what seems to explain the delayed 
chondrogenesis and impaired bone healing caused by smoking also reported by other authors 
[57]. Similarly, alcohol consumption was associated with decreased bone regeneration on 
implantable demineralized matrixes [61]. 
Inflammation is part of bone healing and involves various immune cell populations and 
both pro-inflammatory and anti-inflammatory cytokines and chemokines, as previously 
described. Therefore, the use of painkillers such as non-steroidal anti-inflammatory drugs to 
treat bone fracture symptoms has a deleterious effect on bone tissue regeneration [59]. 
Inhibiting the cyclooxygenase (COX) activity, an enzyme involved in the synthesis of 
prostaglandins, NSAIDs block angiogenesis and osteogenic differentiation of MSCs in bone 
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fracture [62]. Moreover, acute and chronic inflammation at systemic level affect bone healing. 
The impact of chronic diseases, such as rheumatoid arthritis and diabetes mellitus on bone 
remodelling, highlights the relationship between systemic immunity and bone architecture [60; 
63]. Those diseases are characterized by augmented levels of pro-inflammatory cytokines 
such as TNF-a [63] and IL-6 [64], accompanied by an increased prevalence of osteoporosis 
[65]. Unbalanced bone turnover is induced by pro-inflammatory environments where RANKL, 
mostly produced by T cells, promote the activation of osteoclasts. [66]. Polytrauma patients 
also present increased concentration of IL-6 in serum and impaired bone healing [67]. 
Infectious agents lead to complications in fracture healing by modulating the immune system 
towards pro-inflammatory responses. The administration of LPS to rats with bone fracture 
induced hypertrophic callus with low bone mineral density and decreased production of BMP-
2 [68]. Additionally, osteomyelitis caused by bacteria as Staphylococcus aureus lead to 
osteolysis with Th17-driven response and production of TNF-a and IL-1b [69]. Those findings 
highlight the crosstalk between local and systemic immune responses in bone healing. 
 
1.5 Arthritis 
 
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common forms of arthritis 
and constitute major causes of pain, disability, and socioeconomic burden across the globe. 
Rheumatoid arthritis (RA) alone affects 1% of the adult population worldwide, is caused by 
chronic autoimmune response affecting joints [70]. OA is more prevalent than RA [71], with 
studies pointing that 10% of men and 13%-18% of women over 60 years of age are affected 
by this disease [70; 72]. The major risk factors for OA are age, gender, obesity, joint 
abnormalities, malalignments and injuries [70]. 
The pathological response underlying OA is perceived to be mostly confined to the joint 
with limited contribution of systemic inflammation. Early diagnosis of OA is extremely 
challenging since radiographic joint changes are often detected after the disease is already 
established. OA is characterized by the progressive cartilage destruction induced by the 
pathological overproduction of matrix proteases [73]. In healthy conditions, the architecture 
and ECM composition of cartilage, enriched in type II collagen, aggrecan and proteoglycans, 
are finely controlled, as illustrated in Figure 5A. In the context of OA, chondrocytes release 
inflammatory mediators (IL-1b, IL-6, TNF-a) and matrix degrading enzymes (MMPs and 
ADAMTSs), which may be mechanosensitive [70]. Additionally, the released ECM molecules 
and their degradation productions activate the innate immune system through toll-like 
receptors (TLRs), which are expressed by immune cells, but also by chondrocytes [74]. In this 
degenerative environment, chondrocytes became hypertrophic and endochondral ossification 
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occurs, replacing cartilage with bone tissue, and impairing proper joint function (Figure 5B). 
There is no consensus about chondrocytes being the primary trigger for OA. It is possible that 
cartilage is just amplifying a biological response that is already going on, namely in synovial 
tissues and/or subchondral bone. As recently proposed, alarmins, endogenous proteins rapidly 
secreted upon tissue damage, seem to have a major role on OA initiation and progression [75]. 
In OA, alarmins are thought to be released by damaged chondrocytes and necrotic osteocytes, 
activating pattern-recognition receptors (PRRs), like TLRs, which lead to exacerbated immune 
responses, both innate and adaptive immunity, and joint destruction [75]. 
 
 
 
 
Figure 5 - Healthy and osteoarthritic synovial joint. In homeostasis, cartilage tissue is organized in three distinct layers with 
low cellular activity. Moreover, subchondral bone presents a minimal turnover while the synovium produces synovial fluid. 
Osteoarthritic synovial joints are characterized by the narrowing of the joint space as consequence of cartilage erosion and a 
disorganized attempt of regeneration. Additionally, subchondral bone presents augmented turnover, with formation of both bone 
pores and osteophytes with concomitant tissue neo vascularization and innervation. In OA, synovium undergoes inflammation 
with macrophage activation and production of pro-inflammatory cytokines, which contribute for the pathology progression. From 
[70].  
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2 Biomaterials in orthopedic applications 
 
In the previous sections, two major orthopedic problems in terms of socioeconomic 
burden were discussed, whose treatment often involves the application of biomaterials. Bone 
fracture stabilization frequently requires the use of metallic fixation devices (e.g. screws, plates 
and nails), bone defects are filled with grafted materials and prostheses are implanted to 
replace non-functional joints at the end-stage of OA [46].  
Although the treatment of fractures of long bones has a very high success rate, other 
types of fractures (e.g. tibial plateau fracture) and bone healing complications (non-union) 
require bone grafting [76]. In fact, about 10% of orthopedic surgeries involve bone grafting 
procedures using autografts, considered the gold standard, allograft or synthetic bone filler 
materials. The application of autografts is often successfully but 20-30% of the treated patients 
report chronic pain and morbidity at the donor site [77]. Allografts induce generally weaker 
healing responses than autografts, presenting complications, such as fracture, non-union and 
infection in more than 30% of bone grafting procedures. The drawbacks of both auto and 
allografts have prompted the development of synthetic matrices to repair and promote bone 
healing. Natural or synthetic biomimetic matrices are part of the orthobiologic solutions that 
also incorporates biological agents such as BMPs, platelet-rich plasma (PRP), and stem cells, 
to boost bone healing [78; 79]. Despite the interest of research and industry in orthobiologics, 
the majority of the orthopaedic medical devices currently used in clinical practice are still based 
on metal alloys. 
 
2.1 Foreign body response to biomaterials: the key role of macrophages 
 
Conventional materials, often resistant to degradation, frequently fail at promoting 
regenerative responses upon implantation, inducing instead the formation of fibrotic capsules 
and poor integration with surrounding tissues. As revised by Anderson et al [80], the foreign 
body response (FBR) occurs in a wide range of clinical scenarios, involving several immune 
cell populations and regulatory pathways. Monocytes and macrophages play a central role in 
FBR. Upon implantation, plasma proteins adsorb and complement system is activated on the 
biomaterial’s surface. This reaction, of foremost importance for the further stages of the 
response, involves the production of chemokines, molecules that induce the recruitment of 
immune cells, namely polymorphonucleated cells (PMNs) and afterwards monocytes. At the 
injury site, monocytes differentiate into macrophages and phagocyte dead cells, bacteria and 
debris, they also modulate the response of other elements of the immune systems through 
soluble factors or direct receptor interactions. Macrophages can phagocyte particles with few 
Chapter I – General Introduction 
 36 
micrometers in diameter but larger fragments lead to frustrated phagocytosis. At this point, 
macrophages fuse to form foreign body giant cells (FBGCs), in the presence of IL-4 and IL-13. 
FBGCs are specialized cells, which attempt to degrade foreign materials with large 
dimensions, by undergoing metabolic and phenotypic changes that enable them to secrete 
enzymes, reactive oxygen species (ROS) and acid. Similar to the process of osteoclasts 
degrading bone, FBGCs adhere to the foreign particle and create an aggressive environment 
to digest the structure that escaped phagocytosis. When addressing implantable biomaterials 
such as metals, polyethylene and ceramics, designed to be corrosion-proof, FBGCs fail at 
degrading them and promote tissue fibrosis by crosstalk with fibroblasts. Thus, high amounts 
of collagen fibers are produced at the periphery of the implants, surrounding and isolating it in 
a fibrous tissue. 
Macrophages are involved in innate immunity, playing a role of surveillance and host 
defense, especially by phagocytizing and scavenging cellular, bacterial and inorganic debris. 
Although macrophages can differentiate from circulatory monocytes, there are tissue resident 
macrophages in all organs. The plasticity that characterizes the wide range of functions 
performed by macrophages as well as the molecular mediators secreted by these immune 
cells, turn them a simultaneous target and ally for therapeutic applications [81]. In fact, 
macrophages can acquire distinct functional phenotypes in response to environmental signals, 
in a process designated as macrophage polarization. Depending on the stimuli, macrophages 
can differentiate in a continuous spectrum of phenotypes [82], which are frequently 
oversimplified in M1, a more pro-inflammatory population induced by classical activation and 
M2, more pro-healing, tissue remodeling and/or regulator phenotype, in response to alternative 
activation [83]. As presented in Figure 6, the various macrophages subsets are characterized 
by the expression pattern of surface markers, secreted cytokines and chemokines, activation 
of transcription factors and the production of enzymes involved in ECM degradation (e.g. 
MMPs) and cell metabolism (e.g. arginase-1) [82]. 
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Figure 6 – Macrophage activation and polarization. Illustration of major inducers, surface receptors soluble factors and key 
functions involved in macrophage polarization. Classically activated M1 macrophages present a more pro-inflammatory profile in 
comparison to the M2 phenotypes. Depending on the stimuli, M2 macrophages may differentiate in to phenotypes more involved 
in tissue repair (M2a), immune regulation (M2b) or tissue remodeling (M2c). From: [84]. 
 
One of the most used and accepted markers of the human monocytic-lineage is CD14, 
a surface antigen that acts as co-receptor of TLR-4 in the recognition of LPS [85; 86]. Due to 
their high levels of expression and specificity to monocytes and macrophages, CD14 have 
been assessed in combination with other markers in the scope of macrophage polarization 
studies. Human M1 macrophages are characterized by the presence of increased levels of 
CD86 [84; 87], HLA-DR [87; 88], CD80 [84] and CCR7 [89] at the cell surface. It is important 
to state that much of the knowledge on macrophage polarization was observed in murine 
models and there are significant differences on the involvement of certain receptors (e.g. 
arginase-1) [90] and enzymes (e.g. iNOS) [91] in humans and rodents. Human M2 
macrophages display on their surface CD163 (scavenger receptor) [82; 84; 87] and CD206 
(manose receptor) [82; 87; 92], both considered well stablished markers. Moreover, alternative 
activated macrophages may be divided in three different phenotypes M2a, M2b and M2c, all 
expressing CD163, which may be considered a general phenotypic [93]. The M2a subset is 
described as an immune population specially involved in tissue repair and adaptive type II 
responses and together with M2c phenotype, with pro-healing and debris scavenging 
functions, express CD206 on the surface [84; 93]. Due to the regulatory role of M2b 
macrophages these cells present both pro- and anti-inflammatory functions, displaying some 
receptors, as CD86 and MHCII, also displayed by M1 macrophages [84; 93]. 
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The profile of cytokines and chemokines secreted by activated macrophages is also 
influenced by their activation status. As expected, M1 macrophages produce mostly pro-
inflammatory immune mediators such as IL-1, IL-6, IL-12, IL-15, IL-23 and TNF-a [84; 93]. 
Conversely, anti-inflammatory cytokines, IL-10, TGF-b1, IL-1Ra, IGF-1 and PDGF, are 
secreted by M2 phenotypes with some differences associated to the specific subset. As 
example, M2b macrophages can release, depending on the context IL-10 but also TNF-a, IL-
1b and IL-6, with the chemokine CCL1 playing a main role on the maintenance of M2b 
phenotype [94].  
Overall, monocytes/macrophages are central players in the immune response induced 
by biomaterials. Displaying a wide range of functions and using varied biochemical mediators, 
macrophages appear as interesting candidates for new therapies addressing improved 
integration of implantable biomaterials.  
 
2.2 Implantable metallic biomaterials 
 
The mechanical properties of metals have prompted their use in biomedical engineering, 
namely as implantable medical devices. Metals are present in almost all orthopedic devices 
but metal-on-metal (MoM) bearings raise the most concern, due to potential risk of adverse 
biological reactions elicited by excessive generation of metallic particles and ions [95-101]. In 
spite of widespread application of metallic components in joint replacement, these foster major 
concerns related to their safety, when tissues and body fluids are exposed to high levels of 
elements present in metal alloys [102-104].  
On the other hand, it is well known that metal elements are vital for cells, where they play 
structural, catalytic and signaling roles. In fact, cells are able to interact with metal ions at non-
toxic concentrations in the tissue microenvironment, but also at systemic level. Cells are 
sensitive to ions and their mechanisms and behavior may, at least in part, be modulated by 
these inorganic species [105-107]. Therefore, while metal ions are promising tools, a deeper 
understanding about the interactions between them and living systems is still needed, to 
identify the frontiers that limit their safe and therapeutic application. 
In the last decade, metal ions have aroused attention, as tissue regeneration enhancers 
in bone tissue engineering strategies. These approaches promise to improve implant 
integration and tissue regeneration through metal ions release. A new generation of 
biomaterials aiming at a controlled degradation, and whose by-products induce healing 
processes are under intense investigation. 
In this next section, both potential adverse effects and healing properties of metal ions 
and particles released by biomaterials applied in Orthopedic surgery, particular in hip 
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prosthesis, will be addressed. While clinicians mainly perceive metal ions as toxic agents, 
scientists start to use their biological effects to improve the interaction of medical devices with 
surrounding tissues and cells. Thus, we aim at bringing together the two perspectives 
addressing the processes behind the origin of metal ions, their systemic dissemination, 
interaction with immune system and involvement in tissue regeneration.  
Chapter I – General Introduction 
 40 
3 Biological response to the degradation products of hip implants 
 
The current section is largely based on the review article “The two faces of metal ions: 
from implants rejection to tissue repair/regeneration”, published in Biomaterials Journal in 
2016. 
Despite advances in material design and surgical technique, a significant fraction of the 
high number of hip prostheses implanted every year still fail. MoM hip prostheses have raised 
concern among authorities and clinicians, due to the high cumulative revision rates registered 
at 5 years (3-6%), particularly when considering the 1.5% revision rate for metal-on-
polyethylene (MoP) prostheses [95]. However, failed hip implants are an interesting model to 
enhance current knowledge about the biological response to the materials released by these 
medical devices [95]. Hip prostheses are mainly composed of metallic alloys, mostly CoCrMo 
(cobalt-chromium-molybdenum) and Ti6Al4V (titanium-aluminum-vanadium), but their bearing 
surface can be composed of different materials. The bearing surface refers to the superficial 
layer of each component at the articulation interface between the artificial femoral head and 
the acetabular cup [108]. The different categories of hip prosthesis are defined based on the 
materials that constitute their bearing surfaces.  The most popular bearing surfaces used for 
total hip arthroplasty (THA) prostheses are MoP, MoM and ceramic-on-ceramic (CoC). 
Technological advances have contributed to minimize degradation of these materials. 
Nonetheless, wear at bearing surface is still responsible for the generation of the majority of 
prosthetic particles found in surrounding tissues [109]. In terms of amount, MoM bearings 
generate ten-fold more particles than MoP [110], and most of metallic wear particles are 
nanometric-sized (smaller than 100 nm) [110-115] while polymeric particles are around 100-
10000 nm [116]. Thus, metallic nanoparticles are known to be more reactive as their surface 
area per volume is higher than polymeric particles. As the majority of hip joint bearings are 
based on CoCrMo alloys, the particles released are mainly chromium oxide (Cr2O3) with an 
oval to round shape [113; 115]. Also, titanium-based particles may be originated in different 
regions of hip implants, such as the femoral stem and/or acetabular cup [117].  
Wear and corrosion are the mechanisms behind the generation of micro- and 
nanoparticles, as well as metallic ions. The failure of metallic prostheses is multifactorial, and 
likely related to adverse biological responses induced by the by-products that are released 
upon implantation. These agents are shed in synovial fluid, facing the synovial membrane as 
their first interface with the human body. Dimensions, quantity and chemical composition of 
the particles are important factors in assessing biological effects of wear debris, and are closely 
related to the biomaterial that suffers wear and corrosion. [111; 118; 119]. Particles possessing 
diameters up to a few micrometers are phagocytosed by macrophages [111; 120], while bigger 
particles can induce a foreign-body response [80]. The activation of macrophages upon 
Chapter I – General Introduction 
 41 
phagocytosis has been pointed out as a trigger, activating the innate immune response, which 
may ultimately lead to implant failure, through a pathological response sometimes referred to 
as “particle disease” [121; 122]. On the other hand, the physicochemical properties of metallic 
ions (eg. size and charge) allow these agents to reach different targets, such as DNA, 
producing toxic effects in a manner that is different from those caused by particles [123-125]. 
The local and systemic toxic effects and the mechanisms involved in the biological response 
against the most relevant metallic degradation products are discussed bellow. 
 
3.1 Periprosthetic tissue response to MoM hip joints 
 
The biological response behind aseptic loosening of hip implants is the cause of long-
term failure for about 65% of hip prostheses [108] and depends on a set of immunological 
phenomena, including cell interactions and cytokine production. Despite MoM, MoP and CoC 
hip prostheses all potentially failing due to aseptic loosening, the molecular and cellular events 
underling those pathological response appears to be distinct. The immune response taking 
place around MoM hip prostheses is not as studied as the macrophage-mediated foreign body 
reaction to the polymeric wear particles released by MoP prostheses [126-128]. Metallosis, 
pseudotumors and aseptic lymphocytic vasculitis associated lesions (ALVAL) have all been 
associated to failed MoM hip implants [129-132]. The inflammatory response associated to the 
soft tissue lesions presented by some patients with MoM implants is not completely understood 
but thought to be related to the metal-rich periprosthetic environment. Thus, ARMD (Adverse 
Reaction to Metal Debris) [132; 133] or ALTR (Adverse Local Tissue Reaction) [134] have 
been used as umbrella terms. In spite of ARMD being often associated to MoM hip prostheses, 
it occurs only in about 1% of MoM patients [132] and similar histological findings may be found 
in periprosthetic tissues of other types of hip implants, namely where modular metal-metal 
interfaces or impinged metallic components are present [135-137]. Metallic wear debris and 
ions may be released due to wear, corrosion or tribocorrosion processes [138]. Metallic 
particles are deposited in periprosthetic tissues giving them a grey color, which is usually 
named metallosis [139]. This microenvironment may lead to adverse local tissue responses 
such as pseudotumors and ALVAL as presented in detail in Figure 7. 
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Figure 7 - Pathological responses to excessive exposure to metal particles and ions released by hip prostheses. 
Pseudotumors and Aseptic Lymphocyte-dominated Vasculitis-Associated Lesions (ALVAL) are the most relevant Adverse 
Reactions to Metal Debris (ARMD). The accumulation of high amounts of metal degradation products in hip joint space induce 
the formation of pseudotumors around the implant which leads to augmented serum metal ions levels. The mechanisms underlying 
pseudotumors formation appear to be related to the inability of macrophages to clean metal debris, despite the extensive 
recruitment of these immune cells induced by the prosthetic by-products. At intracellular level, high levels of metal particles and 
ions lead to toxic effects that ultimately result in a vicious cycle of cell death. Together with tissue necrosis, compression of femoral 
nerve are though to explain the pain suffered by patients with pseudotumors and ALVAL. Although ALVAL is related to metal 
exposure, it seems to depend more on immune system sensitivity to metal debris than on the amount of metallic particles and 
ions. Perivascular lymphocytic aggregates, where cytotoxic T cells (CD3+CD8+) appear to have a detrimental role, recurrent 
bleeding and tissue necrosis are the key events of ALVAL. In the context of delayed hypersensitivity response, several 
mechanisms were described regarding the influence of metal ions, namely Ni2þ, on antigen T cell activation: producing 
immunogenic antigens by inducing conformational changes; causing structural changes in major histocompatibility molecules 
(MHC) on the surface of antigen presenting cells (APC) such as macrophages and dendritic cells; and boosting T cell activation 
via TCR-MHC interaction (superantigen). 
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Pseudotumors are described as solid or cystic masses that may grow at the implant 
periphery. The prevalence of pseudotumors in MoM patients ranges from 20% to 61%, 
depending on the hip prostheses model [140; 141]. Their etiology is not completely understood 
and pseudotumors are diagnosed in patients with a painful hip, or even asymptomatic patients 
[98]. Despite the fact that pseudotumors are neither malignant nor infectious they may provoke 
pain, due to the compression caused by these masses on other tissues (e.g. muscles or 
nerves) [98; 142]. The continuous release of metallic particles may induce macrophage 
infiltration, which will later die (apoptosis) after phagocyting large amounts of toxic particles 
[132]. These particles will remain in tissues leading to new monocyte recruitment, chronic 
inflammatory response, and cytotoxicity, when their levels are high [143]. Thus, a stressful 
environment is created that may induce tissue destruction (necrosis), a significant feature in 
pseudotumors and failed MoM prostheses [143]. Moreover, the prevalence of pseudotumors 
was positively correlated with serum Co and Cr levels [144]. The excessive wear of MoM 
bearings is related with soft tissue lesion [132; 133; 144] but the extent of tissue destruction is 
not correlated with the amount of metallic particles [132]. These findings highlight the individual 
susceptibility of patients to metallic agents, particles and ions, which likely determines the 
magnitude and type of immune response. Sustained cytotoxic response, hypersensitivity to 
metallic degradation products, or both may be the mechanisms underlying pseudotumor 
formation [132; 143; 144]. 
Patients with ALVAL report pain as symptom [98], whose origin is reported as related to 
the swelling of the vascular endothelium, recurrent bleeding and extensive necrosis [145; 146]. 
The extension of tissue destruction seems to be related with the thickness of lymphocytic 
perivascular cuff [132]. The histological features observed in peri-implant tissues with a metal 
hypersensitivity reaction classify this immune response as ALVAL and may affect 1% of the 
patients with MoM bearings [98; 145; 147; 148]. It is important to state that ALVAL and 
pseudotumors are not directly related and may occur independently [144; 149]. ALVAL is 
characterized by dense perivascular lymphocytic aggregates of T cells (CD3+), B cells (CD20+) 
and some macrophages (CD68+) [99; 143; 147; 150]. Among lymphocytes, CD8+ T cells 
(cytotoxic) seem to be the prevalent lymphocyte population [135; 143; 146]. Diffuse 
lymphocytic infiltrations are also detected, and are composed by T cells only [143]. The 
potential role of metal degradation products on ALVAL is controversial. An association 
between the wear rate of MoM bearings and ALVAL has been successfully established [151], 
but doubts remain regarding the clinical correlation between blood and urine Cr and Co ions 
levels and the development of ALVAL [132; 147]. Overall, the majority of pseudotumors seem 
to be related to excessive generation of metallic wear particles and macrophage infiltration, 
while cases of ALVAL are mostly correlated with unexplained pain or suspected 
hypersensitivity involving T cells [98].  
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Cases of metal hypersensitivity to implanted devices have been reported ever since their 
first use [152; 153]. Presently, the immune response to metal implants is still unpredictable 
and results provided by metal sensitivity tests are controversial [154]. The prevalence of 
dermal metal hypersensitivity in healthy population is reported to be about 14% and nickel 
(Ni2+) and cobalt (Co2+) are the most described offenders [154; 155]. Several reports suggest 
that an increasing proportion of patients, namely women, will develop hypersensitivity to metal 
implants, even in the absence of high wear [99; 154; 156; 157]. 
An immunomodulatory role of T cells in periprosthetic tissue response has been 
reported, but many open questions remain regarding the mechanisms behind the interactions 
with metallic nanoparticles and ions [99; 124; 147; 158-160]. The molecular mechanisms that 
influence the intensity of histologic features observed in MoM surrounding tissues are yet to 
be revealed [99; 124; 147]. On the other hand, the role of each T cell subpopulation on the 
biological response against this type of artificial joint and the influence of particulate and ionic 
degradation products on these immune cells are still unknown [158-160]. The increased 
proportions of T cells in relation to B cells in MoM periprosthetic tissues led the scientific 
community to believe that a type IV cell-mediated immune response was behind the lesions 
observed [101]. T cells may represent 10% of cells at bone-implant interface [160; 161], with 
the helper population (CD3+CD4+) being more frequent in periprosthetic tissues than the 
cytotoxic one (CD3+CD8+) [160]. T helper (Th) 1 cells seem to dominate over the Th2 
population, indicating a more cell-mediated immune response, with the participation of 
macrophages [160; 162; 163]. At systemic level, Hart et al have identified in MoM patients a 
positive correlation between increased cobalt ions and reduced circulating CD8+ T cells [164]. 
In line with these findings, decreased number of circulating CD3+, CD4+ and CD8+ cells, 
together with increased serum interferon-gamma (IFN-γ), indicative of a Th1 response, and 
concomitant decrease of interleukin 4 (IL-4) levels, related to a Th2 response, were found in 
patients two years after large-head MoM THA [162]. 
The mechanisms underlying T cell hypersensitive response are thought to be related to 
antigen processing and presentation in the context of adaptive immunity. Conformational 
alterations at protein/antigens level [124; 165; 166], major histocompatibility complex (MHC) 
and superantigen effect [167] have been pointed as potential action mechanisms of metallic 
ions involved in hypersensitivity, namely to Ni2+. In fact, Ni2+ is the most concerning allergen 
and its effects at major steps of antigen T cell activation have been reported [154; 155; 167; 
168]. Although nickel is many times considered a trace chemical element in metals used for 
hip prostheses, nickel content (percentage by weight) can be up to 0.5%, 0.1% and 0.05% in 
CoCrMo (ASTM F75), Ti alloys (ASTM F136) and pure Ti (ASTM F67), respectively. 
The microenvironment resulting from corrosion of prostheses may promote protein 
conformational changes and metal ions released may act as haptens, contributing to the 
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formation of metalloproteins [124; 165]. Haptens are small agents that can complex with “self” 
proteins, inducing an immune response. Since most proteins are negatively charged at 
physiological pH, their potential to interact with the positively charged metal ions is very high 
[169]. This hapten effect reported for metallic ions appears to be ion-specific and preferential 
molecular targets have been described. Previous studies show that serum proteins with 68 
kDa and 180-330 kDa are the most frequently modified by Cr [124]. On the other hand, it has 
been reported that Ti binds preferentially to transferrin [125]. Also, Ti4+ and Co2+ binding sites 
have been identified in albumin (approx. 68 kDa) [170; 171]. While no conformational changes 
were associated to Ti4+, it was verified that Co2+ binding leads to a conformational transition of 
albumin that exposes more binding sites for Co2+ ions [170; 171]. Proteins with molecular 
weight between 180-250 kDa, probably immunoglobulins, are associated with greater 
lymphocyte reactivity [124; 165]. Moreover, the association of metallic ions with plasmatic 
proteins may facilitate their cellular uptake [125].  
The involvement of some metallic ions in antigen-driven T cell activation seems to be 
related to antigen presentation. It is possible that antigen presenting cells’ (APCs) like 
macrophages and dendritic cells can internalize hapten-modified proteins, process them and 
present as antigens, through human leukocyte antigen molecules, such as HLA-DR+ [159; 168; 
172]. HLA-DR is a MHC class II receptor, present on the surface of APCs, together with co-
stimulatory receptors CD80/CD86 and CD40, that can present antigens to T cells, activating 
them through their counterparts CD28, CD3 and CD40L on the surface of T cells [101]. 
Interestingly, a previous study has shown increased expression of CD86 and HLA-DR on 
peripheral blood monocytes together with a decrease of T cell markers CD3 and CD28 in 
patients with MoM bearings for more than 30 years [161]. 
 
3.2 Interaction of metallic particles and ions with immune cells 
 
The findings reported at the vicinity of hip prostheses have prompted both clinical and 
fundamental research, aimed to clarify the interactions between metal particles (and ions) and 
living systems. In the following sub-sections, current evidence at research and clinical levels 
is discussed, focusing on cobalt chromium alloys and titanium alloys. As these families of 
alloys are widely applied in artificial joints, this review will address the most representative and 
studied prosthetic degradation products. Although when these metal alloys corrode, they 
release Co2+, Cr3+,Cr6+ and Mo5+ (CoCrMo) or Ti4+, Al3+ and V5+ (Ti6Al4V) into the human body, 
the literature has been mostly addressing the metallic ions present in higher percentages in 
those alloys. Thus, toxicity and other effects of metallic particles and ions (Co2+, Cr3+, Cr6+ and 
Ti4+) on the immune response and bone homeostasis will be discussed below, from cellular to 
tissue and systemic levels. 
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3.2.1 Cobalt and Chromium alloys 
3.2.1.1 Research evidence – in vitro and other pre-clinical data 
 
CoCr particles and Co2+, Cr3+ and Cr6+ ions are the main degradation products of 
CoCrMo alloys studied this far. Molybdenum (Mo5+) is not so widely studied, likely due to its 
lower amount in CoCrMo alloys, 5-7% of the weight (ASTM F75), and mild toxicity in 
comparison to Co2+ [163]. Cobalt and chromium potential effects on biological systems are in 
part related with their capacity to be internalized by cells and bind vital molecules such as 
DNA. Competing for targets used to interact with other ions such as Ca2+ or Mg2+, Co2+ and 
Cr3+ can change mechanisms that lead to cellular death [173]. The potential cytotoxic effects 
or the role of cobalt and chromium ions in immune system sensitization is described below. 
The cellular uptake of metallic ions is the first step of this interaction. Co2+ and Cr6+ -more than 
Cr3+- can cross the cytoplasmic membrane trough a non-specific anionic transporter or via an 
endossomal route [169; 174-176]. Inside the cell, Cr6+ and Co2+ may exert time and 
concentration-dependent toxicity or even carcinogenic effects, through similar mechanisms 
[139; 174; 175; 177]. The reduction of these species to Cr3+ and Co3+ respectively generates 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) [175], which saturate the 
cell antioxidant mechanisms and damage cytosolic proteins, lipids or even DNA. Additionally, 
Cr3+ can cross the nuclear membrane and bind to DNA [169] while Co3+ accumulates in cell 
nucleus and surrounding structures [173]. 
Co2+ has toxic effects on macrophages at lower concentrations (8,000 μg/L) than Cr3+ 
(350,000 μg/L) [178]. Higher toxic thresholds, 30,000 μg/L (equivalent to 0.5mM) for Co2+ and 
590,000 μg/L for Cr3+ (equivalent to 10mM), were observed for primary human lymphocytes 
[163]. Moreover, Cr6+ is highly toxic, as quite low concentrations (520 μg/L) significantly impair 
viability and proliferation of human lymphocytes [179]. An experiment with mouse 
macrophages showed induction of apoptosis at 24 h of incubation with Co2+ or Cr3+ and cellular 
necrosis at 48 h, but at very high concentrations (6,000-10,000 μg/L for Co2+ or 150,000 – 
500,000 μg/L for Cr3+) [180]. Necrosis has been reported on some ALVAL observations, but 
such high levels of Co2+ and Cr3+ were never observed in periprosthetic tissues. Metal type, 
concentration and time of exposure seem to be the major factors for macrophage mortality 
induced by metal ions [111]. Reduction of the cytotoxicity induced by CoCr particles after 
phagocytosis by monocytes and fibroblasts has been observed [118]. CoCr particles that 
underwent phagocytosis by monocytes have also presented a reduced genotoxicity, with the 
surface of the particle appearing to be a critical factor in this process [118]. 
Nevertheless, sub-lethal levels of Co and Cr ions seem to play a role in inflammation. In 
mouse macrophages, Co2+ and Cr3+ induced a concentration- and time-dependent increase in 
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tumor necrosis factor-α (TNF-α) secretion [178]. CoCrMo microparticles as well as sub-
millimolar Co2+ levels (4,000-5,900 μg/L) induce primary human macrophages to produce 
proinflammatory cytokines, namely IL-1β, IL-6, and TNF-α, together with ROS and vascular 
endothelial growth factor (VEGF) [181; 182]. Macrophages are reported to sense CoCrMo 
particles via Toll-like receptor 4 (TLR4)-MyD88 signaling pathways, promoting nuclear 
translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) by 
reducing its antagonist I-kB, which results in overexpression of IL-1β, IL-6, IL-8 and TNF-α 
[183; 184]. In addition, CoCrMo particles and Co2+ions, at concentration from 0.01 mM (590 
μg/L) to 0.3 mM (17,700 μg/L), lead to an increase in hypoxia-inducible factor (HIF-1α) protein 
expression what in turn augments NF-kB signaling [182]. Co2+ ions were demonstrated to 
directly activate TLR-4 promoting the secretion of IL-8 and (C-X-C motif) ligand 10 (CXCL10), 
chemokines that are involved in the recruitment of other immune cells [185]. This may also 
occur in ARMD, since the mRNA levels of both cytokines were reported to be 18-fold and 10-
fold higher in peri-implant tissues of metallosis cases [186]. Furthermore, Co2+ may act at 
endothelial cells level easing the migration of immune cells to the periprosthetic environment. 
At 1 mM, Co2+ directly activates endothelial cells leading to increased secretion of IL-8 and 
monocyte chemoattractant protein-1 (MCP-1) and also intercellular adhesion molecule 1 
(ICAM-1) overexpression, which may justify the augmented lymphocyte binding and 
transmigration [187]. Thus, chronic inflammatory response may be supported by the 
proinflammatory role of Co and Cr ions. 
Delayed hypersensitivity reaction is likely to occur in presence of CoCrMo particles and 
ions released by implants. The Th lymphocyte population is thought to play a major role in this 
inflammatory response. T cell activation (up-regulated CD69 expression) has been reported 
after incubation of peripheral blood mononuclear cells (PBMCs) from patients with loosening 
artificial hip joint with Cr ions (36.8 μg/L) [188]. Exposure to CoCrMo alloys appears to lead to 
T cell sensitization, as primary lymphocytes isolated from patients with well-functioning hip 
prostheses present increased reactivity, both frequency and magnitude, to Cr3+ when 
compared to lymphocytes from healthy donors [163]. The same study showed that among the 
tested metallic ions, Co2+, Cr3+, Ni2+ and Ti4+, only Cr3+ significantly promoted the production of 
IFN-γ, often secreted by the Th1 subpopulation. Other molecules involved in T cells stimulation 
(CD80, CD86 and ICAM-1) were up-regulated after incubation with Co2+ (4,000 μg/L) [181]. On 
the other hand, a single study has reported reduced CD3-induced cell proliferation after 48h 
incubation with CoCr nanoparticles at concentrations from 2,500 μg/L to 25,000 μg/L. Under 
the same testing conditions, DCs and B cells were not activated and no direct cytotoxicity to T 
or B cells has assigned to CoCr nanoparticles [189]. When exposed to CoCrMo particles, T 
cells showed overexpression of TNF-α, IL-1β, IL-13, GM-CSF and IL-10 [190]. Interestingly, 
up-regulation of the anti-inflammatory cytokine IL-10 is significantly higher in women than in 
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men [190]. Overall, the effects of metal prosthetic debris on immune cells seems to be highly 
influenced by the individual susceptibility [163; 190]. 
Pathological bone resorption is the major biological event underlining aseptic loosening 
and implant failure. The activity of bone-producer cells (osteoblasts) seems to be reduced at 
48h of exposure to low doses of Co2+ (10 μg/L) whereas the production of proinflammatory 
molecules, such as prostaglandin E2 (PGE2), cyclooxygenase-1 (COX-1), COX-2, IL-8 and 
MCP-1, is up-regulated [191].  
As high systemic levels of metal ions have been reported in THA patients [192], their 
cytotoxicity towards vital organs has also been assessed. However, the concentrations of Co 
or Cr generally tested in vitro experiments tend to be higher than the ones found in clinical 
setting. Furthermore, short exposure time to metallic ions, undetermined local concentrations 
(oral administration) and incomplete protein and ions content of culture media may limit the 
relationship of these results with clinical findings.  
 Lung, intestine, liver and kidney cell lines and primary mouse dendritic cells (DCs) 
exposed to Co2+ ions or Co nanoparticles at concentrations higher than 12,000 μg/L for 48 and 
72 h. Lung cells were the most Co2+ sensitive cell line, presenting signs of toxicity at lower 
concentration (< 3,000 μg/L) and after 72 h of incubation. On the other hand, DCs were the 
most resistant to ions, and one of the most resistant to nanoparticles [123]. The viability of 
macrophages and fibroblasts was reduced by more than 95% after 5 days of incubation with 
Co2+ and Cr3+ levels higher than 300 μg/L. At lower concentration of Co2+ and Cr3’ (about 50 
μg/L), fibroblast viability was more affected (-50%) than that of macrophages (-20%) [111]. 
The systemic effects underlying the dissemination of metallic particles and ions have 
been addressed in animal experiments [193-196]. Differential deposition of ions seems to 
depend on time of tissue exposure to ions/particles, element and tissue. Despite Co 
accumulating more than Cr, both ions levels showed an increase in liver, kidney, spleen, lung, 
heart, brain, testes and serum 48 hours after CoCr particles implantation in the air pouch model 
in mice [193]. Long-term exposure (9 months) to CoCrMo implant led to reduced animal growth 
and demonstrated the accumulation of Cr and Mo but not of Co in the liver, which was likely 
excreted in urine [194]. Moreover, differences on Co and Cr distribution and accumulation were 
associated to intramuscular or peritoneal implantation of a CoCrMo wire [194]. It has been 
reported that the accumulation of metal particles and ions leads to oxidative stress, namely in 
the liver, spleen and kidneys. In these tissues the expression of antioxidant enzymes was 
altered, which correlates with the increased ROS production and DNA damage [193; 195]. The 
toxic effects of Co and Cr seem to persist even after their concentration at systemic level 
decreases [194; 195]. In line with in vitro observations, the implantation of CoCr particles 
induce early immune response with increased production of IL-1β and macrophage infiltration 
[196]. 
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3.2.1.2 Clinical Evidence 
 
According to Hallab et al, more case reports of hypersensitivity reactions are associated 
with CoCrMo alloy implants than with Ti alloy components [197]. Levels of metallic ions in 
serum have been used for monitoring artificial MoM joints in terms of wear generation, risk of 
ARMD and implant functional outcome [129; 130; 149; 159; 198-201]. In summary, increased 
concentrations of metallic ions in body fluids are observed following implantation of MoM 
implants, specially Co2+, even when compared to MoP THA [192].  
Serum Co and Cr levels in healthy control subjects were usually bellow 0.29 μg/L and 
0.34 μg/L, respectively. Nonetheless, levels below 2 μg/L are considered normal by several 
authors, for well-functioning MoM implants [136; 144; 149; 165; 199; 202; 203]. The 
concentrations of both ions usually vary from one to few dozens of μg per liter, in all tested 
human fluids (serum, blood, whole blood, urine) [132; 144; 192; 204]. Clinically, the average 
serum Co and Cr levels after MoM prostheses implantation are often reported to be within the 
range of 1-7 μg/L but failing MoM hip implants, some pseudotumors cases [144], and extensive 
corrosion on the modular MoP stem-neck interface [136] often present concentrations in the 
order of hundreds of μg/L [129-131; 144; 149; 159; 198-201; 203]. There is no international 
consensus on toxic threshold limits for metallic ions concentrations found in the blood and 
urine of patients with hip prostheses, namely with large head MoM bearing (≥36 mm). 
Moreover, it remains unclear the true meaning of these levels. US Food and Drug 
Administration (FDA) has not defined Co or Cr threshold values for MoM management, due to 
the lack of scientific evidence linking serum or whole blood metal ions levels to excessive wear 
or failing of MoM hip implants. Nonetheless, in Europe is recommended that MoM patients 
presenting serum concentration of Co from 2 to 7 μg/L should be followed-up by imaging 
techniques to evaluate ARMD [202]. Serum Co or Cr levels above 7 μg/L may be a sign of 
ARMD and should be considered in discriminating well-functioning from failed MoM hip 
prostheses [205]. Revision surgery should be performed if abnormal radiological findings are 
observed, metal ions levels are steadily rising or serum concentration of Co surpasses 20 μg/L 
[202; 206]. The levels of Co ions in serum were demonstrated to reduce to normal levels (10.96 
μg/L vs 1.61 μg/L) after removal of their source [203]. 
Despite the fact that metallic ions reach the circulatory system, the majority of the 
particles remain entrapped in nearby tissues. Joint capsule is the tissue where higher Co, Cr 
and Ti concentrations have been found, ranging in the thousands of μg/L, what constitutes a 
100 to 1000-fold increase after hip replacement [136; 165]. This is an expectable finding since 
synovial fluid and membrane, capsule and bone constitute the closest biological environment 
to the origin of the metallic debris. Thus, local toxicity may occur, inducing a local biological 
response that provokes swelling in the hip region and impairs the functioning of the implant. 
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The mechanisms underlying the accumulation of metallic particles and ions in the tissues and 
their potential role in regeneration remains vastly unknown.  
The adverse effects of metallic particles and ions at systemic level are a major concern, 
namely in the long-term. Numerous small blood and lymphatic vessels are present in synovial 
membranes [207], allowing particles and metallic ions to travel to distant parts of the body. 
Lymphatic vessels transport molecules and ions from the synovial fluid and allow the trafficking 
of immune cells such as macrophages between the synovial membrane and the lymph nodes 
or other secondary lymphoid tissues, such as spleen. The capacity of macrophages, also 
present in synovial fluid, to phagocyte small particles may be responsible for particle deposition 
in lymph nodes, bone marrow, liver, lungs and spleen [208-210]. Lymph nodes and spleen are 
involved in the filtering of lymphatic fluid and blood, respectively. Thus, it is expectable that 
higher levels of metallic particles are found in those tissues in a free form, inside macrophages 
or in organometallic complexes [208; 210; 211]. Para-aortic lymph nodes are the most affected 
by metallic particles deposition and in severe cases tissue necrosis has been reported [208; 
209]. The fate of wear particles in other organs such as liver, spleen or heart is unknown. 
Probably, they remain trapped and continue to be corroded intracellularly, due to the corrosive 
environment of the phago-lysossome, potentially inducing higher local levels of metal ions, 
even after implant removal [165; 212]. However, environmental sources can also be 
responsible for increased levels of Co, Cr and Ti species in the body [208]. 
One of the most worrying aspects of long-term exposure to increased levels of metallic 
particles and metallic ions is cancer risk. Overall, the incidence of prostate cancer and 
melanoma seems to be higher among THA patients [213; 214], while lung cancer incidence is 
decreased compared to general population [213]. The period of ten years following THA 
appears to register an increased risk of cancer, namely kidney, likely related to the run-in wear 
period, where the amount of metallic debris is often very high, challenging renal clearance 
capacity. Augmented risk of chronic renal disease was observed in a 9-year follow-up of MoM 
patients [215]. In the period between 10 and 20 postoperative years, the general cancer 
incidence seems not to be increased in MoM or MoP THA patients [213]. Nonetheless, there 
is not enough evidence associating metallic debris and increased cancer incidence, so there 
is a need for longer follow-up periods (more than 20 years) and further epidemiological studies. 
Significant increases in mortality due to cardiovascular diseases were verified in patients 
with MoP or MoM bearings, 20 years after implantation [216]. A case report of fatal 
cardiomyopathy secondary to severe wear of CoCr alloy femoral head was previously 
described [217]. The patient presented very high Co levels in the blood (6521 μg/L) and in the 
heart (3.85 μg/L), when compared to Co concentration in heart tissue of healthy individuals, 
which ranges from 0.1 to 0.4 μg/L. Cobalt toxicity at mitochondrial level with subsequent 
fibrosis of cardiac tissue is the most plausible cause of death. 
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Since artificial hip joints such as MoM bearings are being applied in younger patients, 
new problems may arise. For example, the possibility of transplacental transfer of metal ions 
during pregnancy was evaluated. Increased levels of Co2+ and Cr3+ have been detected in the 
umbilical cord of pregnant women with MoM bearings, when compared to controls [200]. 
However, these metal ion concentrations have been lower than 1 μg/L, with the placenta 
appearing to play a modulatory role. 
 
3.2.2 Titanium and titanium alloys 
3.2.2.1 Research evidence – in vitro and other pre-clinical data 
 
Titanium particles and ions are considered less toxic than those derived from cobalt 
[218]. However, Ti ions are prone to bind and induce damage to phosphorus-rich molecules 
(e.g. RNA, DNA and phospholipids) [219; 220], leading to aneuploidy events in vitro and in 
vivo [139]. Although other elements present in titanium alloys are highly toxic (vanadium) or 
known allergen (aluminum), few studies addressing them in the context of implant/prostheses 
are available. 
Particulate and ionic Ti debris are reported to influence the immune system. In 
macrophages, Ti ions appear to increase the production of proinflammatory cytokines (IL-1β, 
IL-6 and TNF-α) with concomitant downregulation of TGF-β expression [221]. Ti ions activate 
T cells, leading to increased expression of CD69, CCR4 and RANKL in a concentration-
dependent manner [219; 220]. Moreover, the ability of Ti ions to promote T cell proliferation 
seems to be affected by pre-existing inflammatory conditions, since rheumatoid arthritis 
patients present augmented reactivity against Ti ions [222]. Recent in vitro evidence indicates 
that Ti4+ ions promote adaptive immune responses, the authors show that human dendritic 
cells (DCs) exposed to Ti4+ are able to select T cells specific for Ti4+, that are not reactive 
against Ti3+ ions [172]. Moreover, Ti4+ ions influence cytokine and surface receptors prolife on 
DCs, towards a Th1 mediated-inflammatory response [219]. Ti-induced delayed 
hypersensitivity may occur due to chronic exposure to Ti ions or TiO2 particles, but it seems 
that Ti allergy is confined to a reduced number of patients [222; 223] even considering that 
TiO2 particles are widely used in food, cosmetics and medicines. Moreover, a proteomic 
evaluation of draining lymph nodes of skin challenged with TiO2 nanoparticles found that the 
expression of proteins related to mRNA processing, immune response and antimicrobial 
activity, and lipid metabolism was significantly decreased [224]. Many details related to metal 
sensitivity are still unclear, since the individual contribution of each element that constitutes 
metal alloys is not fully known and the role of the host susceptibility to allergic response is only 
partially understood [154]. 
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Similarly to other types of particles, Ti microparticles may be phagocytosed by 
macrophages. This process is reported to involve scavenger receptors [225], it affects 
enzymes that manage intracellular ROS level [226] and leads to changes on the surface 
chemistry of Ti particles, inactivating them [227]. In a study comparing human primary 
macrophage response to different types of prosthetic debris, Ti6Al4V, CoCr, alumina and PE 
microparticles, Ti was found to elicit higher expression of proinflammatory cytokines [228]. 
While CoCr particles induced increased secretion of TNF-α, IL-6 and IL-8, exposure to Ti6Al4V 
led to higher concentration of those cytokines and also IL-1β, IL-1a, MCP-1, granulocyte 
macrophage colony-stimulating factor (GM-CSF), but also IL-10 [228]. Concentration of Ti 
particles is critical as IL-1β production was found to be concentration-dependent, in both 
human and mouse macrophages [229]. Moreover, the interaction between Ti microparticles 
and macrophages involves the cellular receptors TLR-2,3,4 and 9, and the intracellular 
adaptors MyD88, TIR-domain-containing adapter-inducing interferon-β (TRIF) and NF-kB, 
whose involvement in particle-induced inflammation has been reported [230]. It is known that 
activation of NF-kB increases secretion of proinflammatory cytokines, such as TNF-α, IL1-β 
and IL-6 [230-232]. 
Some in vitro studies have addressed the effect of Ti microparticles on bone remodeling. 
Osteoblasts incubated with very high concentrations of Ti microparticles (30,000 μg/L) for 48 
h led to increased production of osteoclastogenesis factors, such as receptor activator of 
nuclear factor kappa-B ligand (RANKL) and CSF-1 [233]. Additionally, bone marrow 
stromal/stem cells (MSCs) exposed to Ti microparticles presented impaired osteogenic 
differentiation and increased production of IL-8 [234], a chemokine that is involved in the 
recruitment of neutrophils and is overexpressed in periprosthetic tissues of aseptic loosening 
patients [235].  
Although Ti ions may diffuse systemically, most of the studies evaluate the local 
biological response to Ti particles. This fact may be related with Ti alloys susceptibility to 
degradation by wear, generating particles, accompanied by a high resistance to corrosion 
[236]. Distinct patterns of distribution and accumulation were found in vivo for TiO2 
microparticles, TiO2 nanoparticles and Ti4+ ions. Ti microparticles accumulated mostly in the 
lungs, while TiO2 nanoparticles and Ti4+ ions diffused systemically and are found in several 
different organs, namely spleen, kidneys, lungs, liver, heart, blood and brain [237; 238]. TiO2 
nanoparticles are small enough to overcome the blood–brain barrier (BBB) but further studies 
are required to clarify the neurotoxicity reported by some in vitro and in vivo studies [238]. 
Although Ti exhibits thrombogenic properties [239] cases of orthopedic patients reporting 
altered clothing due to exposure to Ti were not found. This feature seems to be more 
concerning for the performance of other medical devices, such as Ti-based heart valves [240].  
Chapter I – General Introduction 
 53 
Animal experiments have recapitulated the Ti particle-induced immune response and 
associated osteolysis. Intraperitoneal injection of Ti microparticles in mouse caused at short-
term acute inflammation with signs of neutrophil recruitment, IL-1β production and activation 
of NALP3 inflammasome [196; 229]. Fibrous tissue formation and bone resorption were also 
observed one week after Ti microparticles having been injected [241; 242]. Osteolysis was 
also found using the murine calvaria bone defect model [230; 243]. In this context, decreased 
bone density and volume with increased RANKL/osteopontegrin (OPG) ratio, number of 
osteoclasts, and also augmented TNF-α and IL-1β were locally found, in presence of Ti 
microparticles [242; 243]. Interestingly, epithelial cells upon recognizing bacteria via TLR4 
receptor in the presence of Ti ions, were reported to increase the RANKL/OPG ratio and (C-C 
motif) ligand 2 (CCL2) production, which highlights the potential modulatory effect of Ti ions 
during host-pathogen interactions and provides an explanation for increased osteolysis in the 
case of bacterial infection [244]. Another study has found increased serum IFN-γ levels in rats 
two weeks after implantation of Ti plates in muscle tissue, which is positively correlated with 
peri-implant macrophages [245]. 
 
3.2.2.2 Clinical Evidence 
 
Uncemented acetabular and femoral stem components are often made of Ti alloys. 
Although these components do not suffer much wear as materials applied on head-cup 
interface, Ti alloys at particular micromovements, like the interface with bone or other metallic 
prosthetic parts, suffer corrosion releasing metallic ions to surrounding tissues [246]. Soft 
tissues surrounding failed Ti6Al4V femoral stem presented high concentrations of Ti and Al 
ions, when compared to the levels of Co and Cr ions found in patients with both cemented and 
uncemented CoCrMo alloy femoral stems [246]. Locally, the accumulation of Ti debris may 
also occur in the synovial capsule (39400 μg/g) as well as in synovial fluid (556 μg/L) together 
with Al (654 μg/L) and V (62 μg/L) [165]. Ti is more soluble than V but less than Al, so its 
concentrations in serum and synovial fluid are intermediate [247; 248]. Serum Ti ions 
concentrations are from the same order of magnitude as those of Co and Cr ions and may 
achieve less than 4 μg/L for well-functioning hip prostheses and 8 μg/L for failed implants [130; 
208]. Moreover, the concentration of Ti in urine seems to significantly increase after MoM and 
MoP hip replacement [249]. Nevertheless, in the clinical setting, hip implants management is 
not based on Ti levels.  
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4 New therapies for bone repair and regeneration 
 
In response to the adverse biological and impaired healing responses, new bio-inspired 
approaches have been developed in Orthopedics, specially exploring the immunomodulatory 
and pro-regenerative properties of materials and drugs. While immunomodulatory therapies 
for orthopedic applications are still in research phase [250-252], the application of bioactive 
molecules and cells to foster bone, cartilage and soft tissue regeneration is in the clinical arena 
[49; 253; 254]. In the next sections, the new orthobiologic therapies under investigation and 
development will be discussed, focusing on 1) metal ions, 2) protein therapeutics, 3) 
biomimetic biomaterials and 4) immunomodulatory strategies. 
 
4.1 Metal ions 
 
The prevalent idea that ions released from metal-based implants induce negative effects 
on biological systems is changing. Depending on the element, duration of exposure and tissue 
microenvironment, ions can modulate tissue response promoting regeneration or, conversely, 
leading to cell toxicity, oxidative stress and death. New strategies using metal ions are being 
developed focusing on different medical fields. The toxicity of some metal ions at low 
concentrations has been explored for application in Oncology. A bioglass incorporating 
vanadium was engineered to release this metal ion in a controlled fashion, to induce apoptosis 
of cancer cells [255]. Additionally, metal corrosion processes may be tuned to control tumor 
growth or infection, using systems such as galvanically coupled Mg-Ti particles [256]. Metal 
ions can be applied to improve the bioselectivity of surfaces used in medical devices, 
promoting tissue repair in bacterial-challenged environments [257; 258]. The interaction 
between metal ions and proteins may generate metalloproteins such as organic vanadium 
compounds. In this form, the toxicity of inorganic vanadium is diminished, allowing the 
vanadium insulin-mimetic effect to improve bone fracture healing, by accelerating 
angiogenesis and chondrogenesis [259]. Besides vanadium, aluminum (Al) is another metal 
element present in Ti6Al4V alloy that has been applied in vaccine development. Al is currently 
applied as a vaccine adjuvant, due to its capacity to induce a humoral response involving Th2 
lymphocytes, boosting the production of antibodies (mainly IgG1) [260]. Alternatively, and as 
described above, the metal hypersensitivity response to CoCrMo alloys is closer to a Th1 
profile, which has prompted the application of cobalt nanoparticles as alternative adjuvants, 
when IgG2c antibodies (Th1) are also required [261]. 
Amongst the wide potential applications of metallic ions, tissue engineering is certainly 
a promising field, where metals ions may be generated by the biomaterial used or added as a 
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supplement. There is an increasing number of studies reporting successful therapies based 
on metallic ions, highlighting the role of these ionic agents as new tools for tissue engineering 
[262]. Depending on the application, the template/biomaterial may be designed to be durable 
or biodegradable. In the context of joints, application of complete biodegradable biomaterials 
is not yet feasible as the current technologies are not able to promote regeneration of extensive 
defects of bone and cartilage tissues. However, it is tempting to speculate that the pro-
regenerative effects of some metal ions may be used at the interface of metal implants and 
surrounding tissues [263]. The trend in tissue engineering seems to be towards biodegradable 
materials that may incorporate growth factors, drugs or cells. On the other hand, the fabrication 
of biodegradable biomaterials is still a hot topic since there is no effective solution to avoid the 
foreign body response against implants often registered at long-term. The development of 
“smart” biomaterials that are able to degrade at controlled rates for synchronized tissue 
regeneration is at an early stage. Similarly, in Cardiology, the durable metallic stents are being 
substituted by biodegradable drug-eluting stents, aiming to reduce the risk of stent thrombosis 
and to restore vascular physiology [264]. 
The application of metal ions in the development of orthopedic biomaterials is related to 
their positive effect in angiogenesis and osteogenesis. A new generation of biomaterials aiming 
at controlled release of metal ions to induce bone healing has been developed [106; 107; 265; 
266], as summarized in Figure 8. Embedding ions (e.g. magnesium, strontium, cobalt, calcium, 
among others) into ceramic or metallic matrices has been a concept underlying new 
regenerative strategies. In the next section, the application of magnesium and cobalt-based 
strategies for cartilage and bone repair will be discussed as both ions are released by 
orthopedic implants already available in clinical practice. Moreover, the evidence for 
magnesium and cobalt clearly corroborates the importance of the balance between the elicited 
immune response and the effect of a biomaterial on tissue regeneration/repair. While 
magnesium is safe, may have a regulatory effect on immune cells and promote bone tissue 
healing, cobalt is still perceived as a toxic agent and its angiogenic potential trough hypoxia-
mimetic effect is thus far limited by the immune system. 
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Figure 8 - Application of biodegradable materials for controlled release of metal ions in regenerative medicine. In bone 
tissue context, ions are able to promote osteogenesis coupled with a pro-regenerative immune response. The ion-enriched 
environment may induce osteogenic differentiation of mesenchymal stem/stromal cells (MSCs) as well as improve angiogenesis. 
Moreover, metal ions may modulate the response of immune cells to proinflammatory stimuli such as lipopolysaccharide (LPS), 
modifying the expression of cytokines such as TNF-a, IL-1b, IL-6 and PEG2, which ultimately affect the regenerative capacity of 
the tissues. From [70]. 
 
4.1.1 Magnesium 
 
Magnesium and magnesium alloys have been tested for biomedical applications, namely 
in Cardiology, as biodegradable cardiovascular stents [267], or in Orthopedics as screws, 
fixation devices and bone filler materials [268; 269]. Biodegradable magnesium-based metal 
implants are groundbreaking, providing a temporary solution that can fill the gap between the 
corrosion-resistant metallic devices with long-term problems (e.g. infections or hypersensitivity 
response) and the polymeric biodegradable materials with poor biomechanical performance. 
The biodegradability of magnesium and magnesium alloys resides on their corrosion in 
physiological environment, releasing mostly Mg2+ and H2. However, controlling the degradation 
rate of magnesium alloys has been challenging, with implants degrading faster than tissue is 
able to repair, or releasing high amounts of H2 that remains entrapped in periprosthetic tissues 
destabilizing bone-implant interface [269]. Thus, several magnesium alloys have been 
developed, to overcome the described drawbacks, these can be grouped in three families 
[270]: 1-pure magnesium with traces of other elements, 2-Al-containing alloys (e.g. AZ91, 
AZ31 or LAE442) and 3-Al-free alloys (e.g. WE43, WZ21 and Mg-Ca alloy) [268; 269; 271-
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273]. Combining magnesium with other elements such as aluminum (A), zinc (Z), manganese 
(M), yttrium (W), calcium (Ca), strontium (Sr) and rare earth elements (E), leads to improved 
mechanical properties and corrosion behavior. Nonetheless, envisaging orthopedic 
applications further optimization is still required [274]. Moreover, research has been improving 
the biological response to pure Mg and Mg alloys creating hybrid biomaterials combining this 
metal with polymers [275], ceramics [107], ECM proteins and cells [273]. 
Once implanted in animal models, pure Mg and Mg alloys promoted higher bone 
formation and complete fracture healing, overcoming the limited mechanical properties of 
polymeric biodegradable models (e.g. polylactic acid) [268; 269; 273; 276-281]. Moreover, Mg-
based screws supported improved reconstruction of rabbit anterior cruciate ligament, with 
fibrocartilaginous tissue regeneration, when compared to Ti screws [281]. These findings 
prompted a controlled clinical pilot study where MAGNEZIX® screws, a Mg alloy similar to 
WE43, were successfully implanted in 26 patients that underwent orthopedic surgery [271]. 
Mg alloys biodegradability and mechanical properties similar to bone are believed to be the 
major factors underlying their success [282]. However, the ionic magnesium (Mg2+), released 
upon corrosion of magnesium-based implants, may have a critical role in the induced biological 
response. Indeed, Mg2+ is crucial for health and life and is involved in stabilizing key biological 
molecules (e.g. ATP, DNA), acting as a co-factor of enzymes, in cell signaling, and cell 
migration, among other processes that guarantee the proper function of tissues such as 
muscles, heart or nervous system [283-285]. Although not in Orthopedics, Mg2+ is already 
applied in clinics through administration of magnesium sulfate (MgSO4) for neuroprotection 
[286], muscle relaxing and treatment of pre-eclampsia [287]. 
Therapeutic concentrations of Mg2+ have been tested in bone and cartilage tissue 
engineering [288; 289]. Exposing human BMSCs to millimolar levels of Mg2+, from Mg-
containing salts, pure Mg or Mg alloys extracts, increased cell proliferation and osteogenic-
guided differentiation [106; 281; 289; 290]. After 3 days in Mg2+-enriched environment, 
molecules involved in osteogenesis such as TGFβ-1, BMP-2, SMAD4, VEGF and collagen I 
were found increased, while condrogenesis (SOX9) and pluripotency (SOX2) markers were 
downregulated [106]. Interestingly, after 14 days, another study has also reported the 
overexpression of VEGF, BMP-2 and COL2A1 but accompanied by an up-regulation of SOX9, 
which was likely related to the regeneration of fibrocartilaginous tissue observed in vivo [281]. 
In this context, the most described cellular pathways affected by Mg2+ are TGF-β1/SMAD4, 
HIF-2a and PGC-1a but the effect of Mg2+ on osteogenesis depends on the differentiation 
status of human MSCs [106; 289]. In fact, the cellular demand for Mg2+ increases during 
osteogenesis, as reported for rat MSCs overexpressing Mg2+ selective transporter (MagT1), 
whose knockdown led to decreased osteogenic differentiation [291]. Additionally, the 
deposition of bone matrix elements, calcium and collagen type X, were augmented in human 
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MSCs exposed to Mg2+ concentrations of 5 and 10 mM [289]. Despite concentrations of Mg2+ 
up to 15 mM improving osteoclast function [292], animal studies testing Mg alloys for bone 
repair indicate that Mg balances bone remodeling towards repair instead of osteolysis. 
Moreover, Mg2+ accelerate the regeneration of cartilage [288]. The underlying mechanism is 
thought to be linked to integrins, ion-sensitive proteins that mediate the cellular adhesion to 
extracellular matrix [288; 293]. However, Mg2+ concentrations above 20 mM negatively affect 
cartilage mechanical properties by reducing the production of collagen and 
glycosaminoglycans [294].  
In addition to the pro-regenerative stimuli on MSCs, Mg-based strategies can modulate 
the immune response to support tissue healing (Figure 8). Thus, it is vital to understand the 
role of Mg2+ on cells, namely immune cells, where most of the knowledge stems from studies 
involving Mg-deficient models [295-297]. In hypomagnesemia conditions, cells suffer oxidative 
stress and the ability of the immune system to respond to challenges (e.g. infection) is reduced, 
leading to ineffective or uncontrolled responses [105; 295; 297]. On the other hand, Mg2+ 
supplementation was demonstrated to have an immunomodulatory role [105; 298; 299]. The 
production of proinflammatory cytokines such as TNF-α, IL-1β, IL-6 and PEG2 after immune 
cells stimulation with lipopolysaccharide (LPS) was demonstrated to be reduced in the 
presence of increased concentrations of Mg2+ [298-300]. In an osteoarthritis rat model, 
injections of MgSO4 reduced cartilage degeneration, nociception and synovial inflammation, 
while increasing chondrocyte survival [301]. The action of Mg2+ is believed to be NF-kB-
dependent, a central regulator underlying proinflammatory cytokine production [299].  
 
4.1.2 Cobalt 
 
Most of the studies so far address Co as a toxic agent. Environmental sources (e.g. 
mining activity) or failed Co-containing biomaterials provide cases of massive human exposure 
to this element, which may lead to allergic reactions, tissue destruction and ultimately death 
[302; 303]. Nevertheless, sub-toxic concentrations of Co may promote angiogenesis, which 
may contribute for tissue regeneration. 
Novel strategies for bone tissue engineering have been investigated, taking advantage 
of the hypoxic-mimicking conditions generated by Co [304-306]. Biologically, Co signals cells 
for low O2 pressure by stabilizing HIF-1α, which induces the secretion of factors that support 
cell survival in hypoxia environment and promote the formation of new blood vessels. 
A possible strategy consists in pre-conditioning cells, namely stem cells using high doses 
of Co [307; 308]. Enhanced vascularized bone formation was achieved through implantation 
of constructs with human BMSCs pre-treated with media containing 5900 μg/L of Co 
(equivalent to 0.1 mM Co) in rat bone defects [307]. Alternatively, Co-containing ceramics and 
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bioglasses have been developed aiming to mimic hypoxia through Co action [309-312]. Cobalt 
was shown to promote angiogenesis by increasing the production of VEGF and enhancing the 
osteogenic differentiation of human MSCs [309; 311-313], which is in line with the, tube-like 
structures formed in vitro by endothelial cells (HUVECs) when treated with Co [309; 311]. A 
recent work presented a polymeric core-shell scaffold with sustain release of Co2+ and BMP-2 
that successfully promoted early angiogenesis and improved bone formation in rat calvaria 
defect model [306]. 
Notwithstanding, cobalt may be a double-edge sword. The history of Co as pro-
regenerative agent may be spoiled by the immune system response. Immune cells are 
sensitive to Co exposure, macrophage activation and ROS production was found to take place 
at Co concentration used for cell pre-conditioning (0.1 mM) [185]. Exposing human MSCs to 
conditioned media from macrophages treated with extracts from Co-containing ceramic led to 
decreased osteogenesis while osteogenic differentiation was observed when these cells were 
directly treated with the extracts [313]. Of note, the most part of the promising results using 
cobalt-inspired strategies have been obtained in vitro or using the immunocompromised 
animal model SCID mice [307], which could imply an immune system-related impairment of 
the regenerative potential of Co. However, a very recent study reports pro-regenerative results 
obtained using imunocompetent animals and implanting core-shell scaffolds that release small 
amounts of Co2+ (maximum of 14 μM at 6 days) [306]. 
In summary, the success of Co2+ for regenerative purposes seems to be highly 
dependent on the doses used. The current solutions using Co may lead to high concentrations 
of Co at the periphery of implants, such as levels of 20,000 μg/L that were reported in vitro at 
7 days, decreasing then to 1,000 μg/L [311]. The frontiers for therapeutic, immunological and 
toxic Co concentrations are still unclear. The role of Co in the immune response associated to 
bone repair/regeneration, the identification of pro-healing Co levels and the development of 
biomaterials that ensure desirable Co levels and timing should be further investigated.   
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4.2 Protein therapeutics 
 
In Orthopedics, the use of BMPs as a protein therapeutic to induce the formation of bone 
and cartilage has been a topic of intense discussion [314; 315]. Due to the osteoinductive 
effects of BMPs, intensive research has been carried out to enlarge the knowledge on this 
family of morphogenic proteins, with commercial products based on BMP-2 and BMP-7 
reaching the market for spine-fusion surgery and bone non-union [78]. Although BMPs have 
been originally discovered in bone, further studies have shown the contribute of BMP signaling 
on the architecture of different tissues [314]. Moreover, the balance between BMP-like signals 
and other growth factors, specially TGF-b, have been demonstrated to affect tissue 
homeostasis [314]. The safety and efficacy of BMP-based strategies have been under 
surveillance due to the risk of adverse effects (e.g. ectopic bone formation and cancer) and 
cost-effectiveness [315]. Data currently available supports improved efficacy of BMP use in 
the treatment of severe and acute fractures (tibial) but not in non-union cases [78]. BMP-based 
strategies are promising but refined delivery strategies are required to avoid uncontrolled 
protein diffusion and unbalanced tissues response. 
Simultaneously, PRP, blood plasma enriched in platelets has been tested in vivo [316] 
and in clinical trials [317] to promote bone, cartilage and soft tissue repair. The pro-healing 
properties of PRP seem to be related to its supra-physiological levels of autologous cytokines 
and growth factors such as PDGF, TGF, IL-1, VEGF, IGF, osteocalcin, osteonectin, fibrinogen 
(Fg), among others [318]. However, the use of PRP is still limited to experimental works. The 
main drawback pointed by the experts is related with the impact of variable PRP preparation 
methods have on the composition of the cocktail [317; 319]. 
 
 
4.3 Biomimetic material-based approaches 
 
Biomimetic approaches also constitute promising solutions to the drawbacks presented 
by the conventional inert materials. Cells live in an organic and dynamic environment, relying 
on biological clues provided, not only by soluble factors, but also from the ECM. In fact, ECM 
offers both structural and biochemical support to cells. Therefore, ECM components may be 
used in regenerative medicine and tissue engineering. 
Collagen, mostly type I, is one of the most explored ECM components in biomaterials 
field due to the fact of being biodegradable, biocompatible and suitable for different types of 
applications [320]. Although type I collagen is the major organic component of bone ECM, 
other proteins and new preparation methods have been studied with the aim to recapitulate 
several tissues properties. In a recent study, the authors have synthetized elastic-like collagen 
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scaffolds using a new crosslinking method, as alternative to the addition of elastin, to support 
the development of dynamic tissues such as blood vessels and lung tissue [321]. Scaffolds 
based on collagen and glycosaminoglycan or calcium phosphate have also been widely 
explored for applications in cartilage and bone [322]. Alternatively, small bioactive fragments 
of the proteins can be used to improve the biological response of synthetic biomaterials [77]. 
Another strategy that has been considered in the field of protein-based materials is the use of 
decellularized matrices [323; 324]. These 3D structures are prepared by removing the cellular 
component from tissues but maintaining the biochemical composition of ECM, establishing an 
interesting pro-healing microenvironment with interesting results upon re-cellularization and in 
vivo implantation [323; 324]. 
Fibrinogen-based materials have been addressed by numerous studies and clinical 
investigations, especially as fibrin sealants [325]. The rational underlying this type of material 
is inspired in the blood clot formation, where a fibrin mesh is formed by fibrinogen cleaved by 
thrombin to stop bleeding and form a provisional ECM. Thus, most applications of fibrin 
sealants are related to their hemostatic properties [326]. However, fibrin hydrogels and 
constructs have been explored in research for tissue engineering and drug delivery purposes 
[252; 254; 327; 328]. Due to their viscoelastic properties and their biological composition that 
resembles the primordial and temporary matrix formed upon blood cloth, fibrin hydrogels have 
been tested as carrier for cell therapies [252; 327]. A study showed that when implanted in 
plate-stabilized rat femoral defects, fibrin hydrogels with MSCs lead to the overexpression of 
VEGF at day 3 as well as the recruitment of higher ratio of M1 macrophages (CD68+CCR7+) 
over M2 macrophages (CD68+CD163+) at the periphery of the implant, when compared with 
the fibrin hydrogels alone [252]. The application of fibrin materials in Orthopedics and Dental 
Medicine has been tested combining fibrin with constructs with mechanical properties similar 
to bone such as demineralized bone [329], calcium phosphate granules [330] and metallic 
implants [331]. Additional strategies to tune the biological response induced by fibrin-based 
materials have also been explored and involved the adsorption of other proteins [327] and the 
use of fibrin materials as delivery systems of soluble factors such as BMPs [254; 331]. 
Previous work from our group has shown that modifying chitosan materials by fibrinogen 
adsorption led to their interaction with monocytes through TLR4, leading to the production of 
BMP-2 [332], enhanced macrophage secretion of pro-osteogenic and angiogenic factors [333], 
NK cell capacity of recruiting MSC [334]. Also, in vivo fibrinogen improved the bone 
regenerative response to chitosan biomaterials, which was related to changes in the systemic 
immune response [251]. Although many promising results have been achieved applying fibrin-
based materials in vitro and in small animal models, further studies involving larger animal 
models and humans are still required previously to their translation to clinics. 
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4.4 Immunomodulatory strategies 
 
Recent works have been reflecting a paradigm shift, from “fighting” to “modulating” the 
immune response to biomaterials [251; 335; 336]. The key role of the immune system on the 
establishment and progression of musculoskeletal pathologies such as OA, aseptic loosening 
and bone defects have prompted the study of immunomodulatory biomaterials [336]. 
As previously discussed, macrophages are an important immune cell population in 
clinical scenarios such as aseptic loosening. Upon implantation, conventional biomaterials and 
their degradation products lead to pro-inflammatory microenvironments characterized by 
macrophage-driven chronic inflammation. In this context, pro-regenerative pathways are 
dampened while scar formation occurs as part of FBR. Therefore, macrophage polarization 
has been a hot topic in the biomaterials field [337]. 
The use of resolvins, lipid mediators that induce resolution of inflammation, for 
immunomodulation purposes has been successfully tested in our group [338]. The 
incorporation of resolvin D1 in chitosan scaffolds led to decreased recruitment of immune cells 
to the implant while promoted increased local ratio of M2/M1 macrophages in comparison to 
the control [338]. Moreover, lower levels of pro-inflammatory cytokines such as IL-1a, IL-1b, 
MIP-1a, MIP-1b, MIP-2, IL-6 and IL-16 were found 4 days post-implantation in the local 
exudates of animals with resolving D1-chitosan scaffolds [338]. Other strategy to polarize non 
activated (M0), and even classically activated (M1) macrophage towards pro-regenerative M2 
phenotypes is through IL-4 stimuli, which anti-inflammatory effects are well known [339]. A 
recent report has shown improved implant integration by applying a layer-by-layer coating, 
designed for gradually elute IL-4, on Gynemesh®, a non-absorbable polypropylene mesh used 
for vaginal wall prolapse surgical treatment [340]. This diminished formation of fibrotic tissue 
around the medical device observed using mouse subcutaneous implantation model was also 
correlated with a local increase of the proportion of M2 with concomitant decrease of M1 
macrophages [340]. 
As an alternative approach, therapies based on cells such as MSCs, reported to have 
pro-regenerative and immunomodulatory effects, are explored to improve the host response 
to biomaterials [83; 250]. Although undifferentiated MSCs reduce the production of pro-
inflammatory cytokines TNF-a and IL-6, attenuating in vivo fibrosis associated to FBR, the 
modulatory role of MSCs is lost as the cells undergo osteogenic differentiation [250]. However, 
the role of MSCs on the immune response and tissue healing is not completely understood. In 
a study focused on the tissue engineering approach, the seeding and culture of MSCs in two 
types of constructs during 28 days previous to cranial implantation in rats, led to decreased 
bone repair when compared to the controls without cells. Moreover, increased M1 
macrophages were found at the periphery of the scaffolds seeded with MSCs [322]. Cell 
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therapies based on MSCs are promising, but the mixed results from clinical trials assessing 
their immunomodulatory effect highlight the need to understand the mechanisms involved in 
the crosstalk between MSC and immune cell populations. Additionally, the translation of MSC 
therapies to clinical practice is still facing challenges regarding the cell quality, dose and origin, 
both in terms of donor and tissue differences [341].   
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5 Aims of the Thesis 
 
Orthopedic biomaterials have been designed to simultaneously restore skeletal integrity 
and motion to patients and to be “stealth” to the host immune response. Inflammation is natural 
to occur upon injury or biomaterials implantation, being a crucial part of the tissue healing 
process. Upon implantation, orthopedic devices degrade, releasing prosthetic debris that elicit 
adverse immune responses, lead to tissue destruction and, ultimately, to implant failure. These 
clinical findings stress the need of a new generation of biomaterials that are able to actively 
interact with the host, namely with the immune system.  
The main objective of this PhD thesis is to understand and challenge the role of 
inflammation in the response to biomaterials, providing new tools to modulate the immune 
response towards regenerative microenvironments.  
Thereby, the following specific objectives were defined: 
 
1) Dissect the local players at tissue, cellular and molecular levels with potential systemic 
translation, in the context of hip osteoarthritis and aseptic implant loosening. 
 
In order to achieve this objective, peri-articular soft tissues and blood were collected 
from patients during total hip replacement and hip revision surgeries. Histopathological 
evaluation, gene expression and serological analyses combined with clinical data 
assessment were carried out to provide an integrated perspective of the local and 
systemic immune response underlying osteoarthritis and aseptic implant loosening. 
These results are presented within Chapter II, highlighting the role of macrophages as 
a key immune cell population in the particle-induced inflammation and consequent 
medical device failure. 
 
2) Development of a new biomaterial to modulate the immune response in orthopedics 
applications 
 
A biomimetic approach was chosen, and scaffolds made exclusively of fibrinogen ere 
(Fg-3D). Fg-3D were firstly characterized in vitro in terms of morphology and porosity 
(SEM), protein structure (FTIR and NMR), endotoxin levels, degradability and 
cytotoxicity. A critical-size bone defect rat model was used to evaluate the biological 
response to Fg-3D at two time-points: at 6 days post-injury, to assess the transition 
between the acute and chronic stage of inflammation, and at 8 weeks, to investigate 
the effect of Fg-3D on bone repair. Histological evaluation revealed that improved bone 
tissue healing and changes in systemic immune response at 6 days in presence of Fg-
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3D, which correlated with extensive bone repair at 8 weeks. These results are 
described within Chapter III. 
 
3) Use of magnesium ions to modulate macrophage behavior in pro-inflammatory 
scenarios 
 
The clinical application of biodegradable magnesium alloys, in orthopedics, and the 
administration of MgSO4 in Obstetrics to damp placental and fetal immune responses 
have inspired the use of magnesium ions to modulate macrophage response. Primary 
human macrophages were exposed to three concentrations of Mg2+ and their 
morphology, survival rate, macrophage polarization surface markers and cytokine 
production were evaluated. The role of the factors secreted by macrophages on the 
osteogenic differentiation of mesenchymal stem/stromal cells was also assessed. The 
obtained results showed that magnesium ions have an anti-inflammatory effect, 
particularly in presence of M1 polarizing stimuli, such as LPS. These findings are 
integrated in Chapter IV.  
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Abstract 
 
Aseptic loosening (AL) of hip prosthesis presents inflammation and pain as sign and 
symptom similarly to arthritis pathologies. Still, the immune and innervation profiles in hip AL 
remain unclear and their interplay is poorly explored. Herein, local tissue inflammatory 
response, sensory and sympathetic innervation as well as associated local mediators were 
assessed in hip joint microenvironment underlying AL and compared to osteoarthritis (OA). 
The profile of immune cells (macrophages, T, B cells and PMNs) and sensory and 
sympathetic nerve fibers (Substance P+, CGRP+, TH+) were analyzed on tissues retrieved 
from patients with failed hip prostheses due to AL (n=20) and hip OA (n=15) by 
immunohistochemistry. Additionally, transcriptional levels of pro-inflammatory cytokines (TNF-
α, IL-1β, IL-6, IL-12a, iNOS), anti-inflammatory cytokine (IL-10), osteoclastic factor (RANKL) 
and bone remodeling factor (TGF-β1) were locally evaluated by qRT-PCR. Serum TGF-β1 
levels were assessed preoperatively by ELISA. 
Histopathological analysis revealed that aseptic interface membranes of AL patients had 
distinct tissue architecture and immune cells profile when compared to OA synovial tissues. 
Macrophages, T cells and B cells showed significant differences in tissue distribution. In OA, 
inflammation is mostly confined to the vicinity of synovial membrane while in AL macrophages 
infiltrated throughout the tissue. This differential immune profile was also accompanied with a 
distinct pattern of sensory and sympathetic innervation. Importantly, in AL patients, a lack of 
sympathetic innervation aseptic interface membranes without compensation mechanisms at 
cellular levels was observed with simultaneous reorganization of sensorial innervation. Despite 
the different histopathological portrait, AL and OA patients exhibited similar transcriptional 
levels of genes encoding key proteins in local immune response. Nevertheless, in both 
pathologies, TGF-β1 expression was prominent in sites where the inflammation is occurring. 
However, at systemic level no differences were found. 
These findings indicate that AL patients exhibit different local inflammatory response and 
innervation signatures from OA patients in hip joint. These insights shed the light on neuro-
immune interplay in AL and highlight the need to better understand this crosstalk to unravel 
potential mechanisms for targeted-therapies to improve hip joint lifetime and treatment. 
 
 
 
Keywords: osteoarthritis, aseptic loosening, prosthetic debris, immune response, hip 
innervation 
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Introduction 
 
Osteoarthritis (OA) has long been considered a cartilage driven “wear and tear” disease 
that may lead to hip joint failure [1; 2]. The pain and diminished hip joint motion induced by OA 
may be effectively treated through primary hip replacement [3; 4]. Unfortunately, hip 
replacement is not a permanent solution as prostheses often fail 15-25 years after primary 
surgery, mostly due to aseptic loosening (AL), infection and dislocation [5; 6]. Other therapeutic 
solutions are then urgently required to expand implants’ lifetime. 
Inflammation is common to AL and OA [1; 7; 8]. Immune cells and cytokines have been 
previously reported in both clinical scenarios [8-11]. Synovial inflammation is often observed 
in OA patients and is frequently characterized by the infiltration of specific immune cell 
populations, such as macrophages, T cells and mast cells, as well as by the expression of pro-
inflammatory cytokines, as Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) [7]. 
Nevertheless, these findings were mostly described in studies focusing on the knee or in 
studies combining data from both knee and hip, without anatomical discrimination [7]. On the 
other hand, periprosthetic joint inflammation is commonly known as a complex local biological 
response that takes place on synovial membrane-like interface tissues, triggered by implant 
released by-products (particles and ions) [12-15]. Of note, the nature, size and amount of 
released particles are recognized to define the inflammatory profile [13-16]. While polymeric 
particles such as polyethylene (PE) and polymethylmethacrylate (PMMA) are often associated 
with macrophage mediated foreign body reaction and tissue fibrosis, high levels of metallic 
particles and ions have been demonstrated to promote tissue necrosis and lymphocyte-driven 
responses [17].  
Pain is one of the clinical features observed in both AL and OA conditions [18; 19]. 
Innervation profile is mostly studied in the context of arthritic diseases but not in the presence 
of implantable biomaterials. Patients and animal studies highlighted innervation of synovial 
tissues as a possible player in the pain process and, based on anatomical mapping, suggested 
a coupling of innervation and inflammation in osteoarthritic synovial tissues [20; 21]. It is well 
documented that both sympathetic, tyrosine-hydroxylase (TH)+ or neuropeptide Y (NPY)+, and 
sensory nerve fibers, substance P+ and calcitonin gene related peptide (CGRP)+, are present 
in OA synovial tissue and grow towards cartilage along blood vessels [21]. On the other hand, 
so far, two studies addressed the innervation of the interface membranes surrounding AL hip 
prostheses [19; 22]. Unfortunately, the data is still unclear. Niissalo et al reported that the 
synovial membrane-like interface did not contain C-sensory peptidergic or sympathetic neural 
structures while Ahmed et al identified sympathetic nerve fibers in these interface membranes 
[19; 22]. Thus, innervation profile and its possible association with periprosthetic joint 
inflammation, triggered by prosthetic debris in AL scenario, should be revised. Furthermore, 
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the comparison of the inflammatory versus innervation profiles of AL and OA has never been 
examined and requires further investigation. In this study, the immune and innervation profiles 
of AL and OA were addressed dissecting local players at tissue, cellular and molecular levels 
with potential systemic translation.  
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Materials and methods 
 
Patients and Samples 
 
Centro Hospitalar São João ethics committee approved this study and all patients 
consented to the use of their tissue and blood for research purposes. The followed procedures 
were in accordance with the Helsinki Declaration of 1975, as revised in 2000. Samples from 
synovial membrane-like interface tissue/aseptic interface membrane were collected from 
twenty patients during hip revision surgeries due to AL of hip prostheses. All revised hips had 
a metal-on-polyethylene (MoP) coupling, eleven out twenty cemented and bone defects were 
classified according to the Paprosky classification [23]. Relevant clinical information is 
summarized in Table 1. Infection, recurrent dislocation and periprosthetic fracture were 
considered exclusion criteria in the aseptic loosening group. Osteoarthritic synovial tissues 
were collected from fifteen patients undergoing primary hip replacement surgeries for primary 
OA. OA patients were classified for OA severity according Tönnis OA grade [24] and presented 
scores from moderate (2) to severe (3). The clinical information of these patients is 
summarized in Table 2. For both OA and AL groups, the same orthopedic team performed the 
collection of tissue samples. Previously to surgery, blood was collected and leukograms and 
plain radiographies were registered. 
Immediately after excision, both OA synovial tissues and aseptic interface tissues were 
split. Half of the tissue was immersed in formalin for further histological analysis, while dry ice 
was used to freeze the remaining tissue until storage at -80ºC. No more than 4 hours elapsed 
between tissue collection and storage. 
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Table 1 - Clinical data from aseptic loosening patients 
Aseptic 
Loosening 
Case 
Number 
Age Gender 
Hip 
prostheses 
type 
Implant 
Fixation 
Time to 
Revision 
(months) 
Component 
Revised 
Type 
of 
bone 
defect 
Metallosis 
1 79 M MoP Cemented 13 Acetabular 2B No 
2 61 F MoP Cemented 24 Acetabular 2A No 
3 74 F MoP Cemented 23 Acetabular 2B No 
4 86 F MoP Cemented 46 Acetabular 2B No 
5 50 F MoP Uncemented 56 Acetabular 
Femoral 
3A 
1 
Yes 
6 79 F MoP Cemented 96 Ac tabular 3A No 
7 73 M MoP Cemented 108 Acetabular 3A No 
8 69 F MoP Cemented 117 Acetabular 2C No 
9 74 M MoP Cemented 120 Acetabular 
Femural 
2A 
1 
No 
10 77 M MoP Uncemented 120 Ac tabular 
Femoral 
2B 
1 
No 
11 45 F MoP Uncemented 129 Ac tabular 3A No 
12 73 F MoP Uncemented 130 Acetabular 1 Yes 
13 63 F MoP Cemented 138 Acetabular 3A No 
14 75 M MoP Cemented 144 Acetabular 3A No 
15 62 F MoP Uncemented 153 Acetabular 2C No 
16 53 F MoP Uncemented 156 Acetabular 2A No 
17 86 F MoP Cemented 168 Acetabular 
Femoral 
2A 
1 
No 
18 71 F MoP Uncemented 204 Ac tabular No 
19 82 F MoP Uncemented 216 Acetabular 1 Yes 
20 75 M MoP Uncemented 240 Acetabular 1 Yes 
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Table 2 - Clinical data from osteoarthritis patients. 
Osteoarthritis 
Case Number 
Age Gender 
OA severity 
(Tonnis Classification) 
1 79 F 2 
2 45 F 3 
3 54 F 3 
4 80 F 3 
5 55 M 3 
6 49 F 2 
7 76 M 3 
8 51 F 2 
9 56 F 3 
10 71 M 3 
11 74 F 3 
12 83 M 3 
13 37 F 3 
14 74 M 3 
15 66 M 2 
 
Histochemistry and immunostaining 
 
Half of collected tissues were formaldehyde-fixed paraffin embedded and cross-sections 
of 3 μm thickness were cut. Contiguous sections were stained with hematoxylin & eosin (H&E) 
and Masson’s trichrome (MT). For immunohistochemistry, tissue sections were deparaffinized 
and rehydrated before heat induced antigen retrieval (98ºC, 10 mM citrate buffer, pH 6.0). 
Endogenous peroxidases were blocked using 3% H2O2 and non-specific binding sites were 
blocked using Background Block (Cell Marque, USA), previously to the incubation with 
antibody diluent 1% BSA (negative control) or with primary antibodies: anti-CD3 (clone PS1, 
dilution 1:100, Biocare Medical, USA), anti-CD20 (clone L26, dilution 1:100, Cell Marque, 
USA), anti-CD68 (clone 514H12, dilution 1:100, Novocastra, UK), anti-CD163 (clone MRQ-26, 
dilution 1:150, Cell Marque, USA), anti-HLA-DR (clone TAL1B5, dilution 1:5000, Abcam, USA) 
and anti-TGF-b1 (clone TB21, dilution 1:2000, Abcam, USA). After primary antibody 
incubation, tissue sections were incubated with BrightVision Poly-HRP-Anti Mouse/Rabbit/Rat 
IgG (Immunologic, the Netherlands) and then revealed using DAB Plus Substrate System 
(Thermo Scientific, USA), before hematoxylin counterstaining. The specificity of 
immunostainings of CD20, CD163, CD68, HLA-DR and CD3 was confirmed using human 
spleen as positive control.  
For immunofluorescence studies, tissue sections were deparaffinized and antigen 
retrieval of rehydrated sections was performed using Proteinase K (0.2 mg/mL in PBS) for 
NF200 immunostaining and incubated for 20 min at 98ºC in Citrate buffer (pH 6.0), or TE Buffer 
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(pH 9.0) for Substance P and CGRP staining, respectively. After quenching endogenous 
fluorescence with 0.1 % sodium borohydride and 100 mM NH4Cl, sections were incubated with 
blocking buffer (10 % FBS, 1 % BSA, 0.2 % Triton X-100). Primary antibody rabbit anti-human 
neurofilament heavy subunit (NF200) (dilution 1:1000, Abcam, USA), anti-Substance P 
(dilution 1: 1000, Millipore, USA), anti-TH (dilution 1:100, Millipore, USA), anti-CGRP (dilution 
1:4000, Sigma-Aldrich, USA) or blocking buffer (negative control) was applied overnight at 4 
ºC. For signal detection, tissue sections were incubated with anti-rabbit Alexa Fluor 568 
antibody (dilution 1:1000, Life Technologies, USA), incubated with DAPI and then mounted 
with Fluoroshield Mounting Medium (Abcam, USA). The specificity of immunostainings for 
NF200, Substance P, TH and CGRP was confirmed using a specimen of human Morton’s 
neuroma as positive control. 
 
Semi-quantitative histopathological evaluation 
 
In order to characterize synovial microenvironment, tissues were semi-quantified 
considering the total immunoreactive area and scored into four categories: absent (0), present 
(1), frequent (2) or abundant (3), according to the histological grading system illustrated in the 
supplementary figures Figure S1 (tissue reaction), Figure S2 (prosthetic debris accumulation) 
and Figure S3 (immune cells distribution), similarly to the methodology followed by others [25; 
26].  
Structural changes, fibrosis and necrosis in OA synovial tissues and aseptic interface 
tissues were evaluated after H&E and MT staining. The thickening/hyperplasia and increased 
villi of synovial membrane were assessed in OA patients. The accumulation of polymeric, 
ceramic and metallic particles was assessed in synovial membrane-like interface tissues. A 
polarized filter was used to detect polymeric particles. Ceramic and metallic particles were 
studied through Scanning Electron Microscopy (SEM) and their elemental composition 
assessed by Energy Dispersive Spectroscopy (EDS). Additionally, a phase contrast filter (Ph3) 
was used with an optical microscope to ease the detection of clusters of ceramic or metallic 
particles in histological slices, allowing a deep study of the interaction between particles and 
cells. The infiltration of target immune cell populations, identified by immunohistochemistry, 
was determined regarding the presence of macrophages (CD68+ cells), T cells (CD3+ cells) 
and B cells (CD20+ cells). The semi-quantification of polymorphonucleated cells (PMNs) was 
performed after PMNs identification as these cells have a lobed nucleus while multinucleated 
giant cells (GC) were detected due to their bigger size, multiples nucleus and CD68+ labeling.  
Tissue samples retrieved from five out thirty-five patients (4/15 OA and 1/20 AL) were 
excluded from histopathological evaluation because they do not correspond to OA synovial 
tissue or aseptic interface tissue. H&E, MT and immunohistochemistry slices were analyzed 
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using a light microscope Olympus CX31 while immunofluorescence, polarized light and phase 
contrast Ph3 images were captured on Carls Zeiss Axiovert 200 inverted microscope. 
 
Gene expression analysis 
 
Synovial tissues were homogenized in liquid nitrogen using a mortar and pestle to 
preserve RNA integrity. RNA was extracted and purified using TRIzol (Invitrogen, UK) and 
Direct-zol™ RNA MiniPrep (ZYMO Research, USA), according to the manufacturers’ 
instructions. The amount and quality of extracted RNA were evaluated by Nanodrop ND-1000 
(Thermo Fisher Scientific, USA) and running RNA samples in a 2% agarose gel. The 
transcriptional levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12a and iNOS), anti-
inflammatory cytokine (IL-10), osteoclastic factor (RANKL) and bone remodeling factor (TGF-
β1) were evaluated by quantitative real time PCR (qRT-PCR) in PCR iQ™5 system (Bio-rad, 
USA). All used primers, listed in Table 3, were optimized and melting curves of PCR products 
were evaluated to guarantee primers specificity. β2 microglobulin (B2M) and β-actin were used 
as reference genes. Experiments were performed in triplicated. Relative gene expression 
levels were calculated using the quantification cycle (Cq) method, according to MIQE 
guidelines [27]. Fourteen out thirty-six cases (5/15 OA and 9/20 aseptic loosening) were 
excluded from gene expression analysis when average Cq for reference genes was above 26, 
to avoid bias in the evaluation of genes with later expression. 
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Table 3 - List of primers used for quantitative qRT-PCR analysis  
Gene 
GenBank 
number 
Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
B2M [NM_004048] CCAGCGTACTCCAAAGATTCAG AGTCAACTTCAATGTCGGATGG 
β-actin [NM_001101] TACCTCATGAAGATCCTCA TTCGTGGATGCCACAGGAC 
IL-1β [NM_000576] CTTCAGCCAATCTTCATT CACTGTAATAAGCCATCAT 
IL-6 [NM_000600] CAATCTGGATTCAATGAGGAGACT CTGTTCTGGAGGTACTCTAGGTAT 
IL-10 [NM_000572] GGAGAACCTGAAGACCCTCA TATAGAGTCGCCACCCTGAT 
IL-12a [NM_000882] TACCAGGTGGAGTTCAAG GTTCTTCAAGGGAGGATTT 
iNOS [NM_000625] AATTGAATGAGGAGCAGGTC TCCTTCTTCGCCTCGTAA 
TNF-α [NM_000594] TCTCTCTAATCAGCCCTCTG TGCTACAACATGGGCTACAG 
RANKL [NM_003701] GGATGGCTCATGGTTAGA CAAGAGGACAGACTCACTT 
TGF-β1 [NM_000660] CCTGGACACCAACTATTG CTTGCGGAAGTCAATGTA 
Y1R [NM_000909] AAGAGGATTGTTCAGTTCA GATTGGTTTGGTTGTTATAGA 
Y2R [NM_000910] ACTCTTACCTATACCTTAATG GTGATTGTGGATACTTGT 
Y5R [NM_006174] AAGGAAGGGAAAGGGTGTTAC CGAGTGGCAGCAGTATTATTCT 
VMAT2 [NM_003054] TGCGGGATTCTGCATCATGT CATCCAAGAGTACCAGGGCG 
 
 
ELISA  
 
Serum transforming growth factor β1 (TGF-β1) concentrations were measured using 
Quantikine® ELISA Kit for human TGF-β1 (R&D Systems, USA), according to the 
manufacturer’s protocol. Cytokine concentration was calculated against a standard curve. 
 
Statistical analysis 
 
Statistical analysis was performed using SPSS 21.0 (SPSS Inc. Chicago, IL, USA). The 
level of significance was set at p< 0.05 (*). Visual histogram analysis and Kolmogorov-Smirnov 
test were used to evaluate the normal distribution of continuous variables (gene expression 
data, TGF-β1 plasma concentration and percentage of immune cells in blood). Accordingly, 
these variables were analyzed using Student’s t-test or its non-parametric counterpart, Mann-
Whitney test. Tissue immune response and innervation was histologically classified in different 
grading categories and comparisons between aseptic interface tissues and OA synovial were 
done using Chi-square test. All graphs were prepared using Prism software (GraphPad 
software, San Diego, CA, USA). 
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Results 
 
Local immune responses in OA synovial tissues and synovial membrane-like 
interface tissue 
 
In this study, fifteen patients underwent primary hip replacement due to OA (Figure 1A) 
and twenty hip implants were revised and their acetabular defects classified by X-ray imaging 
(Figure 1B). Macroscopically, the collected synovial tissues at primary and revision surgeries 
were morphologically distinct. Synovial surface was white and with diffuse papillary 
architecture (dashed black line, Figure 1C and D) whereas synovial membrane-like interface 
tissues were highly fibrotic (Figure 1E) or with greyish appearance (Figure 1F), in case of 
metallosis. 
 
Figure 1 - Radiological and macroscopic tissue features of OA, AL and metallosis. (A) Anteroposterior X-rays showing OA 
of the hip. (B) Failed metal-on-polyethylene total hip joint due to AL. (C,D) Macroscopic images of OA synovial tissue collected at 
primary hip replacement. (E) Synovial membrane-like interface tissue retrieved at hip revision surgery due to AL. (F) Metallic 
debris accumulation in synovial membrane-like tissue from AL patient with metallosis. 
 
Semi-quantitative analysis of tissue organization and immune cell distribution in OA 
synovial tissue and aseptic interface tissues showed distinct local profiles. OA synovial 
membranes displayed a bicellular lining layer (LL) and a sublining layer (SLL) (Figure 2A) 
enriched in blood vessels (black arrows) and collagen (Figure 2B), as well as structural 
changes induced by synovial inflammation, such as synovial hyperplasia (Figure 2C and D) 
and increased number of villi (Figure 2E and F). OA patients presented at least one sign of 
synovial inflammation (thickening or villi) but their magnitude was variable among patients 
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(Figure 2C and E). Synovial membrane-like interface tissues presented fibrotic stroma with 
increased collagen deposition (Figure 2G and H) than OA synovial tissues (p=0.001) and with 
some necrotic regions (Figure 2I). 
 
Figure 2 - Histological evaluation of tissues organization. (A) OA synovial tissue is composed by different cell types and 
matrixes organized in synovial lining layer (LL) and sublining layer (SLL). (B) Dense net of blood vessels (black arrows) was found 
in SLL together with loose connective tissue (blue stain). (C) Histological grading for synovial membrane thickening in OA. (D) 
Synovial membrane thickening (ST) with reactive neo vascularization. (E) Histological grading for synovial villous expansion in 
OA. (F) OA synovial membrane presenting villous hypertrophy (SV). (G) Histological grading for tissue fibrosis. (H) Synovial 
membrane-like interface tissue showing fibrosis characterized by intense deposition of collagen fibers (blue stain). (I) Histological 
grading for tissue necrosis. Masson’s trichrome (A,B,D,F,H) staining. Scale bars correspond to 500 μm (B,F,H), 200 μm (D) and 
50 μm (A). Semi-quantitative histological evaluation of tissue architecture was performed in specimens retrieved from 11/15 OA 
and 19/20 AL patients. *** p<0.001. Chi-square test was used to compare OA and AL groups. 
 
The accumulation of prosthetic debris in synovial membrane-like interface tissues was 
semi-quantified. Polymeric particles were just detected in 11/20 analyzed aseptic interface 
tissues (Figure 3A) after tissue analysis under polarized light (Figure 3B and C). No significant 
difference was found between AL patients with cemented and uncemented MoP bearings 
regarding the amount of polymeric particles entrapped in synovial membrane-like tissues. 
Zirconia particles (ZrO2) were observed in almost all synovial membrane-like interface tissues 
retrieved from patients with loose cemented prostheses (Figure 3D-F) and mainly 
phagocytized by macrophages or multinucleated giant cells (Figure 3G). Ph3 contrast filter 
eased the detection of ZrO2 particles (Figure 3E and F). White color particles under Ph3 filter 
were confirmed to be ZrO2 and to be organized in clusters of nanoparticles by SEM/EDS 
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(Figure 3H and I). Intense deposition of metallic particles was just found in the four cases of 
metallosis that were patients with uncemented metal-back acetabular cups (Figure 3J). Aseptic 
interface membranes with metallosis presented high deposition of metallic particles with 
concomitant macrophage infiltration (Figure 3K), tissue fibrosis (Figure 3L) and necrosis 
(Figure 3M). Under Ph3 filter, metallic nanoparticles and haemoglobin presented violet and red 
color respectively, which allow distinguishing them from ZrO2 particles (Figure 3N and O). 
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Figure 3 - Prosthetic debris accumulation in synovial membrane-like tissues. (A) Histological grading for accumulation of 
polymeric particles (PP) in aseptic interface membranes. (B) PP surrounded by macrophages (brown cells). (C) Same section of 
(H) under polarized light showing birefringent PP. (D) Histological grading for deposition of ZrO2 particles in synovial membrane-
like interface tissues. (E) H&E image of aseptic interface membrane with intense deposition of ZrO2 particles (black arrows) using 
conventional light microscopy. (F) Same tissue region observed using Ph3 filter with white and bright particles corresponding to 
ZrO2 debris (white arrows). (G) Macrophages (brown cells) phagocytizing ZrO2 debris (black arrows). (H) SEM image of synovial 
membrane-like interface tissues containing clusters (Z1) and sole (Z2) ZrO2 nanoparticles. (I) EDS analysis confirming the 
elemental composition of ZrO2 nanoparticles. (J) Histological grading for entrapment of metallic particles in tissues. (K) 
Macrophages (brown cells, CD68+ cells) with phagocytized metallic particles. (L) Metallic particles co-localized with macrophages 
and high deposition of collagen (blue stain). (M) Necrosis (N) in regions of aseptic interface membranes with massive 
accumulation of metallic particles. (N) Tissue from an AL patient with metallosis showing metallic particles and erythrocytes. (O) 
Same tissue section shwoing bright metallic particles and erythrocytes but exhibited under Ph3 filter violet and red colors, 
respectively. H&E staining (E,M,N), polarized light (C), Ph3 filter (F,O), Masson’s trichrome (L) immunohistochemistry (B,G,K), 
SEM imaging (H) and EDS spectra (I). Scale bars correspond to 500 μm (E,M), 50 μm (B,K,L) and 20 μm (G,N,O). Semi-
quantitative histological evaluation was performed in tissues retrieved from 19/20 AL patients. 
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Immune cell distribution was studied in tissues from AL and OA patients. In AL, 
macrophages (CD68+ cells) were more abundant than in AL (p=0.007; Figure 4A), often 
confined to lining layer in OA patients (Figure 4B), while significant macrophage infiltration was 
found in synovial membrane-like interface tissues (Figure 4C). In these tissues, co-localization 
between polymeric particles and macrophages was often found (Figure 4D) and a similar 
pattern was observed in AL patients with cemented and uncemented MoP bearings. In AL 
patients, macrophages were the most prevalent immune cell population, even in metallosis 
cases, and in overall highly express M1 (HLA-DR; Figure 4E) and M2 (CD163; Figure 4F) 
markers. Multinucleated giant cells in foreign body reaction setting were mostly found in 
synovial membrane-like interface tissues (p=0.037, Figure 4G) surrounding big polymeric 
particles, likely PMMA, with ZrO2 particles entrapped inside (Figure 4H). T cells (CD3+ cells) 
(Figure 4J), and B cells (CD20+ cells; Figure 4L) in lower number, could be detected in the 
majority of tissues collected from AL and OA patients (Figure 4I and K), including AL patients 
with uncemented implants or signs of metallosis. Moreover, the number of PMNs was also low 
in both aseptic interface membranes and OA synovial tissues (Figure 4M and N). Overall, the 
immune cell populations addressed, namely macrophages, T cells, B cells and PMNs, in this 
study were most located in the vicinity of synovial membrane in OA patients, while in AL 
patients these cells were identified throughout the aseptic interface membranes. 
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Figure 4 - Immune cells distribution in OA synovial tissues and aseptic interface membranes. (A) Histological grading for 
macrophage (CD68+ cells) infiltration in tissues. (B) In OA, macrophages (brown cells) were almost found at LL. (C) Intense 
macrophage (brown cells) infiltration was detected in synovial membrane-like interface tissues. (D) In aseptic interface tissues, 
macrophages (brown cells) were often found surrounding or phagocytizing prosthetic debris such as polymeric particles (PP) and 
ZrO2 particles (black arrows). (E) HLA-DR+ cells – an M1 macrophage marker. (F) CD163+ cells – an M2 macrophage marker. 
(G) Histological grading for multinucleated giant cells in tissues  (H) Multinucleated giant cells (GC) phagocyting a big PP particle 
with ZrO2 particles (black arrows) entrapped inside. (I) Histological grading for T cells (CD3+ cells). (J) Perivascular T cells (brown 
cells) clusters in OA synovial tissue. (K) Histological grading for B cells (CD20+ cells). (L) B cells (brown cells) in lymphocyte 
aggregates around blood vessels but in lower number than T cells. (M) Histological grading for polymorphonucleated cells (PMNs). 
(N) Increased number of PMNs (black arrows) in synovial membrane-like tissue with macrophages (brown cells, CD68+ cells). 
Masson’s trichrome staining (H) and immunohistochemistry (B,C,D,E,F,J,L,N). Scale bars correspond to 500 μm (B,C) and 50 μm 
(D,E,F,H,J,L,N). Semi-quantitative histological evaluation was performed in synovial tissues retrieved from 11/15 OA and 19/20 
AL patients. * p<0.05, *** p<0.001. Chi-square test was used to compare OA and AL groups. 
Chapter II – Immune response and innervation signatures in aseptic hip implant loosening 
 121 
Local innervation in AL and OA patients 
 
Myelinated nerve fibers identified by NF200 immunoreactivity were detected in both 
synovial membrane-like interface tissues and OA synovial tissues. They were presented as 
single fibers (Figure 5A and C) and were preferentially arranged around blood vessels (Figure 
5C) particularly in tissue regions of reactive vascularization induced by immune responses 
underlying AL and OA. Alternatively, nerve fibers were also found in neurome-like structures 
(Figure 5B and D) in both AL and OA patients. Sensory and sympathetic innervation, as seen 
by immunohistochemical markers of sensory nerve-associated peptides (Substance P and 
CGRP) and catecholaminergic marker of sympathetic neurons (TH), showed different pattern 
between OA patients and AL patients. TH immunoreactive nerve fibers were observed in OA 
synovial tissues (Figure 5F) but not in synovial membrane-like interface tissues (Figure 5G 
and H). Substance P and CGRP were found both in OA synovial tissues and synovial 
membrane-like interface tissues but showed different pattern. In OA synovial tissues, nerve 
fibers immunoreactive to Substance P and SGRP were observed mainly around blood vessels 
in the vicinity of synovial membrane (Figure 5J and N). In addition, a high number of cells in 
the OA synovial membrane also stained for TH, Substance P and CGRP (Figure 5E, I and M). 
In synovial membrane-like interface tissues, the expression of Substance P and CGRP was 
also found in both nerve fibers and cells but with a broad distribution throughout the tissue 
(Figure 5K, L, O and P). 
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Figure 5 - Local tissue innervation in OA and AL patients. (A-D) NF200+ fibers (red) as sole fiber or organized in neurome-
like structures in OA synovial tissues as well as in aseptic interface membranes. (E) Synovial cells expressing TH (red). (F) TH+ 
fiber surround a blood vessel. (G,H) Nor fibrotic nor reactive tisue with giant cells presented positive labelling for TH. (I) Substance 
P+ cells in OA synovium membrane. (J) Substance P+ fibers and cells surrounding a blood vessel located at subintimia of OA 
synovial tissue. (K,L) In AL patients, Substance P+ fibers were just found in fibrotic regions. (M) CGRP+ cells in synovial 
membrane. (N) CGRP+ fibers along a blood vessel in OA synovial tissue. (O,P) Some cells expressing CGRP in aspetic interface 
tissue. red=NF200+ or TH+ or Substance P+ or CGRP+, blue=cell nuclei, green=autofluorescence) Scale bars correspond to 50 
μm (A,B,D,F,G,H,I,J,K,L,M,N,O,P) and 200 μm (E). 100 μm (C). 
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Local gene expression profile 
 
The expression levels of pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β) and IL-6 were similar in aseptic interface tissues and OA synovial tissues 
(Figure 6A-C). Inducible nitric oxide synthase (iNOS) and IL-12a expression levels were found 
to be low when compared with the TNF-α, IL-1β and IL-6 mRNA levels detected in AL and OA 
groups (Figure 6D and E). Interestingly, the anti-inflammatory cytokine IL-10 presented a 
tendency (p=0.084) to be higher expressed in synovial membrane-like tissues than in OA 
synovial tissues (Figure 6F). Two genes involved in bone remodeling were evaluated: TGF-β1 
and receptor activator of nuclear factor kappa-B ligand (RANKL). The mRNA levels of TGF-β1 
were significantly reduced (p=0.038) in aseptic interface tissues when compared to OA 
synovial tissues (Figure 6G). However, no differences between AL and OA patients were 
verified for RANKL (Figure 6H) and no correlation was found between mRNA levels of RANKL 
and the bone defect type. 
 
 
 
Figure 6 - Gene expression profiles of cytokines in aseptic interface membrane and OA synovial tissues. Relative 
expression levels of genes of interest determined through qRT-PCR and normalized by two reference genes, β-actin and B2M: 
(A) IL-1β, (B) TNF-α, (C) IL-6, (D) iNOS, (E) IL-12a, (F) IL-10, (G) TGF-β1 and (H) RANKL. Data of 10/15 OA patients and 11/20 
AL patients are shown. Significant difference of TGF-β1 expression between AL and OA groups (*p < 0.05). Mann-Whitney test 
was utilized to compare and analyze the obtainded data. 
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Local production of TGF-β1 
 
In both AL and OA patients, TGF-β1 was detected in blood vessels endothelium cells 
(Figure 7A), macrophages (Figure 7B) and fibroblasts (Figure 7C). Interestingly, differences in 
the pattern of TGF-β1 expression were found between AL patients and OA. Aseptic interface 
tissues presented a trend (p=0.1672) toward increased number of regions expressing TGF-β1 
(Figure 7D). In OA synovial tissues, TGF-β1 was present in the sublining layer of synovial 
membrane (Figure 7E), in aggregates of lymphocytes (Figure 7F) and blood vessels. In 
synovial membrane-like interface tissues, the distribution of TGF-β1-positive regions was 
heterogeneous (Figure 7G and H). 
 
 
Figure 7 - TGF-β1 expression in synovial membrane-like interface tissues and OA synovial tissues. (A) TGF-β1+ 
endothelial cells in aseptic interface tissue with metallosis. (B) TGF-β1+ macrophages in synovial membrane-like interface tissue. 
(C) TGF-β1+ fibroblast in aseptic interface membrane. (D) Number of OA and AL patients classified with score from 0 to 3 
regarding the presence of TGF-β1 in tissue. (E) OA synovial membrane with positive labelling at sublining layer and endotethelium 
(black arrows). (F) Lymphocyte aggregate in OA synovial tissue with positive cells for TGF-β1. (G) Aseptic interface membrane 
presenting heterogenous TGF-β1 labelling. (H) Multinucleated giant cell (GC) phagocyting a polymeric particle (PP) with ZrO2 
particles inside (black clusters) with TGF-β1+ endothelial cells in the vicinity. Scale bars correspond to 500 μm (G) and 50 μm 
(A,B,C,E,F,H). Data was collected for 11/15 OA patients and for 19/20 AL patients. Chi-square test was used to compare OA and 
AL groups. 
  
Chapter II – Immune response and innervation signatures in aseptic hip implant loosening 
 125 
Immune cells proportions and TGF-β1 concentration in blood 
 
The preoperative leukograms were analyzed and the concentration of TGF-β1 
determined in plasma of both AL and OA patients. The percentage of circulating monocytes in 
both groups tended to be similar (Figure 8A). Interestingly, the percentage of lymphocytes 
seemed to be low in AL patients but within the reference interval in OA group (Figure 8B). 
Neutrophils did not present significant alterations compared with the reference values (Figure 
8C). Remarkably, the levels of TGF-β1 in serum were similar in both groups (Figure 8D). 
 
 
 
Figure 8 - Pre-operative evaluation of immune populations and TGF-β1 in blood. Data regarding the percentage of the 
following immune population in leukocytes count. (A) Monocytes. (B) Lymphocytes. (C) Neutrophils. Data was collected for 14/15 
OA patients and for 17/20 AL patients. Dashed lines represent minimum and maximum reference values. (D) TGF-β1 serum 
concentration was determined for 13/15 OA patients and for all 20 AL patients. 
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Discussion 
 
AL and OA differences rely on tissue architecture, immune cell distribution, local TGF-
β1 expression as well as sensory and sympathetic synovial innervation. On the other hand, 
both pathologies share identical mRNA profiles of inflammatory mediators and similar TGF-β1 
concentrations in serum, as summarized in Figure 9. 
 
 
Figure 9 - Overview of hip microenvironment in OA and AL.  
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Synovial membrane-like interface tissues, present in the vicinity of loose prostheses, 
showed a macrophage-driven chronic inflammation. This immune response is likely influenced 
by both OA inflammatory background and the presence of prosthetic debris, leading to 
significant changes of local TGF-β1 expression but not systemically. 
Distinct tissue organization and immune cell distribution were found in the tissues 
retrieved from the hip joint of AL and OA patients. OA synovial tissues presented signs of 
synovial inflammation (synovitis), such as synovial hyperplasia and villous hypertrophy, while 
aseptic interface membranes, formed after primary hip replacement, exhibited a particle-driven 
chronic inflammation. Intense infiltration of macrophages (CD68+ cells) was observed in AL 
patients in comparison to OA synovial tissues. In synovial membrane-like interface tissues 
retrieved from AL patients, macrophages were the predominant immune cell type and were 
involved in the phagocytosis of small particles (< 10μm) or encapsulating bigger polymeric 
particles as multinucleated giant cells, in line with previous works about the role of 
macrophages on AL [28]. Although PE particles, released by MoP prostheses, have been 
pointed out as AL catalyzers [29; 30], other types of particles may play a role on the pro-
inflammatory microenvironment underlying osteolysis. Large amounts of metallic particles 
were observed in four out nine AL patients due to impingement of metallic components of 
uncemented MoP bearings. 
Ceramic ZrO2 particles, incorporated in bone cements for implants fixation as 
radiopacifier agent, were found in synovial membrane-like interface tissues from all the 
patients with cemented prostheses. Light microscopy with Ph3 contrast filter and SEM/EDS 
analysis revealed that ZrO2 gradually migrate from cement particles (PMMA) to other regions 
of aseptic interface tissues in high number, namely after being phagocytized by macrophages. 
ZrO2 particles were shown to be moderately toxic, activate macrophages, promote the 
expression of pro-inflammatory cytokines (TNF-α) and induce osteolysis in vivo [31; 32]. 
Despite reported not toxic as metallic particles or studied as polymeric debris [12; 33; 34], ZrO2 
particles should not be neglected, as they are numerous, common and nano-sized with 
potential to unbalance inflammation towards osteolysis. It has been reported that particle-
induced response is prone to drive macrophages towards M1 phenotype and that M1:M2 ratio 
was higher in synovial membrane-like interface tissue than in OA synovial tissues [35; 36]. 
However, macrophage polarization in joint tissues remains controversial. In this study, the 
density of polymeric, metallic or ZrO2 particles on aseptic interface tissues did not lead to local 
preferential macrophage polarization in M1 pro-inflammatory (HLA-DR+) or M2 pro-
regenerative phenotypes (CD163+) as both receptors were similarly expressed on 
macrophages. In addition to the involvement of macrophages and lymphocytes in local 
inflammatory response, preoperative leukograms suggested monocyte expansion and 
contraction of lymphoid population in AL group. 
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Cytokines expression profile was found similar in synovial membrane-like interface 
tissues and OA synovial tissues, despite their distinct tissue architecture and immune cell 
distribution. The response of macrophages to prosthetic debris is believed to induce the 
production of the pro-inflammatory markers such as TNF-α, IL-1β, IL-6, IL-12a, and iNOS [28; 
34; 37]. However those genes revealed similar mRNA levels in AL and OA patients, which is 
in line with comparable studies [26; 30; 38]. The changes in cytokine expression induced by 
AL seem to be controversial [25]. Reduced mRNA levels of IL-6 have also been described in 
aseptic interface membranes [26] while IL-6 was found significantly increase in synovial fluid 
of AL patients [25; 30]. A trend for higher mRNA levels of the anti-inflammatory cytokine IL-10 
was observed in synovial membrane-like interface tissues in comparison to OA synovial 
tissues (p=0.084). This result corroborates with other findings showing significant increase of 
IL10 protein levels in synovial fluid and interface tissues of AL patients [25; 26; 30]. The up-
regulation of IL-10 in aseptic interface tissues may constitute an attempt to balance the pro-
inflammatory microenvironment induced by prosthetic debris [39; 40].  
Although RANKL is involved in osteoclastogenesis and osteolysis, similar mRNA levels 
were found in AL and OA patients, in agreement with other authors [26; 30; 38; 41]. In overall, 
identical pattern regarding the expression of cytokines was found in AL and OA patients. In 
the context of AL, no significant differences were registered between polyethylene-drive and 
metallosis cases as previously shown [42]. The expression of TGF-β1 mRNA in synovial 
membrane-like interface tissues was found significantly lower than in OA synovial tissues but 
local TGF-β1 immunostaining suggested increased expression of this protein in AL patients in 
comparison to OA patients. These findings corroborate the results presented by other authors 
that have also found increased TGF-β1 mRNA levels in OA cartilage [9; 43; 44] and augmented 
TGF-β1 expression in synovial membrane-like interface tissues [45]. In both AL and OA, TGF-
β1+ labeling was prominent in sites where the inflammation is occurring and mostly expressed 
in macrophages, fibroblasts and endothelium cells. However, while in OA the TGF-β1+ cells 
were found in the region of synovial membrane, in AL, the distribution was more 
heterogeneous and throughout different tissue regions. These results suggest a possible 
association between TGF-β1 and the immune responses that underlie AL and OA. Despite a 
previous report indicates that in OA pathogenesis, TGF-β1 might have a pro-inflammatory 
effect by inducing fibroblasts to express TNF-α and IL-1β [46], its involvement in inflammatory 
response is not fully understood. Although the involvement of TGF-β1 in fibrosis is widely 
described, this growth factor may have dual effects on arthritic diseases [47]. Both immune 
cells and fibroblasts are part of the complex microenvironments that underlie AL and OA and 
in which TGF-β1 may have different effects depending on levels of other inflammatory 
mediators. Additionally, in the context of particle-induced immune response, TGF-β1 has a 
conjoint role with other factors on bone remodeling [12].  
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Moreover, previous studies demonstrated that serum TGF-β1 has not predictive value 
to assess OA incidence and progression [48; 49]. In our study, despite the difference in tissues 
regarding TGF-β1, AL and OA patients presented similar concentrations of TGF-β1 in serum.  
 The crosstalk between inflammation and innervation has been widely investigated in 
several joint-related disorders but not in presence of prostheses [50; 51]. Previous studies 
have reported sensory and sympathetic innervation in joints diseases namely OA and 
rheumatoid arthritis (RA), where an inflammatory response is taken place within synovial 
tissues or in the vicinity of the articulation. Our study demonstrated for the first time distinct 
pattern of sensory and sympathetic innervation in AL patients characterized by a loss of 
sympathetic nerve fibers when compared to OA patients. This differential profile has been also 
described in a comparative study showing lack of sympathetic innervation in RA patients while 
in OA patients this does not occur [52]. The authors suggested that the reduction or absence 
of sympathetic innervation might be a consequence of the initial synovial inflammation, 
probably involving nerve repellent molecules [53], and a key factor to its maintenance in RA. 
In AL, a sustained chronic inflammatory response is maintained by the presence of prosthetic 
debris, primarily generated at the bearing surface of hip prostheses. Therefore, our findings, 
supported by those described in RA, strongly indicate a close correlation between sympathetic 
innervation pattern and the degree of the inflammatory response. A previous study described 
the appearance of TH+ cells in the collagen-induced arthritis in mice and hypothesized that the 
presence of those cells might be a compensatory mechanism to the deprivation of sympathetic 
neurotransmitters in the joint [54]. In AL patients, TH+ catecholamine-producing cells were not 
detected in the synovial membrane-like interface, suggesting total uncoupling of local joint 
inflammation from the sympathetic activity (nerve fibers and cells).  
Several animal and human studies have addressed the pattern of the sensory 
innervation in arthritis, namely in OA, and reported a significant re-organization of the sensory 
nerve fibers characterized by an alteration in the morphology, density and sprouting into areas 
of the joint that are normally poorly innervated [21]. In this study, we showed that there is also 
alteration in the sensorial innervation of synovial membrane-like interface tissues in AL patients 
with a notable distinct tissue distribution when compared to OA. Substance P and CGRP 
immunoreactive nerve fibers were observed in subintima regions (outer layer) mainly around 
blood vessels while in AL they were distributed throughout synovial membrane-like interface 
tissues. Of note, Substance P+ and CGRP+ cells were also found in these tissues as an 
additional source of these neuropeptides. Although, Substance P and CGRP are recognized 
as neuro-inflammatory modulators in arthritic joints, their functional role in the inflammatory 
response associated to prosthetic debris as well as in the reorganization of sensory and 
sympathetic nerve fibers in inflamed joint need to be clarified. 
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We acknowledge certain limitations in this study. To study the differences between AL 
and OA, thirty-five patients were included in our study, an average number in the field [40]. OA 
synovial tissues and synovial membrane-like interface tissues were retrieved by the same 
surgeon to minimize location bias. The histological semi-quantification of accumulation of 
prosthetic debris in aseptic interface tissues was limited to micro-sized particles, or clusters of 
nanoparticles, although tissues have been previously evaluated by SEM. Gene expression 
analysis was successfully performed in eleven out of twenty AL patients due to low RNA 
quality. Patients’ stratification concerning implant fixation and metallosis (AL group) or disease 
severity (OA group) was performed but no significant effect was identified. On the other hand, 
the interpretation of the variability between patients may not be just influenced by a specific 
biological response in joint region but by other factors such as patient’s comorbidities (e.g. 
diabetes mellitus and dyslipidemia), geriatric condition, or genetic susceptibility to AL [16; 55]. 
  
Chapter II – Immune response and innervation signatures in aseptic hip implant loosening 
 131 
Conclusions 
 
Overall this study showed that AL and OA are two joint pathologies characterized by 
local immune response however with distinct tissue organization and immune cell distribution. 
This differential immune profile is also accompanied with changes of sensory and sympathetic 
innervation in hip joint. These findings highlight that the interplay between inflammation and 
innervation may be joint pathology-specific. Therefore, a deeper and conjoint understanding 
of these processes will constitute a solid base for targeted-therapies to improve hip joint 
lifetime and treatment. 
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Figure S1 - Histological grading applied in semi-quantification of OA synovial tissues inflammation and tissue fibrosis, 
necrosis, innervation (NF200) and TGF-β1 in tissues collected from OA and AL patients. 
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Figure S2 - Histological grading applied in semi-quantification regarding the accumulation of prosthetic debris in 
synovial membrane-like interface tissues. 
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Figure S3 - Histological grading applied in semi-quantification of immune cells prevalence and distribution in tissues 
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Abstract 
 
The hypothesis behind this work is that fibrinogen (Fg), classically considered a pro-
inflammatory protein, can promote bone repair/regeneration. Injury and biomaterial 
implantation naturally lead to an inflammatory response, which should be under control, but 
not necessarily minimized. Herein, porous scaffolds entirely constituted of Fg (Fg-3D) were 
implanted in a femoral rat bone defect and investigated at two important time points, 
addressing the bone regenerative process and the local and systemic immune responses, both 
crucial to elucidate the mechanisms of tissue remodelling. Fg-3D led to early infiltration of 
granulation tissue (6 days post-implantation), followed by bone defect closure, including 
periosteum repair (8 weeks post-injury). In the acute inflammatory phase (6 days) local gene 
expression analysis revealed significant increases of pro-inflammatory cytokines IL-6 and IL-
8, when compared with non-operated animals. This correlated with modified proportions of 
systemic immune cell populations, namely increased T cells and decreased B, NK and NKT 
lymphocytes and myeloid cell, including the Mac-1+ (CD18+/CD11b+) subpopulation. At 8 
weeks, Fg-3D led to decreased plasma levels of IL-1b and increased TGF-b1. Thus, our data 
supports the hypothesis, establishing a link between bone repair induced by Fg-3D and the 
immune response. In this sense, Fg-3D scaffolds may be considered immunomodulatory 
biomaterials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: fibrinogen, in vivo, bone repair/regeneration, inflammation, biomaterial 
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Introduction 
 
Upon injury and/or biomaterial implantation there is an inflammatory response, which is 
required for the regenerative process to begin. This inflammatory response to implantable, and 
particularly non-degradable biomaterials, can culminate in a foreign body reaction, which is 
related with the failure to establish a pro-regenerative environment [1]. First generations of 
materials applied in clinics aimed at restoration of the physical properties of the damaged 
tissues, while minimizing or even avoiding the immune response. Most of the currently used 
dental and orthopaedic implants are examples of biomaterials that still follow that strategy [2]. 
However, in terms of biomedical research the paradigm is shifting from “fighting inflammation” 
to “modulating inflammation” [3]. 
Inflammation, repair and remodelling are the three stages that compose bone healing 
[4]. First, a blood clot forms after bone injury, which provides a temporary matrix for immune 
cell recruitment to the injury site. Polymorphonuclear leukocytes (PMN) quickly migrate to bone 
injury and interact with damaged tissue during the first 24 hours. Monocytes/Macrophages and 
lymphocytes (NK, T and B cells) are attracted to the injury in the next days [5]. Although acute 
inflammation is described as lasting 4 days and the chronic inflammation to be over in about 2 
weeks, immune cells have an active role throughout bone repair and remodelling [4; 5]. In fact, 
the balance between cytokines, chemokines and immune cell populations in the injury 
microenvironment is essential for tissue regeneration. This can be impaired by infection or 
chronic inflammatory conditions, such as autoimmune diseases and the foreign body response 
against a biomaterial, and when inflammation does not resolve and tissue healing is impaired 
[4; 6]. In agreement, previous work has shown that successful osteointegration of implants 
correlates with systemic changes in immune cells [7]. 
Fibrinogen (Fg) is a blood protein involved in blood clotting. During haemorrhage, a fibrin 
clot is formed from Fg cleaved by thrombin, which prevents extensive blood loss. The Fg-
derived clot is the primordial extracellular matrix (ECM) that supports tissue regeneration, thus 
providing Fg with pro-healing properties [8; 9]. Two arginine-glycine-aspartate (RGD) motifs 
were identified in Fg structure [10], which are related with improved cell adhesion to Fg-
modified materials [11]. Additionally, Mac-1, an important receptor of activated immune cells, 
finds numerous binding sites on the Fg molecule [12]. Also, vascular endothelial growth factor 
(VEGF), an important factor for neovascularization, binds Fg with high affinity [13], what may 
explain the improved angiogenesis induced by Fg [7; 14]. 
Clinically, fibrinogen is applied together with thrombin as fibrin hydrogels that are used 
as biological adhesives [15]. Beyond their well-known haemostatic and sealant properties, 
alternative applications in tissue engineering have been tested, combining fibrin with ceramics, 
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cells or other proteins [16-20]. Although the use of thrombin is a standard in fibrin sealants, it 
increases the risk of thrombosis and life-threatening complications. 
The strategy of Fg delivery appears to be of paramount importance to the host response. 
Soluble Fg does not enhance wound healing [11], instead elicits autoimmunity and nervous 
tissue damage [21]. The pro-regenerative potential of Fg-incorporating biomaterials has been 
previously reported by us [7] and others [22]. We have explored the potential of adsorbed Fg 
to modulate immune cell responses and induce regeneration. Materials modified with Fg led 
to increased recruitment of mesenchymal stem/stromal cells (MSC) mediated by different 
immune cells [23], downregulation of pro-inflammatory molecules and up-regulation of bone 
and angiogenic factors secreted by macrophages [24]. The degradation of chitosan films by 
osteoclasts was also accelerated by Fg adsorption [25]. Most importantly, our previous work 
showed that implantation of Fg-modified chitosan scaffolds in a femoral critical bone defect led 
to increased angiogenesis and new bone formation at the defect periphery, together with 
significant changes in myeloid and B cell populations in the draining lymph nodes [7]. 
Due to the potential revealed by Fg-modified materials [7; 23; 24], whole-Fg scaffolds 
(Fg-3D) were here produced to assess the hypothesis that, when stabilized in a 3D porous 
structure, Fg can promote a pro-regenerative microenvironment, mimicking the blood clot. Fg-
3D scaffolds were produced by freeze drying, without addition of any exogenous enzymatic 
compound, and their capacity to stimulate bone repair was addressed. For that, Fg-3D were 
extensively characterized by SEM, ATR-FTIR and NMR, their degradation profile, cytotoxicity 
and endotoxin levels were assessed, following the international standard ISO 10993-5:2009. 
Fg-3D scaffolds were then implanted in a load-bearing bone defect in the rat femur. Local and 
systemic immune responses were analysed at two critical time points post-implantation, 6 days 
and 8 weeks. A combination of flow cytometry and ELISA was used to investigate the systemic 
response, while qRT-PCR complemented the histological analysis of the local response. Bone 
repair was also more closely evaluated by micro-CT. By assessing the early and long-term 
biological response we aim at understanding the impact of Fg-3D on the inflammatory 
response and subsequent influence on bone tissue repair (Figure 1). 
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Figure 1. Biomimetic Fg scaffolds (Fg-3D) for immunomodulation and bone repair. Fg-3D were produced by freeze-drying 
without the use of thrombin and implanted in a femoral bone defect. The biological response induced by Fg-3D scaffolds was 
evaluated at local and systemic levels. At 6 days post-implantation, the biomaterial promoted a pro-regenerative microenvironment 
with granulation tissue infiltration and changes in the proportions of immune cell populations in spleen, draining lymph nodes and 
blood. Interestingly, bone defect, including periosteum, was repaired in the animals with Fg-3D, 8 weeks upon injury. 
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Materials and methods 
 
Preparation of Fg-3D Scaffolds 
 
Fibrinogen 3D scaffolds (Fg-3D) were prepared by freeze-drying, similarly to chitosan 
scaffolds previously prepared by our group [7]. A solution of human Fg (fraction I, type III from 
human plasma; cat. F4129, Sigma), 70 mg/mL, was prepared in Phosphate Buffered Saline 
Solution (PBS) at neutral pH (7.4). The solution was then casted into 48-well plate (800 μl/well), 
frozen overnight at -20ºC in a horizontal surface and freeze-dried at -80°C for 48 h to produce 
scaffolds. These were removed from the plate and cut in the shape of cylinders with 4 mm 
diameter and 5 mm height. Scaffolds were neutralized and disinfected through impregnation 
under vacuum in a gradient of ethanol solutions (99.9%, for 10 min, 70% for 30 min, 50% and 
25% for 10 min each), followed by three 10 min washes in sterile PBS. Fg-3D scaffolds were 
maintained overnight in sterile PBS at 4°C protected from light, before further analysis or 
implantation.  
 
Scanning Electron Microscopy Characterization 
 
Cross-sections of 1 mm thickness were cut and mounted with carbon tape, for scanning 
electron microscopy (SEM) analysis. Samples were sputter-coated with gold and observed 
with a JEOL JSM-6301F SEM, at 15 kV and magnifications of 30x or 250x. Twenty-five pores 
and interconnecting pores were measured in a representative scaffold to determine the range 
of pore sizes. 
 
ATR-FTIR Spectroscopy 
 
Previously to FTIR analysis, all samples were dried in a vacuum chamber overnight at 
room temperature. ATR-FTIR spectra of Fg powder, lyophilized Fg scaffolds and after ethanol 
neutralization (Fg-3D) were obtained using a FTIR spectrophotometer (SpectrumTwo, Perkin 
Elmer). All samples were submitted to the same pressure and 16 scans were collected with 4 
cm−1 resolution. Peak analysis was performed through spectra analysis and evaluation of first 
and second derivatives. 
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NMR Analysis 
 
The 13C NMR spectra were recorded using a Bruker Avance III (9.4 T) spectrometer 
operating at 400 MHz for proton and a 4-mm double-bearing magic-angle spinning (MAS) 
probe. For the 13C cross-polarization and MAS (CP-MAS) NMR experiments, we used 90° 
pulse lengths of 3–5 µs, a 2 ms contact time, a 5 s recycle delay and a spinning rate of 12 kHz. 
For the 13C Single Pulse Excitation (SPE) spectra, 90º pulse lengths of 4-5 µs, a 20s recycle 
delay and a spinning rate of 12 kHz were employed. 
 
Measuring Endotoxin Levels 
 
Extracts were prepared from 35mg of Fg-3D scaffolds in 1.4 ml of endotoxin-free water 
(40 mL per g of material) by continuous shaking (250 rpm) at 50 ºC for 24 h. Endotoxin levels 
were assessed using the Food and Drug Administration (FDA, USA) approved EndosafeTM-
PTS system (Charles River, USA). The analysis was performed and certified by an external 
entity (Analytical Services Unit, IBET/ITQB, Oeiras, Portugal). Extracts from Fg-3D scaffolds 
revealed endotoxin levels of 0.132 EU/mL (EU: unit of measurement for endotoxin activity), 
which are far below the recommended FDA limit (0.500 EU/mL). 
 
Degradation assay 
 
Fg-3D were incubated at 37ºC with distilled water or heat-inactivated fetal bovine serum 
(FBS) to evaluate hydrolysis and proteolysis at 0.1 mg of scaffold to 1 mL of fluid according to 
ISO 10993-5:2009 standard. Supernatants were discarded after 6, 24, 48 and 100 h of 
incubation and remaining scaffolds were freeze-dried and weighted. 
 
Evaluation of cytotoxicity 
 
The cytotoxicity of Fg-3D was assessed using the MC3T3 cell line according to the 
guidelines presented in ISO 10993-5:2009 standard. In detail, MC3T3 cells were seeded in a 
96-well plate at a final density of 10,000 cells per well in supplemented minimum essential 
medium eagle-alpha modification (α-MEM, with 10% v/v FBS and 1% v/v 
penicillin/streptomycin) and allowed to adhere for 24 h at 37ºC. Afterwards, the medium was 
removed and the experimental conditions were set: control (only basal medium), direct contact 
(in presence of Fg-3D) and four conditions using 100, 75, 50 and 25% of Fg extract 
complemented with α-MEM without FBS. Extracts were produced by incubating Fg-3D in α-
Chapter III – Fibrinogen scaffolds with immunomodulatory properties promote in vivo bone regeneration 
 154 
MEM at 100 mg/mL under agitation (100 rpm), for 24 h at 37 ºC. After 24 h the medium and 
the scaffolds were removed and 300 μL of 10% resazurin solution in basal medium was added. 
Supernatants were transferred to a black 96-well plate 3 hours after incubation at 37 ºC and 
fluorescence was read (excitation λ=530 nm, emission λ=590 nm). Experiments were done in 
triplicate and data were normalized by the control. Conditions that lead to a percentage of 
metabolic activity bellow 70% of the control were considered cytotoxic. 
 
Animal Model 
 
All animal experiments were conducted following protocols approved by the Ethics 
Committee of the Portuguese Official Authority on Animal Welfare and Experimentation (DGV). 
We have used a critical size bone defect model, adapted from the study of Le Guehennec L et 
al [26], and previously used by our team [7]. Briefly, three months old male Wistar rats (n=17 
per group, 12 for analysis after 6 days, and 5 after 8 weeks) were operated under general 
anaesthesia performed by inhalation of isoflurane. The knees were shaved and disinfected. 
An incision was made in the skin, and both skin and muscle were retracted. After lateral knee 
arthrotomy, a cylindrical defect with 3 mm diameter and depth of approximately 4 mm was 
created using a surgical drill in the anterior wall of the lateral condyle of the right femur. Animal 
care and analgesics (subcutaneous injection of Buprex-buprenorphine, 0.05mg/kg) were 
provided during post-surgery. Surgery was performed in only one femur per animal and defects 
either received Fg-3D or remained empty. Non-operated animals were used as control.  
 
Blood, Spleen and Lymph Nodes Collection 
 
The number and type of biological samples collected at 6 days and 8 weeks post-implantation 
as well as the methods applied in their analysis are summarized in Figure S1. Twelve animals 
per group were sacrificed 6 days post-injury while five were euthanized at 8 weeks. 
Unfortunately, three animals from the empty group at 6 days were excluded from the analysis, 
two due to infection and one due to non-standard defect size. For tissue collection and 
euthanasia, animals were anesthetized and kept under general anaesthesia by inhalation of 
isoflurane. Blood was collected by intracardiac puncture and placed in a tube containing 
heparin solution (B.Braun) at a 1:10 dilution, to avoid blood coagulation. Animals were then 
dissected and the spleen, as well as the inguinal and popliteal lymph nodes on the side of 
injury, were collected into a tube with 2mL of RPMI supplemented with 10% FBS to maintain 
cell viability until processing.  
Bone Collection 
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Immediately after organs collection, the muscle tissue around the defect region was 
carefully removed and femurs were retrieved. At 6 days, 7 out of 12 femurs per group were 
prepared for gene expression analysis. Briefly, the femur to be analysed was placed in a Teflon 
holder and a cylindrical sample including the bone defect with or without Fg-3D and peripheral 
bone tissue was cut using a 5 mm diameter driller. Bone cylinders were transferred to 1.5 mL 
tubes and gently swirled in liquid nitrogen until completely frozen. Samples were maintained 
at -80ºC until RNA extraction. The remaining five femurs were collected for histological 
analysis at day 6 and 8 weeks upon injury. 
 
Bone Histological Analysis 
 
Femurs were retrieved, fixed, decalcified, dehydrated and defatted before embedding in 
paraffin, as previously described [7; 27; 28], in five animals per group.  Sagittal tissue sections, 
3 μm thick, were mounted on pre-coated poly-L-lysine glass slides and dried overnight at 37ºC. 
Prior to the different staining procedures, the sections were first deparaffinized in xylol (3 x 5 
min) and rehydrated through a decreasing ethanol series (2 x 100% ethanol, 96% ethanol, 
70% ethanol, 50% ethanol, distilled water, 3 min each). Contiguous sections were stained with 
haematoxylin & eosin (H&E) and Masson’s trichrome (MT) at three depths, and analysed using 
a light microscope Olympus CX31 for both studied time-points. Images were acquired with 
Olympus DP 25 camera, using the Cell B software.  
The inflammatory response was evaluated at day 6, namely the presence of PMN and 
the infiltration of granulation tissue in the vicinity of the bone defect. Tartrate resistant acid 
phosphatase (TRAP) assay (Sigma–Aldrich) was performed according to the manufacturer’s 
instructions. After rehydration, slices were immersed in a staining solution containing water, 
acetate, naphthol and one capsule of fast garnet GBC salt for 1 h at 37 °C in the dark, and 
counterstained with acid haematoxylin solution. For alkaline phosphatase (ALP) staining slices 
were incubated in a Naphtol AS-MX phosphate solution containing the Fast Violet B salt (both 
from Sigma) for 30 min at 37 ºC. 
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Micro-Computed Tomography (micro-CT) 
 
New bone formation was evaluated 8 weeks post-injury using a high-resolution micro-
CT Sky-Scan 1072 (Skyscan, Belgium) at 3B’s Services and Consulting (Caldas das Taipas, 
Portugal). Images were acquired using a pixel size of 17.58 µm and an exposure time of 8550 
ms. The X-ray source was set at 80 kV and 104 μA. Approximately 400 projections were 
acquired over a rotation range of 180°, with a rotation step of 0.45°. Datasets were 
reconstructed using standardized cone-beam reconstruction software NRecon® and CTvox® 
software (SkyScan, Belgium). The amount of calcified tissue was quantified in cylindrical 
volume of interest (VOI) with 3 mm in diameter and 114 slices in deepness (2 mm). The VOI 
was centred with the defect region (Figure S2), and bone parameters were quantified using 
CTan® software (Skyscan, Belgium). Threshold was set at 70 to define calcified tissue. The 
mean grayscale within the VOI was determined to evaluate bone density. Changes in bone 
architecture were assessed in the VOI by 3D analysis of bone volume/tissue volume (BV/TV), 
trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp). 
Parameters are shown following ASBMR nomenclature [29]. 
 
Local qRT-PCR Analysis 
 
Local gene expression of pro-inflammatory cytokines and growth factors at the 
defect/implant site was analysed in 7 animals for each condition 6 days upon injury. N2 shock-
frozen bone cylinders were pulverized using a micro-dismembrator (B Braun Biotech, 
Germany) at 3000 rpm for 2 min and total RNA was extracted using Mirvana RNA extraction 
kit (Invitrogen) immediately after. RNA was quantified by Nanodrop ND-1000 (Thermo Fisher 
Scientific). cDNA was obtained from 1 µg of total RNA with oligo(dT) primers (Qiagen) using 
Superscript II kit (Invitrogen) according to manufacturer instructions. All used primers, listed in 
Supplementary Table 1, were designed using Primer 3 software to be inter-exonic and were 
obtained from Eurofins Genomics (Ebersberg, Germany). Primer pairs for IL-1β, IL-2, IL-6, IL-
8 (MIP-2), IL-10, OC, TNF-α and VEGF evaluation were designed and used previously [18]. 
Quantitative real time PCR (qRT-PCR) reactions containing 12.5 μL of SYBR Green PCR 
Mastermix (Thermo), 2 μL of 5 times diluted cDNA template, 0.5 μL of forward and reverse 
primers (100 pmol/µL) and 9.5 μL of RNAse free water were carried out on a LightCycler 96 
(Roche). The reactions were pre-incubated for 10 min at 95 ºC, followed by 40 thermal cycles 
of amplification (95 ºC for 15 s; 58 ºC for 10 s; 72 ºC for 30 s), ending with a melting cycle 95 
ºC for 30 s; 58 ºC for 60 s; 95 ºC for 1 s. Relative gene expression was calculated using the 2-
ΔCt method and normalized using GAPDH as reference gene. 
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Tissue Processing and Flow Cytometry 
 
Peripheral blood mononuclear cells were isolated from blood by density centrifugation 
over Lymphoprep (Axis-Shield) at 800g, for 30 min without brake, at room temperature. Plasma 
was collected, spun to remove cell debris and kept at -80ºC until further analysis. Cells were 
collected from the interface between plasma and Lymphoprep and washed twice with PBS. 
Lymph node cells were obtained by placing lymph nodes on top of a 100 µm pore cell strainer 
and gently crushing with the end of a syringe piston. The strainer was then washed with PBS. 
To collect cells from the spleen, half of this organ was injected with 100 U/ml Collagenase I 
(Sigma) and gently crushed with the top of a syringe piston on the top of a 100 μm pore cell 
strainer. The strainer was then washed with PBS and red blood cells (RBC) were lysed with 
RBC lysis buffer (10 mM Tris, 150 mM NH4Cl, pH 7.4) for 8 min at 37ºC. The cells obtained 
from each tissue were washed with PBS and transferred to 96-well U-bottom plates. Cells were 
incubated for 5 min on ice with 1 µl per sample of Mouse Anti-Rat CD32 (FcγII Receptor) 
Monoclonal Antibody (BD), diluted in PBS, 0.5% BSA, 0.01% sodium azide, to prevent 
unspecific binding to Fc receptors. Cell surface staining for flow cytometry was then performed 
by incubating for 30 min on ice with the following antibodies diluted in PBS, 0.5% BSA, 0.01% 
sodium azide: anti-rat CD45R-PE (clone HIS24, 4 μg/mL), anti-rat TCR-PerCP (clone R73, 2 
μg/mL), anti-rat CD4-APC (clone OX35, 2μg/mL), anti-rat CD4-V450 (clone OX-35, 4 μg/mL), 
anti-rat CD8-V450 (clone OX-8, 4 μg/mL), anti-rat CD18-FITC (clone WT.3, 2 μg/mL), anti-rat 
CD161a-FITC (clone 10/78, 2 μg/mL), anti-rat MHC class II-AlexaFluor 647 (clone OX-6, 2 
μg/mL) and anti-rat CD11b/c-PE-Cy7 (clone OX-42, 4 μg/mL), all from BD. Cells were also 
stained with the corresponding isotype controls. Samples were then washed 4 times in PBS, 
followed by fixation in paraformaldehyde 4%, 20 min on ice, and washed twice with PBS. 
Samples were acquired on a Flow Cytometer (FACSCanto, Becton Dickinson) and data was 
analysed with FlowJo software. Only samples resulting in more than 10,000 gated events were 
considered for further analysis. 
 
Cytokine Production 
 
For cytokine evaluation, plasma from each animal was assayed by ELISA specific for 
TNF-α, IL-6, IL-17A and TGF-β1 (Legend Max Rat ELISA kits, BioLegend, CA, USA) and IL-
1β ( Rat IL-1β Mini ABTS ELISA Development Kit, Peprotech, NJ, USA) according to the 
manufacturer’s protocol. Cytokine concentration was calculated against a standard curve. 
  
Chapter III – Fibrinogen scaffolds with immunomodulatory properties promote in vivo bone regeneration 
 158 
Statistical Analysis 
 
Statistical analysis was performed using Prism software. Visual histogram analysis and 
Kolmogorov-Smirnov test were used to evaluate the normal distribution of the studied variables 
(all continuous). To compare data from two different groups, Mann-Whitney U test (or its 
parametric counterpart Student’s t-test) were used. When comparing three different groups, 
Kruskal-Wallis followed by Dunn’s Multiple Comparison test (or their parametric counterpart 
ANOVA) were used. Statistical significance was considered for p<0.05 (*) (**: p<0.01, ***: 
p<0.001).  
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Results 
 
To test our hypothesis that fibrinogen (Fg) can promote bone repair/regeneration when 
stabilized as a 3D structure, Fg-3D scaffolds were produced, characterized and implanted in 
a rat femoral defect. Bone regeneration/repair was evaluated at 6 days (acute phase of 
inflammation) and 8 weeks (repair of bone defect) post-injury, together with the local and 
systemic immune responses.  
 
Production and characterization of Fg-3D scaffolds 
 
Fg scaffolds were produced using freeze-drying methodologies, as previously described 
for other materials [7]. The influence of the major steps involved in the preparation of Fg-3D 
(lyophilization and ethanol neutralization) on the protein structure was characterized by ATR-
FTIR spectroscopy and solid state 13C NMR spectroscopy (Figure 2).  
Fg secondary structures are known to comprise segments in α-helix, β-sheet, β-turn and 
random coils, which can be evaluated through the IR spectra fingerprint region (1800-1000 
cm-1), namely the Amide I (1700-1600 cm-1) and Amide II (1600-1500 cm-1) band regions [30; 
31]. ATR-FTIR analysis of Fg powder showed bands at 1644 cm-1 (random coil), 1548 cm-1 (α-
helix), 1532 cm-1 (β-sheet), 1516 cm-1 (tyrosine side chains), 1398 cm-1 (COO- symmetric 
stretching band and/or the deformation of CH2 and CH3) and 1078 cm-1 (C-O stretching modes 
of glycoprotein in the Fg structure) (Figure 2A). Lyophilized Fg scaffold presented a relative 
increase of the peak at 1591 cm-1 (compression carboxylate side chains of amino acids) and 
at 1610 cm-1 (β-sheet aggregates structure) together with changes in 1235-1270 band region, 
which are related with the C-N stretching in Amide III region. The spectrum obtained for the 
neutralized Fg scaffold (Fg-3D) was broadly similar to that obtained for Fg powder. Moreover, 
the hydration water of Fg was not modified by the production of Fg-3D, as no significant 
changes of the ratios between Amides and hydrogen bonds (Amide I/3280 cm-1 and Amide 
II/3280 cm-1 ratios) were observed. Remarkably, a relevant decrease of intensity of peaks at 
1398 cm-1 and 1591 cm-1 were registered in Fg-3D.  
Human Fg is a dimeric glycoprotein composed of three pairs of peptide chains, where 
all 20 amino acids are present, and the corresponding 13C CP-MAS spectrum showed a typical 
protein profile (Figure 2B). Some spectral changes were noted between lyophilized Fg 
scaffolds and Fg-3D. Upon scaffold neutralization, the 13C CP-MAS spectrum revealed a profile 
with increased resolution, indicating that there is increased molecular organization in the rigid 
domains of the protein for Fg-3D. Concomitantly, the 13C SPE spectrum also showed better 
resolved resonances in the neutralized Fg samples, which points towards increased molecular 
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mobility of the more mobile protein domains. Moreover, a peak clearly observed at 76 ppm in 
the CP-MAS spectrum of the lyophilized Fg scaffolds, was no longer observed upon 
neutralization. 
 
 
Figure 2. ATR-FTIR and solid-state 13C NMR spectra of Fg at critical stages of scaffolds preparation. (A) Representative 
ATR-FTIR spectra of Fg powder (blue), lyophilized Fg (red) and ethanol-neutralized Fg (Fg-3D; green) with the most relevant 
peaks identified and the Amide I and II band regions details presenting first derivate of IR spectra to clarify the determination of 
the wavenumbers of the peaks. (B) 13C solid-state NMR analysis of Fg scaffolds: 13C CP-MAS (top) and SPE (bottom) spectra.  
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Fg-3D scaffolds have interconnected porosity, are degradable and non-cytotoxic 
 
To determine their structure and porosity, Fg-3D scaffolds were observed using scanning 
electron microscopy (SEM), and after haematoxylin-eosin (H&E) staining by light microscopy 
(Figure S3). Overall, Fg scaffolds presented a uniform porous network with macroporosity 
ranging from 104 to 165 μm in diameter and interconnecting micropores varying in diameter 
between 17 and 57 μm (Figure 3 A and B). 
Then, the susceptibility of Fg-3D to hydrolysis and proteolysis was evaluated through 
incubation at 37ºC for up to 4 days in water and in serum (FBS) (Figure 3C). Fg-3D showed a 
fast degradation rate in water (82% of mass loss at 100 h), most of it during the first 6 h (54% 
of mass loss). In FBS, Fg-3D degraded less (42% of mass loss at 100 h) but exhibited a similar 
degradation rate during the first 6 h (40% of mass loss) to the one observed in water. 
The cytotoxicity of Fg-3D was evaluated following the recommendations in the 
ISO10993-5 standard. It was estimated by quantifying the metabolic activity of MC3T3 (murine 
pre-osteoblasts) cells after 24 h in culture with scaffolds (direct contact) or with extracts of Fg-
3D, and expressing the results as a percentage relative to tissue culture plastic control 
conditions. Higher concentrations of Fg-3D extracts (75% and 100%) seemed to cause stress 
to the cells, but the loss of metabolic activity was less than 30% (Figure 3D). Moreover, cells 
in direct contact with a scaffold or in media containing 25% or 50% extracts presented a small 
increase (up to 18%) in their metabolic activity after 24 h of incubation. 
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Figure 3. Structure, degradability and cytotoxicity of Fg 3D scaffolds. (A) Macroscopic view of Fg 3D scaffolds (Fg-3D) (B) 
Evaluation of the porous structure of Fg-3D by SEM analysis: general view of Fg-3D showing their porous interconnected structure 
(left) and high magnification image where large pores (104-165 μm in diameter) and interconnecting pores (17-57 μm in diameter) 
were visible (right). (C) Degradation profiles of Fg-3D during 100 h of incubation in water or serum (FBS). Results presented in 
percentage of remaining weight according to original weight. (D) Metabolic activity of the cell line MC3T3 incubated with Fg 
scaffolds (Fg-3D) or extracts. Error bars represent the standard deviation (n=3/condition). Kruskal-Wallis test was used to compare 
the data.   
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Fg-3D stimulated bone repair/regeneration  
 
The osteogenic potential of Fg-3D was tested in vivo using a critical bone defect model 
in the rat (Figure 4A). The follow up, was performed 6 days and 8 weeks post-implantation. A 
favourable evolution of the repair process was observed in presence of Fg-3D (Figure 4B). At 
6 days post-injury Fg-3D led to an increased number of cells related with granulation tissue 
(GT) infiltration in the centre of the defect, while few cells and no granulation tissue were 
detected in the animals where no biomaterial was implanted (empty). The images reveal that 
acute immune response had already subsided, as PMN were hardly detected in either group. 
Furthermore, Fg-3D appear well-preserved and in intimate contact with surrounding bone, 
without visible fibrous capsule. After 8 weeks of implantation new bone tissue had formed filling 
in the defects and Fg-3D were no longer observable. Moreover, no chronic immune reaction 
was detectable. Residual granulation tissue was still identifiable in four out of five animals 
implanted with Fg-3D, particularly closer to the surface of the defect, and surrounded by newly 
formed bone tissue and bone marrow. The newly formed bone was mostly woven bone, 
presenting a disorganized structure and enriched in collagen (blue stained fibres). Mature bone 
was also observed, with a distinctive trabecular organization, oriented along the lines of stress. 
The new trabecular bone formed in the defect region was functional, since bone mineralization 
regions, with ALP activity, and bone resorption pits with osteoclasts (TRAP positive cells; 
Figure 4C) were observed, indicating that bone was going through remodelling. Bone 
remodelling is a dynamic process, requiring coupling between bone apposition and resorption 
processes, and Fg-3D seems to control the initial immune response to injury, while supporting 
bone repair/regeneration. 
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Figure 4. Histological evaluation of bone repair upon Fg-3D scaffolds implantation. (A) Photographs of a bone defect left 
empty and implanted with Fg-3D (black arrow). (B) Histological images of Masson’s trichrome stained slices of 6 days empty (left 
column) and Fg-3D filled (middle column) defects; and 8 weeks Fg-3D implanted (right column) defects. Arrowheads point to 
PMN. (C) Histological view of bone remodelling in progress at 8 weeks with tartrate resistant acid phosphatase (TRAP) positive 
cells (arrowheads, left image) and alkaline phosphatase (ALP) positive regions (asterisk, right image). B indicates the bone tissue, 
BD the bone defect area, GT the infiltrating granulation tissue, BM is the bone marrow, NB notes new bone, while WB corresponds 
to woven and MB to mature bone.  
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In order to further confirm the new bone formation observed by histological analysis, we 
performed micro-CT analysis. This corroborated the induction of new bone formation and 
additionally revealed periosteal repair in femurs implanted with Fg-3D, at 8 weeks post-injury 
(Figure 5A). In detail, the quantification of calcified tissue in the original defect region (dashed 
line) revealed that two out of three animals of the Fg group showed higher bone density and 
bone volume than animals with empty defects (Figure 5B and C). Moreover, all injured animals 
showed higher trabecular bone separation (Tb.Sp) and trabecular number (Tb.N), when 
compared to the non-operated animal (Figure 5D and E). Importantly, Fg-3D-treated animals 
showed a tendency to present a higher trabecular bone thickness (Tb.Th) compared to empty 
animals (p=0.1, Figure 5F), which is likely related to the bone remodelling that is still occurring 
8 weeks post-injury. Together, histological analysis and micro-CT evaluation showed that Fg-
3D supported bone repair with formation of new and thicker bone trabeculae, which contributed 
to the closure of the bone defects. 
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Figure 5. Evaluation of bone regeneration at defect region 8 weeks post-implantation. (A) X-ray images and 3D reconstruction of 
non-operated (n=1), versus injured femurs, left empty (n=3) or implanted with Fg-3D (n=3): sagittal plane X-ray images indicating 
the centre of the original defect that is pointed at the intersection of green and red lines (top row) and 3D reconstruction of femurs 
indicating the cylindrical volume of interest (dashed line) with 3 mm in diameter (Ø) and 2 mm in deepness (bottom row), where 
the following parameters related to bone architecture were quantified. (B) mean grayscale in a pixel intensity scale from 0 to 255. 
(C) percentage of bone volume (BV) relative to total tissue volume (TV). (D) trabecular bone separation (Tb.Sp) in mm. (E) 
trabecular bone number (Tb.N). (F) trabecular bone thickness (Tb.Th) in mm. Data is presented as dot plots, with the mean as a 
horizontal line and standard deviation as whiskers. Mann Whitney test was used to compare the data.  
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Fg-3D modulates cytokine production  
 
In order to understand the mechanisms involved in stimulation of bone 
repair/regeneration induced by Fg-3D, the expression levels of inflammatory and pro-
regenerative related genes at the bone defect site were evaluated 6 days after injury. 
Bone/implant cylinders were cut to include the bone defect with the implant and some of the 
surrounding tissue and then analysed for gene expression. Regarding inflammatory cytokines, 
a significant up-regulation of both IL-6 and IL-8 (p<0.05), but not of IL-1β, was observed for 
both empty defects and Fg-3D, in comparison with non-operated animals (NO; Figure 6 A-C). 
Other cytokines that could be involved in regulation of an immune response, IL-2, IL-4, IL-10, 
TNF-α and IFN-γ, were not detected. Gene expression of growth factors involved in 
angiogenesis and bone remodelling was also analysed. Similar levels of osteocalcin (OC) were 
observed for all tested groups (Figure 6D). A tendency for transforming growth factor beta 1 
(TGF-β1) up-regulation in operated animals was registered, though not statistically significant 
(Figure 6E). On the other hand, VEGF was up-regulated in operated rats whose defect 
remained empty comparatively to NO animals (p<0.01; Figure 6F), but there were no 
statistically significant differences to the Fg-3D group. This difference in the extent of reactive 
angiogenesis, that is part of the response to injury, may be explained by the stronger 
inflammatory response in empty animals, that is dampened in Fg-3D implanted animals. 
The systemic concentration of TNF-α, IL-1β, IL-17a, IL-6 and TGF-β1 was evaluated in 
the plasma, since they are crucial mediators of immune responses and regenerative 
processes. No detectable levels of TNF-α, IL-17a and IL-6 were found in plasma for any of the 
animals. Systemic levels of IL-1β (Figure 6G) were significantly decreased for the Fg-3D group 
at 8 weeks post-implantation, when compared to Fg-3D at 6 days and with a strong tendency 
to be decreased, when compared to the Empty at 8 weeks (p=0,0521) and the NO (p=0,0600) 
groups. Also, systemic levels of TGF-β1 (Figure 6H) were significantly higher for empty-defect 
animals at 6 days post-injury and for Fg-3D animals at 8 weeks post-implantation, both when 
compared with NO animals. The time-dependent modulation of TGF- β1 production is likely 
involved in the wound healing processes, and its sustained increase up to 8 weeks in the 
animals implanted with Fg-3D may contribute to the regenerative response observed.  
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Figure 6. Cytokine levels upon Fg-3D implantation. Local relative mRNA expression levels, normalized by GAPDH expression, 
were determined for non-operated (NO) animals (n=7), animals with empty defects (Empty; n=6) and Fg-3D implanted animals 
(n=7) for the following targets: (A) IL-1β, (B) IL-6, (C) IL-8, (D) osteocalcin (OC), (E) transforming growth factor beta 1 (TGF-β1) 
and (F) vascular endothelial growth factor (VEGF). Systemic concentrations of (G) IL-1β and (H) TGF-β1 were determined in the 
plasma of NO, empty and Fg-3D animals at 6 days (n=11/group) and 8 weeks (n=7 empty group, n=5 Fg-3D) post-injury by ELISA. 
Results are presented as box and whiskers graphs (box represents median and quartiles while whiskers represent min to 
maximum values); *p < 0.05 and **p < 0.01. Mann Whitney test was used to compare the data.  
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Implantation of Fg-3D leads to sustained alterations in systemic immune 
responses  
 
In order to evaluate the impact of Fg-3D on the systemic immune response, blood, 
spleen and draining lymph nodes were recovered to study the proportions of the different 
immune cell populations. Representative plots of the flow cytometry analysis illustrating the 
gates and surface markers used to evaluate the different immune populations are presented 
in supplementary data (Figure S4). 
The proportions of the different immune cell populations were analysed at 6 days post-
implantation, in blood (BL), spleen (SP) and lymph nodes (LN) (Figure 7). The response 
induced by the bone injury itself (empty group), when compared with NO animals was mild, 
and by comparison, the Fg-3D implanted group showed some significant differences to NO 
and in some cases also to empty animals. In BL and SP, empty and Fg-3D groups followed 
the same tendency for the most abundant subsets, increased T cells and decreased B cells 
(Figure 7A). While in BL the reduction is also significant for NK, NKT and myeloid cells, 
particularly for Fg-3D implanted animals, in SP these populations do not show significant 
differences (Figure 7A and B). On the other hand, in draining LN the response of empty and 
Fg-3D groups was in opposite directions, at least for the most abundant T and B cell 
populations. Empty defects led to increased B cells and decreased T cells, while the Fg-3D 
implanted group remained closer to NO and significantly different from empty in the B cells. 
Additionally, the percentage of T cells with downregulated TCR (TCRdim), which can be 
correlated with T cell activation, was lower in the SP of animals with Fg-3D, when compared 
with NO animals. The proportions of CD4+ T cells and CD8+ T cells were similar between 
different groups in BL, LN and SP. 
We then examined the cells expressing Mac-1 (CD11b/c+/CD18+), the receptor for Fg 
[12; 32], and found that Mac-1 expression was significantly decreased in the BL, LN and SP 
of animals implanted with Fg-3D, in comparison with animals with an empty defect (Figure 7C). 
CD4 and CD8 co-receptors are reported to enhance FcR responses in myeloid cells [33], so 
we analysed if myeloid cell decrease preferentially occurred within CD4 or CD8 positive 
populations. The results obtained indicate that implantation of Fg-3D led to a reduction in the 
percentages of CD4+ cells amongst CD11b/c+ cells in all assessed tissues from animals with 
Fg-3D when compared with animals with empty defect (Figure 7B). A significant decrease of 
the percentage of CD8+ cells, within the CD11b/c+ population, in animals of the Fg-group, was 
also found, but only in SP.  
Furthermore, the percentage of positive cells for MHC class II (MHC-II), a molecule 
expressed mainly on the surface of antigen presenting cells, was also analysed (Figure 7C). 
Fg-implanted animals presented lower percentages of MHC-II+CD11b/c+ cells, in BL, LN and 
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SP in comparison with NO group. In addition, the percentage of MHC-II+ cells within CD11b/c+ 
cells showed also a tendency to decrease in empty and Fg-3D groups when compared to NO 
animals, but differences were only statistically significant in the BL, when comparing Fg-3D 
with NO groups. Overall, these results clearly show that implantation of Fg-3D impacts the 
host response at systemic level, involving different immune cell populations and their activation 
status.  
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Figure 7. Characterization of systemic immune cell populations. At 6 days post-implantation immune cells in blood (BL), 
draining lymph nodes (LN) and spleen (SP) were analysed by FACS. (A) Main lymphoid populations: percentage of B cells 
(CD45R+TCR-), T cells (TCR+CD161a-), NK cells (CD161a+TCR-), NKT cells (CD161a+TCR+), TCRdim T cells and CD4+ and 
CD8+ T cells. (B) Myeloid populations and subpopulations: percentage of myeloid cells (CD11b/c+CD161a-TCR-), CD4+ in 
CD11b/c+ cells, and CD8+ in CD11b/c+ cells. (C) Percentage of Mac-1+ cells (CD18+/CD11b/c+), MHC-II+CD11b/c+ cells and 
MHC-II+ within CD11b/c+ cells. NO - non-operated (n=6), empty (n=10) and Fg-3D (n=12). Results are presented as box and 
whiskers graphs (box represents median and quartiles while whiskers represent min to maximum values); *p < 0.05, **p < 0.01 
and ***p < 0.001. Kruskal-Wallis test (or ANOVA when data distributions were normal) were used to analyse the data. 
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The systemic immune cell populations were also analysed at 8 weeks post-implantation, 
by looking at the percentages of B cells, T cells and myeloid cells (Figure 8). These cell 
populations had been found to be altered in the BL and LN in response to Fg-modified implants 
in this late time point [7]. In this study, it was interesting to observe that the decreased 
frequencies of B cells and myeloid cells in the BL at 6 days were still observed 8 weeks after 
injury in the Fg-3D group. In the LN of animals with Fg-3D, the percentage of B cells was still 
decreased 8 weeks post-injury, while the percentage of T cells is increased (79.28% in NO vs. 
85.50% in Fg-3D). In parallel to the ongoing process of bone repair observed at 8 weeks in the 
Fg-3D group, the changes induced by Fg-3D in immune cells populations in BL and LN are 
still detectable, suggesting a relation between the two biological events. 
 
 
 
Figure 8. Evaluation of long-term effect of Fg-3D implantation on immune cell populations at a systemic level. (A) 
Percentage of B cells (CD45R+TCR-), (B) T cells (TCR+CD161a-) and (C) myeloid cells (CD163+) in blood (BL) and draining 
lymph nodes (LN) of non-operated (NO, n=6), and implanted with Fg-3D injured femurs (Fg-3D, n=5) at 8 weeks post-implantation. 
Results are presented as box and whiskers graphs (box represents median and quartiles while whiskers represent min to 
maximum values); *p < 0.05 and **p < 0.01. Mann Whitney test was used to compare the data. 
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Discussion 
 
In this study, we have found that scaffolds made of fibrinogen (Fg-3D) promote bone 
repair and impact the inflammatory and immune responses both at local and systemic levels. 
We have observed a pro-regenerative local environment, with a resolving inflammatory 
response and granulation tissue formation at 6 days after implantation of Fg-3D. This 
translated to extensive bone repair at 8 weeks post injury. Importantly, bone tissue healing 
observed in the presence of Fg-3D was correlated with significant changes in the systemic 
immune cell balance. We believe that this is a crucial aspect of the response to biomaterials, 
that has been generally overlooked in other studies. 
To the best of our knowledge, the current study is the first one describing the preparation 
of pure Fg scaffolds by freeze-drying, without using exogenous enzymes. Here, we present a 
biomimetic approach where Fg lyophilized scaffolds are neutralized using ethanol in order to 
reduce their solubility, easing their manipulation and implantation. Neutralization using ethanol 
resembles the application of methanol in the development of 3D matrices of fibroin [34]. 
Previously, other groups [18; 19; 35; 36] have prepared solutions of Fg and exogenous 
thrombin, leading to polymerization into fibrin networks, carried out outside the animal. Ethanol 
precipitated porous Fg scaffolds, further crosslinked with genipin have also been produced by 
microsphere templating, and compared to thrombin polymerized ones [37]. However, the 
authors proceeded to more extensive in vitro and in vivo characterization only with the thrombin 
polymerized materials [38]. 
Our rationale for not using thrombin was to develop a new, simpler and cheaper 
biomaterial, without the problems associated with the use of exogenous thrombin. As reviewed 
by Lew WK et al, thrombin delivery may elicit adverse immune reactions and the co-injection 
of thrombin increases the risk of thrombosis [39]. However, as thrombin is present at injury 
settings, we investigated if it could further stabilize Fg-3D structure. FTIR analysis of Fg-3D 
performed before and after incubation with thrombin, revealed similar spectral profiles (Figure 
S5), indicating that added thrombin does not lead to significant changes in the molecular 
conformation of Fg. Although we cannot completely rule out that host endogenous thrombin 
can contribute to further stabilize the Fg-3D structure, we believe that any contribution of 
endogenous thrombin would be advantageous for the biomaterial and its integration with the 
surrounding tissue. 
The spectrum obtained here for Fg powder was in agreement with previous studies [30]. 
The findings obtained for lyophilized Fg scaffolds are in line with the reversible changes in 
secondary structure of proteins induced by lyophilization, namely increasing β-sheet content 
and decreasing α-helix content, previously reported by others [40]. Upon neutralization, Fg-3D 
presented an IR spectrum similar to Fg powder but the detailed Amide I and Amide II band 
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structure of neutralized Fg scaffolds suggested a slight increase of β-sheet content, consistent 
with the transition from α-helix to β-sheet described for fibrin formation [31]. In fact, similar 
peaks, albeit less intense, were observed when our Fg solution was polymerized using 
thrombin (Figure S5).   
On the other hand, the reduction observed in the intensity peak in carboxylate side 
chains in Fg-3D may explain their lower solubility in comparison to the lyophilized Fg scaffolds 
or Fg powder. Fg carboxyl groups participate in fibrin formation (polymerization pocket “a” is 
located at carboxyl region), and may affect cell adhesion (cellular integrins interacts with 
carboxyl-terminal RGD) [41; 42]. Moreover, NMR spectroscopy revealed that the peak at 76 
ppm in the CP-MAS spectrum is no longer visible after Fg scaffolds neutralization. This peak 
at 76 ppm in the CP-MAS spectrum may arise from the small amounts of carbohydrate moieties 
that bind to Fg, that is, N-acetylglucosamine, mannose, galactose, N-acetylneuraminic acid. 
The fact that this peak is no longer visible after neutralization suggests that the sugars moieties 
in neutralized Fg scaffolds become significantly more mobile, while the rigid glycoprotein 
domains become more organized or crystalline. Notably, no significant conformational 
changes are observed in the rigid protein environment, since the conformation-dependent 
carbonyl region in the CP-MAS spectra remains unchanged (peak at 173 ppm with shoulders 
at 175, 177 and 180 ppm), probably due to the large bandwidth noted. 
Fg-3D scaffolds presented an interconnected porous network, similar to the one 
observed for chitosan scaffolds produced using similar methodology [7]. The macro pores 
observed in Fg scaffolds likely support cell migration, bone ingrowth and capillaries formation 
while micro pores favour a suitable hypoxic microenvironment for the cartilage formation that 
occurs during osteogenesis, as described for other biomaterials [43]. The in vitro degradation 
of Fg-3D mostly occurred during the first six hours and was faster in water than in presence of 
FBS. This behaviour was most likely due to a protective role of calcium ions and residual 
thrombin present in FBS towards the Fg-3D [44]. The results obtained when culturing pre-
osteoblastic cells with Fg-3D extracts indicate that the material was not cytotoxic, according to 
the ISO10993-5 standard. 
When Fg-3D scaffolds were implanted in a femoral bone defect, the histological 
evaluation performed 6 days post-injury revealed that the scaffold structure was still present. 
It is possible that a fraction of the fibrinogen in Fg-3D could be polymerized by the host 
thrombin present at defect region. However, any potential polymerization was not extensive, 
as the porous scaffold structure is still similar to non-implanted materials (Figures 3B and S1), 
and different from the endogenously formed fibrin mesh identified in the empty defects. 
Moreover, the histological findings support that Fg-3D eased cell migration and induced 
granulation tissue infiltration, correlating with a decrease in the size of the defect area. 
Importantly, in the context of bone healing, granulation tissue replaces hematoma during the 
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early stage of bone repair [45; 46]. Previous reports showed that Fg cell-binding domains can 
promote migration [11] and proliferation [47] of human fibroblasts, a key cell population 
involved in granulation tissue formation and wound healing [48].  
Eight weeks upon implantation, newly formed bone was detected, presenting bone 
marrow cavity-like morphology. In some animals residual highly vascularized soft tissue could 
still be observed in the centre of the defect, which may be related with the fact that bone repair 
occurs from the periphery to the central region of the defect [49]. No trace of the Fg-3D was 
observed 8 weeks post-implantation, suggesting scaffold biodegradation by fibrinolysis without 
impairing tissue regeneration. When compared to our previous results, using chitosan-based 
materials modified or not by Fg adsorption, in the same animal model and at the same time 
post-implantation [7], the outcome here reveals a much more advanced stage of bone 
formation and repair, with complete degradation of Fg-3D material and its replacement with 
new bone, in the vast majority of the defect area. 
Bone repair was further characterized by micro-CT, revealing that animals implanted with 
Fg-3D were at an early stage of bone healing, having formed compact bone tissue in the defect 
region. This compact bone is expected to be gradually remodelled to trabecular bone. Mature 
bone is structurally more porous and presents lower percentages of calcified tissue, as 
observed in the micro-CT of the non-operated animal, whose bone parameters were in 
agreement with the literature [50; 51]. Importantly, Fg-3D implanted, but not empty defect, 
animals presented periosteal repair, which is reported to have a positive effect on 
biomechanics and bone healing, as it constitutes an important reservoir of bone cell precursors 
[52; 53]. The bone repair process described here is in line with what has been found in vivo 
after implanting fibrin glue combined with cells or calcium phosphate particles in a critical rabbit 
calvarial bone defect model [35; 54]. Conversely, a previous study in the mouse calvarial defect 
reported that fibrin porous scaffolds, produced by sphere templating and thrombin 
polymerization, only promoted new bone formation when modified to incorporate calcium 
phosphate [38]. Interestingly, although their evaluation was at 45 days post-implantation, by 
that point the fibrin material was already undetectable at implant site. In the current study Fg-
3D scaffolds were implanted alone, relying on the host cells to promote self-regeneration of 
bone tissue.  
The local gene expression results indicate a mild inflammatory response in empty 
animals that is not augmented when Fg-3D are present. Our findings on the local immune 
response indicate that the bone injury seems to be the driving force underlying the increase of 
IL-8, IL-6 and IL-1β. Cytokines such as IL-4 and IL-10, which have anti-inflammatory roles 
were not detected 6 days post-injury at the mRNA level. This is in line with a previous report 
on bone injury in a sheep model, where the highest mRNA IL-10 levels were found 24 hours 
post-osteotomy followed by decreasing levels of this cytokine until the end of the experiment 
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(60 h) [6]. The slight increase of IL-8 levels locally detected may be related to the 
chemoattraction of PMN, which were histologically identified. A significant increase of IL-6 
mRNA levels was observed in the bone defect of both operated groups, while plasma IL-6 
levels were bellow detection in all groups (data not shown). IL-6 is a pleiotropic cytokine and 
its role in bone healing, namely in the early stage, is believed to be related with angiogenesis 
and osteoclastogenesis, whose malfunction delays bone maturation [55]. Interestingly, 
augmented levels of local and systemic IL-6 and IL-8 concentrations have been found in 
patients with bone trauma [56]. Other pro-inflammatory cytokines such as IL-17a, associated 
with graft rejection and autoimmunity, or TNF-α, highly related with exacerbated inflammation 
and infection, were not detected in the plasma of these animals (data not shown). Of note, the 
presence of Fg-3D significantly homogenized the host response, dampening the immune 
reaction. This can be confirmed by a lower coefficient of variation of the Fg-3D implanted 
group, for the majority of the different molecules evaluated by gene expression analysis, FACS 
and ELISA (Supplementary Table 2).  
Although at 6 days no significant differences in local IL-1β mRNA levels or systemic 
protein levels, a significant reduction of IL-1β in plasma was found at 8 weeks post-implantation 
for Fg-3D group. These findings are in line with the literature as the first peak of IL-1β, induced 
by the initial immune response, is expected to occur 24h after the injury and a second peak at 
3 weeks later [57]. At later stage, IL-1β is reported to be mainly produced by osteoblasts during 
bone remodelling [57]. In this sense, the lower concentration of IL-1b in the plasma of the 
animals implanted with Fg-3D should be likely related to the stage of bone repair observed at 
8 weeks post-implantation.  
TGF-β1 has been reported as an instrumental player in a balanced bone remodelling 
[58]. The results obtained showed a tendency for TGF-β1 increase at early time-points locally 
at mRNA level, and systemically at the protein level. Interestingly, its protein levels in plasma 
remained high for Fg-3D implanted animals at 8 weeks post-implantation, when compared with 
NO animals. This is in line with our previous results showing an increase in plasma levels of 
TGF-b1 at 8 weeks post-implantation, when bone regeneration was promoted using Fg-
modified chitosan implants [7]. Additionally, TGF-β1 is considered an immunoregulatory factor 
due to its effects on immune cell populations. Regulatory T cells produce TGF-β1 and IL-10 to 
inhibit other T cell population [59], and TGF-b1 signaling in T cell affects bone metabolism [60]. 
The function of B cells may also be modulated by TGF-b1 [61]. Moreover, TGF-b1 induces 
and regulates the recruitment of myeloid cells, namely monocytes [62; 63], and is produced by 
the pro-healing M2 macrophages. 
Angiogenesis is expected to occur during bone repair involving the angiogenic factor 
VEGF, whose production is reported to be stimulated in presence of Fg [14]. The mRNA levels 
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of VEGF were significantly higher in the empty group than in NO animals, while Fg-3D animals 
showed intermediate expression levels. The peak of local up-regulation of VEGF expression 
has been seen to occur between 24 and 36 h after bone defect surgery followed by a decrease 
[6], and high VEGF production may be linked to inflammation. 
Overall, the data obtained suggests that the bone defect induced a mild inflammatory 
response, which was not potentiated by Fg-3D implantation. The short-term evaluation at 6 
days post-injury is a snapshot that allows evaluating the transition from acute inflammation to 
chronic inflammation. Thus, it cannot be excluded that some early biological events might have 
been missed, namely infiltration of neutrophils, T cells and B cells and occurrence of a peak in 
the local levels of cytokines (e.g. IL-1β and TNF-α) [5; 6; 64]. 
How key immune cell populations present in blood (BL), spleen (SP) and draining lymph 
nodes (LN) react to the critical bone injury and to the implantation of Fg-3D was of paramount 
importance to understand the host response to Fg-3D. In our previous work Fg-adsorbed 
chitosan scaffolds prepared by freeze-drying were evaluated using the same animal model. 
Fg-adsorbed scaffolds led to a different systemic response with heighten percentage of B cells 
and myeloid cells (defined as CD163+ cells) with a decrease in the percentage of T cells in the 
draining LN [7] at 8 weeks. Interestingly, here the systemic immune response in Fg-3D 
implanted animals showed a decrease in the percentage of myeloid cells, B cells, NK and NKT 
cells and higher T cell proportional representation, may be related to bone tissue response to 
injury. The increased percentages of circulating and SP T cells in Fg-3D group and the 
concomitant decrease in the proportion of B cells in BL, LN and SP could be part of the new 
equilibrium within lymphoid populations to support bone debris scavenging, needed in these 
initial stages of bone repair. Previous reports have noted a local increase in T cells starting 
24h after fracture which is maintained until 21 days, as part of dynamics of immune cell 
infiltration in to the lesion site as elegantly described by [5]. Scaglione et al reported an 
increase in circulating lymphocytes and platelets 4 days after subcutaneous biomaterial 
implantation, while circulating monocytes decrease [65]. In agreement with these findings we 
also observed an increase in T cells and decrease in myeloid cells 6 days after implantation. 
Other studies showed that augmented CD8+ T cells correlated with a poorer bone healing, 
which can be reverted upon depletion of CD8+ T cells [66; 67]. Importantly, we did not find 
significant differences in CD8+ T cells, being the CD4+ T cells the predominant subset 
identified as expected. Moreover, Elisseeff’s group recently proposed a pro-regenerative 
biomaterial through the modulation of the adaptive immune response. In this study, 
hypertrophic draining lymph nodes, accompanied by IL-4 expression, were observed in the 
animals with functional muscle tissue restore. Additionally, CD4+ Th2 T cells were identified 
as the main subset involved in this systemic response while B cells and CD8+ T cells were 
suggested to be potentially involved [68]. 
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In terms of immune cell activation markers, a decrease of TCRdim T cells with an 
increased proportion of splenic T cells of animals with Fg-3D may be correlated with reduced 
activation of T cells in this secondary lymphoid organ. This change in splenic T cell population 
was accompanied by a decrease in the proportion of CD45R expressing B cells, which could 
also be related with the loss of CD45R expression during differentiation to plasma cells, in 
response to the human Fg, upon a T-cell dependent immune response, as previously 
described in mice [69]. As we are implanting human Fg in rat we cannot exclude the possibility 
of an immune response from the rat against the human protein, especially when considering 
that the homology percentages between human and rat fibrinogen varies from 52% to 66% 
[70]. However, the perfect integration of Fg-3D scaffolds in bone, the reduced immune cell 
infiltration at 6 days, and the absence of fibrous capsule at 8 weeks, all argue against a strong 
immune response in this sense. The decreased percentage of MHC-II+ cells within the 
CD11b/c+ population may reflect reduced levels of expression, which by becoming lower than 
the detectable minimum appear as negative. An increase of the percentage of CD8+, CD161+ 
and MHC-II+ cells was observed in other studies, namely in graft rejection [71; 72]. Therefore, 
the systemic decrease of the percentage of blood cells expressing MHC-II and CD11b/c in 
animals with Fg-3D scaffold might be related with a good integration of the implant in the bone. 
Together, our findings support the pro-regenerative potential of Fg-3D and the systemic 
impact of injury and biomaterials implantation. Upon Fg-3D implantation, bone defect closure 
was faster and with periosteal repair, and promoted a more controlled biological response in 
comparison to the empty group. In future, new studies are required to acquire a comprehensive 
understanding how Fg-3D support bone healing and impact the immune system. This study is 
the first identifying the key immune cell populations and mediators, calling for further studies 
on the mechanisms and the role of these cell populations on establishing the pro-regenerative 
microenvironment.   
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Conclusions 
 
The results discussed above show that Fg-3D scaffolds provided a temporary support 
and promoted a pro-regenerative microenvironment, which led to periosteal bone repair after 
8 weeks of implantation. The significant changes observed draw attention to the systemic 
nature of response to injury and the potential for immunomodulation upon biomaterial 
implantation. The current study constitutes a basis for the development of Fg-based 
biomaterials, exploring Fg immunomodulatory properties for regenerative medicine. 
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Supplementary information 
 
 
Figure S1. Experimental design diagram: bone defects were performed in Wistar rats and immune response and bone 
remodelling were evaluated at 6 days and 8 weeks post-injury. The methods applied in the evaluation of each sample type are 
indicated as well as the number of animals studied per condition (non-operated, empty defect and with Fg-3D scaffold). 
 
 
 
 
Figure S2. Cylindrical VOI with 3 mm in diameter and 2 mm in deepness used for microCT analysis of bone defect region at 8 
weeks post-implantation. 
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Figure S3 Light microscopy images of Fg-3D scaffolds after H&E staining. Interconnecting pores are indicated with asterisks. 
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Figure S4. Representative plots of the flow cytometry analysis illustrating the gates and surface markers used to evaluate the 
different immune populations: T cells, NK cells, NKT cells and the subsets CD4+ T cells and CD8+ T cells (a), myeloid cells (b), 
activated cells (c), Mac-1+ cells (d), B cells (e) and CD4+ and CD8+ myeloid cells (f). 
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Figure S5. ATR-FTIR spectra of Fg powder, Fg-3D before and after incubation with thrombin solution at 10 or 100 IU/ml, 40 mM 
CaCl2 and 37ºC. 
 
 
Supplementary Table 1. List of primers used for quantitative RT-PCR analysis 
Gene Accession 
number 
Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
GAPDH [NM_017008.4] CTGGAGAAACCTGCCAAGTA TACTCCTTGGAGGCCATGTA 
IFN-ϒ [NM_138880.2] GGCCATCAGCAACAACATA GACAGCTTTGTGCTGGATCT 
IL-1β [NM_031512.2] GACAAGCAACGACAAAATCC ACCGCTTTTCCATCTTCTTC 
IL-2 [NM_053836.1] AGCGTGTGTTGGATTTGACT TCTCCTCAGAAATTCCACCA 
IL-4 [NM_201270.1] TCCGTGCTTGAAGAACAAGT CCAGGAAGTCTTTCAGTGTTGT 
IL-6 [NM_012589.2] AGCCAGAGTCATTCAGAGCA AGTTGGATGGTCTTGGTCCT 
IL-8 (MIP-2) [NM_053647.1] TGAAGTTTGTCTCAACCCTGA GGTGCAGTTCGTTTCTTTTCT 
IL-10 [NM_012854.2] GACGCTGTCATCGATTTCTC TTCATGGCCTTGTAGACACC 
Osteocalcin [NM_013414.1] AGGGCAGTAAGGTGGTGAAT CTAAACGGTGGTGCCATAGA 
TNF-α [NM_012675.3] TCTACTGAACTTCGGGGTGA CCACCAGTTGGTTGTCTTTG 
TGF-β1 [NM_021578.2] CGGACTACTACGCCAAAGAA CCCGAATGTCTGACGTATTG 
VEGFa [NM_031836.3] CAATGATGAAGCCCTGGA CTATGCTGCAGGAAGCTCAT 
 
  
Chapter III – Fibrinogen scaffolds with immunomodulatory properties promote in vivo bone regeneration 
 186 
Supplementary Table 2. Coefficients of variation for the most important biological parameters assessed in this study 
 
Methodology Molecule analyzed 
Animal group 
NO Empty Fg-3D 
Gene 
expression 
OC 79,4 96,4 54,3 
VEGF 35,7 89,1 47,8 
TGF-b1 81,7 95,0 75,5 
IL-1b 53,4 115,6 24,1 
IL-6 87,0 133,3 65,9 
IL-8 45,4 177,8 34,0 
Flow 
Cytometry 
Myeloid cells - blood 14,4 81,0 61,3 
Myeloid cells – spleen 26,2 46,6 34,6 
Myeloid cells – lymph nodes 12,2 66,6 58,0 
B cells – blood 13,5 34,8 51,7 
B cells – spleen 12,2 11,4 30,7 
B cells – lymph nodes 25,3 38,3 33,4 
T cells – blood 13,6 7,5 13,2 
T cells – spleen 15,7 26,0 11,4 
T cells – lymph nodes 10,0 19,6 8,0 
ELISA 
TGF-b1 98,1 65,5 58,6 
IL-1b 26,4 43,6 28,9 
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Abstract 
 
With the advent of immunomodulatory biomaterials, many strategies have been explored 
to promote pro-regenerative responses. Among those new therapies, the use of metal ions 
constitutes a promising tool to interact and modulate immune cells. Magnesium ions have been 
applied in clinics and research for several purposes, but their role on macrophage behavior 
remains unclear. 
Herein, primary human macrophages were differentiated to macrophages in presence 
of extracellular levels of Mg2+ up to 10 mM. In this range of concentrations, Mg2+ ions were not 
cytotoxic and did not induce macrophage apoptosis. Cell elongation was observed for doses 
of 2.5 mM and 10 mM Mg2+, but it was not accompanied by major changes on the levels of cell 
surface molecules and cytokine secretion. Anti-inflammatory effects of Mg2+ were observed in 
LPS-induced M1 macrophages. Remarkably, the expression of CD86 and secretion of IL-8 
was significantly decreased in M1 macrophages exposed to levels of 2.5 mM and 10 mM Mg2+. 
Likewise, for 10 mM Mg2+, IL-10 levels were found reduced with concomitant increase of TGF-
b1 production. A slight increase in TGF-b1 secretion was observed in IL-10-induced M2 
macrophages exposed to a concentration of 2.5 mM of Mg2+. 
The influence of the altered macrophages secretome on the osteogenic differentiation of 
primary MSC was also assessed. Our findings showed that conditioned media from Mg2+-
treated macrophages led to ALP up-regulation at day 7. However, no significant changes were 
detected for key transcription factors involved in chondrogenesis (SOX9) and osteogenesis 
(RUNX2), what points that Mg2+ is supporting both differentiation pathways. 
The ability of Mg2+ to control the inflammatory response and enhance tissue healing may 
prove valuable in maximizing the longevity of implantable biomaterials. Therefore, magnesium-
based implants constitute interesting delivery systems of Mg2+ that can have an 
immunomodulatory role on the host response. 
 
 
 
 
 
 
 
Keywords: magnesium, human macrophage, inflammation, immunomodulation 
  
Chapter IV – The presence of magnesium ions impairs M1 macrophage polarization: impact on the crosstalk with MSCs 
 200 
  
Chapter IV – The presence of magnesium ions impairs M1 macrophage polarization: impact on the crosstalk with MSCs 
 201 
Introduction 
 
The central role of the immune response in tissue regeneration and in the long-term 
performance of medical devices has prompted many attempts to develop immunomodulatory 
biomaterials [1]. In this context, interesting results have been obtained by using metal ions to 
modulate inflammation and healing processes [2]. Among metal ions, magnesium (Mg2+) has 
been gathering increasing interest due to its recognized immunomodulatory properties [3; 4]. 
The fact that Mg is already applied in clinical practice, as an ion [5; 6] and as the major 
component of metal alloys used to fabricate implants [7; 8], which then release Mg2+ ions. 
The interactions of Mg2+ and the immune system have been explored, with Mg2+ reported 
as exerting both pro-inflammatory [3] and anti-inflammatory effects [5; 9; 10]. In detail, 
exposing human NK and CD8+ T cells to 10 mM Mg2+ restored their cytotoxic functions against 
EBV-infected cells, which were previously impaired due to a deficiency in the magnesium 
transporter MAGT1 [3]. Conversely, other studies showed that LPS-induced production of pro-
inflammatory cytokines (TNF-a, IL-6 and CCL2) may be reduced by treating both immune cells 
[5] and organs ex-vivo [10] with Mg2+. Moreover, animal studies addressing the effects of Mg2+ 
deficiency revealed unbalanced immune responses, with increased production of pro-
inflammatory cytokines [10; 11], and also impaired cartilage [12] and bone formation [13].  
In research, magnesium supplementation has also been tested towards improved tissue 
engineering strategies with optimal results in response to levels up to 10 mM [14-16]. The 
direct effect of high extracellular concentrations of Mg2+ on mesenchymal stem/stromal cells 
(MSCs) have been studied, showing improved cell adhesion and promotion of chondrogenesis 
[15] and osteogenesis [17]. MSCs exposed to Mg2+-enriched media revealed higher production 
of ALP and up-regulation of the pro-regenerative molecules TGF-b1, BMP-2 and SMAD4 [17].  
Although the crosstalk between macrophages and MSC is recognized as critical for 
tissue healing and repair [18], the influence of Mg2+-enriched environments on human 
macrophage polarization remains unclear. Therefore, the effect of therapeutic doses of Mg2+ 
on pro-inflammatory M1 (LPS-activated) and anti-inflammatory M2 (IL-10-activated) 
macrophages was explored here. Moreover, as MSC differentiation is affected by soluble 
factors released the immune cells [19], the indirect effect of Mg2+ supplementation of 
macrophages on MSC osteogenic differentiation was also assessed.  
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Materials and methods 
 
Ethics statement 
 
All samples obtained and procedures performed were according to the principles of the 
Declaration of Helsinki. The monocytes used in this study were isolated from surplus buffy 
coats (BC) from healthy blood donors kindly donated by the Immunohemotherapy department 
of Centro Hospitalar de São João (CHSJ; Porto, Portugal). All experimental protocols were 
conducted following the approval and recommendations of the Ethics Committee for Health 
from CHSJ. All samples were analyzed anonymously since researchers were not informed 
about age, gender or any identifying element. 
 
Primary Human Monocyte Isolation and Culture 
 
Human monocytes were isolated from healthy blood donors by negative selection, as 
previously described in [20]. Briefly, BCs were centrifuged (35 min, 1200 g, room temperature, 
without brake) and peripheral blood mononuclear cells (PBMCs) were collected. PBMCs were 
then incubated for 20 min with RosetteSep® human monocyte enrichment cocktail (StemCell 
Technologies, Grenoble, France), following manufacturer’s instructions. After 1:1 dilution in 
PBS supplemented with 2% FBS (heat inactivated, Biowest, Nuaillé, France), cells were 
carefully layered over Histopaque®-1077 (Sigma-Aldrich, Madrid, Spain) and centrifuged (35 
min, 1200 g, room temperature, without brake). The monocyte-enriched layer was collected 
and washed three times with PBS through centrifugation (17 min, 700 rpm, room temperature). 
Population purity was evaluated by flow cytometry analysis (FACS) and over 70% of the cells 
were found to be CD14+, as previously reported by our team [20]. Monocytes were seeded at 
106 cells/ml on glass coverslip in 6 well or 24 well plates and cultured for 13 days to allow cells 
differentiation into macrophages. 
Cells were incubated in a humidified incubator at 37ºC and with 5%CO2 in RPMI 1610 
medium supplemented with 10% heat inactivated FBS (Biowest) and 1% penicillin G-
streptomycin (P/S, Invitrogen, Paisley, UK), without supplementation with M-CSF. Three 
extracellular levels of magnesium were tested since cell seeding:  0.4 mM Mg2+, the basal Mg2+ 
concentration in RPMI, or supplemented with MgSO4 (pharma grade, Sigma) to a final 
concentration of 2.5 mM and 10 mM. At day 10, media were replaced keeping the same levels 
of Mg2+ and part of monocytes/macrophages were activated with 10 ng/ml of Escherichia coli 
derived lipopolysaccharide (LPS, Sigma) or 10 ng/ml of IL-10 (Immunotools, Germany), for 
additional 72h, to induce macrophage polarization into pro-inflammatory M1 and anti-
Chapter IV – The presence of magnesium ions impairs M1 macrophage polarization: impact on the crosstalk with MSCs 
 203 
inflammatory M2 phenotypes, respectively. Supernatants were collected under sterile 
conditions at day 13, centrifuged (13 000 rpm, 5min, 4ºC) and stored at -20ºC until further 
analysis or use to prepare conditioned media for MSC cultures. 
 
Macrophage morphology 
 
Macrophage aspect ratio was quantified using ImageJ software on brightfield images of 
macrophages incubated in 0.4 mM, 2.5 mM and 10 mM Mg2+ RPMI during 13 days. Aspect 
ratio was calculated as the quotient between the length of each cell major and minor axes, as 
previously described [21].  
 
Magnesium cytotoxic effects assessment 
 
The potential cytotoxicity of Mg2+-enriched media on monocytes/macrophages was 
evaluated after 13 days of culture by live/dead staining and apoptosis evaluation. Briefly, 
live/dead assay was performed to evaluate the integrity of cell membrane. After washing with 
PBS, cells were incubated in the dark at 37ºC with calcein solution at 2 µM for 20 min, 
propidium iodide solution at 2 µM for 1 min, and afterwards images were acquired in an 
inverted fluorescence microscope (Carl Zeiss Axiovert 200). Additionally, cell viability was 
assessed and quantified by flow cytometry. Macrophages were gently detached incubating 
with accutase™ (BD Biosciences) for 30 min at 37ºC and stained using the BD Pharmingen™ 
Annexin V FITC apoptosis detection kit (BD Biosciences). Cells were acquired in a BD 
FACSCanto II™ using FACSDiva™ software, both from BD Biosciences. The proportion of 
dead cells (PI+), apoptotic cells (AnnexinV+ / PI-) and viable cells were quantified using Flow 
Jo software. 
 
Metabolic activity quantification of macrophages in Mg2+-enriched media 
 
The metabolic activity of macrophages exposed to supra-physiological concentrations of 
Mg2+ and polarization stimuli (LPS and IL-10) was assessed using a resazurin assay. Briefly, 
culture media were replaced by resazurin solutions at 0.1mg/mL (Sigma), prepared using 0.4 
mM, 2.5 mM and 10 mM Mg2+ RPMI, and incubated for 2 h. After incubation time, the medium 
was collected, 100 μL was transferred to a well of a black 96-well plate (triplicates were made) 
and the intensity of fluorescence at 590 nm after excitation at 530 nm was read using a 
microplate reader (Biotek – Sinergy HT). Fluorescence values obtained for 0.4 mM, 2.5 mM 
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and 10 mM Mg2+ RPMI in absence of cells were used as background control, and subtracted 
in the final analysis. 
 
Analysis of macrophage surface molecules 
 
The potential changes induced by enriched-Mg2+ media on the expression of cell surface 
molecules were assessed by FACS. At day 13, macrophages were gently harvested, washed 
and resuspended in FACS buffer- (PBS/2%FBS/0.01%Azide). Cell surface staining for FACS 
analysis was then performed by incubating for 30 min on ice with the following antibodies 
diluted in FACS buffer: anti-human CD14-APC (clone MEM-18), anti-human CD86-FITC 
(clone BU63), anti-human HLA-DR-FITC (clone MEM-12), all from Immunotools, anti-human 
CD163-PE (clone GHI/61, BD Biosciences) and anti-human CD206 (clone 19.2, BD 
Biosciences). Macrophages were also stained with the corresponding isotype controls, all from 
ImmunoTools, used to define background staining. Samples were then washed three times 
with FACS buffer, followed by fixation in 1% paraformaldehyde on ice until sample analysis 
(máx 24h). Cells were acquired on a Flow Cytometer (FACSCanto™ II, BD Biosciences) and 
10.000 events were collected per sample. Data was analyzed using FlowJo software and mean 
fluorescence intensity (MFI) values were calculated by subtracting the corresponding isotype 
control. 
 
Analysis of IL-6, IL-8, IL-10, IL-12, TNF-a and TGF-b1 concentration 
 
The levels of secreted cytokines in culture supernatants were quantified by ELISA 
according to manufactures’ instructions. The concentration of IL-6, IL-8, IL-10, IL-12, TNF-a 
were determined using Mini ELISA Development Kits (PeproTech) while the amount of TGF-
b1 in supernatants was quantified by DuoSet® ELISA development system (R&D systems). 
Concentrations were determined for, at least, five donors per condition (n=5-8) and the 
percentages of effect were calculated by normalizing the concentrations by the value obtained 
for the basal condition (0.4 mM Mg2+ without LPS or IL-10 stimuli). Of note, the 10 ng/mL of IL-
10 used to polarize M2 macrophages was subtracted to the levels of IL-10 determined in the 
supernatants of those macrophages. 
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Isolation and culture of primary human bone marrow mesenchymal 
stem/stromal cells 
 
Human bone marrow MSC (mesenchymal stem/stromal cell) were isolated and 
characterized according the international stem cell society criteria, as previously described by 
our team [22]. Cells were cultured in flasks with Dulbecco's Modified Eagle Medium (DMEM; 
GIbco), low-glucose, supplemented with glutamax, 10% FBS Hyclone (MSC qualified) and 1% 
P/S. Media was changed twice a week. Cells were passaged at 80% confluence by washing 
twice the culture with warm PBS and detaching cells by using 0.05% trypsin EDTA (Gibco) for 
5 min at 37ºC. Complete medium was added to inhibit trypsin and cells were transferred to a 
tube and centrifuged at 300 g for 10 min. The viable cells were counted using trypan blue and 
plated at a density of 3000 cells/cm2 in 150 cm2 tissue culture flasks (BD Falcon). 
 
Osteogenic differentiation 
 
MSC were used in passages 6 and 7. A total of 10x103 cells were seeded on 24 well 
plate and incubated at 37ºC for 24 h in 10% FBS Hyclone and 1% P/S. Afterwards, medium 
was completely changed for DMEM 10% FBS Gibco and 1% P/S to stop MSC expansion and 
stablish conditions that allow cell differentiation. Four controls were used: positive control 
(osteogenic medium: DMEM with 10% FBS, 1% P/S, 100 mM dexamethasone, 0.05 mM 
ascorbic acid and 10 mM β-glicerophosphate), negative control (basal medium: DMEM with 
10% FBS and 1% P/S) and basal media with Mg2+ concentration adjusted to 2.5 mM and 10 
mM using MgSO4, as previously performed for monocyte/macrophage cell culture. Conditioned 
media from day 13 of culture with macrophages, from six different donors, were diluted in basal 
medium 1:2. For each condition, four replicates were prepared for gene expression analysis 
while two replicates were made for colorimetric evaluation of ALP synthesis. Media was 
changed twice a week until day 7 (gene expression) or day 14 (ALP staining). 
 
Gene expression analysis 
 
MSCs were homogenized at day 7 using TRIzol® (Life Technologies) according to the 
manufacturer’s instructions. The amount and quality of extracted total RNA were evaluated by 
Nanodrop ND-1000 (Thermo Fisher Scientific) and by running RNA samples in a 2 % agarose 
gel. Samples were then treated with TURBO DNA-free™ kit (Life Technologies) to remove 
contaminating DNA from RNA preparations. cDNA was obtained from 1.2 µg of DNAse-treated 
RNA with random hexamers (Invitrogen) using Superscript III kit (Invitrogen) according to 
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manufacturer instructions. All primers used in qRT-PCR were inter-exonic and included: β2M, 
sense, 5’-CCAGCGTACTCCAAAGATTCAG-3’, anti-sense, 5’-
AGTCAACTTCAATGTCGGATGG -3’; ALP, sense, 5’-GACGGACCCGTCACTCTC-3’, anti-
sense, 5’-GTGCCCGTGGTCAATTCT-3’; RUNX2, sense, 5’-CCTGAACTCTGCACCAAGTC-
3’, anti-sense, 5’-GAGGTGGCAGTGTCATCATC-3’; SOX-9, sense, 5’-
TTCCTCCTGCCTTTGCTTGT-3’, anti-sense, 5’-CGTGCTTGAAACATTCCCAGAAC-3’. β2 
microglobulin (B2M) was used as reference gene. Relative gene expression levels were 
calculated using the quantification cycle (Cq) method, according to MIQE guidelines [23]. 
 
ALP staining 
 
Previous to ALP staining at day 14, MSC were washed twice with PBS and fixed with 
4% paraformaldehyde. Cells were then incubated for 45 min at room temperature with ALP 
substrate, composed by 4% Naphtol AS-MX phosphate alkaline solution in Fast Violet B 
solution (both from Sigma). Samples were washed twice and kept in PBS at 4ºC until being 
observed and photographed using a stereomicroscope (Olympus). The acquired images were 
analyzed using an algorithm developed in Matlab to quantify ALP staining, as previously 
described by our team [24]. In detail, ALP-positive regions were empirically defined as red > 
76; red > 1.1 x green; green < 1.12 x blue and the number of pixels that fulfil those criteria 
were quantified over the total image area.  
 
Statistical analysis 
 
Statistical analysis was performed using Prism software. Normality of data was assessed 
by visual inspection of histograms and Kolmogorov-Smirnov test. Student's t-test or repeated 
measures ANOVA with Bonferroni Correction, or their non-parametric counterpart (Friedman 
with Dunn’s Multiple Comparison) were used to analyze data with Gaussian distribution. 
Statistical significance was considered for p < 0.05 (*); p < 0.01 (**) and p < 0.001 (***).   
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Results 
 
Magnesium supplementation induced elongated macrophage morphology 
 
The potential of Mg2+ to modulate monocytes/macrophages was assessed by 
supplementing cell culture media with magnesium sulfate to increase Mg2+ concentration up 
to 2.5 mM and 10 mM. Macrophages exposed to 2.5 and 10 mM Mg2+ for 13 days presented 
altered morphologies in comparison to the control (0.4 mM Mg2+). When observed by light 
microscopy, macrophages cultured in 0.4 mM Mg2+ were a mixed population of round and 
stretched cells (Figure 1A). The proportion of elongated cells was slightly augmented in the 
2.5 mM Mg2+ (Figure 1B) and longer membrane extensions were observed for 10 mM Mg2+ 
(Figure 1C). These observations were confirmed after quantification of the cell area (Figure 
1D) and elongation factor (Figure 1E), which were significantly altered in a dose-dependent 
manner in macrophages exposed to increased levels of Mg2+. 
 
 
Figure 1. Macrophage elongation in response to increased levels of extracellular Mg2+. (A-C) Light microscopy images of 
macrophages cultured along 13 days in presence of: (A) 0.4 mM, (B) 2.5 mM and (C) 10 mM Mg2+. Results shown in A, B and C 
are representative of all donors tested (n=6). (D) Cell area and (E) elongation factor presented by macrophages in culture. Scale 
bars correspond to 300 µm while in small boxes value 30 µm. Results of all donors tested are presented (n=6). Repeated 
measures ANOVA with Bonferroni Correction was used to analyze data, *: p<0.05; **: p<0.01.  
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Macrophage survival was not affected by Mg2+ supplementation 
 
To exclude possible cytotoxic effects induced by high levels of Mg2+, we evaluated cell 
membrane integrity, apoptosis and metabolic activity presented by macrophages. The analysis 
of live/dead staining revealed similar number of dead cells (stained in red) for 0.4 mM, 2.5 mM 
and 10 mM Mg2+ (Figure 2A-C). Furthermore, similar percentages of apoptotic cells (Annexin 
V+ / PI -) and dead cells (PI +) were found for the three concentrations of Mg2+ (Figures 2D-
F). When these were quantified over different donors, no significant differences were observed 
(Figure 2G). Moreover, the metabolic activity of macrophages cultured in Mg2+-enriched media 
and activated with LPS or IL-10 was evaluated by measuring the fluorescence of resazurin 
reduced by cell mitochondria (Figure 2H). Data showed a significant increase of metabolic 
activity in macrophages exposed to 2.5 mM Mg2+, but not to 10 mM Mg2+, when compared to 
control (0.4 mM Mg2+). 
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Figure 2. Mg2+-enriched media did not induce cell apoptosis and death and 2.5 mM Mg2+ promotes higher metabolic 
activity. (A-C) Fluorescence microscopy images of macrophages cultured in 0.4 mM (A), 2.5 mM (B) and 10 mM Mg2+ RPMI (C) 
after calcein/propidium iodide staining at day 13. Live cells stained green while cells with damage membrane presented a red 
color. (D-F) Representative dot plots of macrophages stained with annexin V-FITC (X axis) and propidium iodide (Y axis) after 
exposure to 0.4 mM (D), 2.5 mM (E) and 10 mM Mg2+ levels (F). (G) Proportion of live (AnnexinV- / PI-), dead (PI+) and apoptotic 
(AnnexinV+ / PI-) cells determined by FACS analysis. (H) Metabolic activity of macrophages at day 13 analyzed by resazurin 
assay. Results of all donors tested are presented (n=6). Repeated measures ANOVA with Bonferroni Correction was used to 
analyze data, *: p<0.05). 
 
 
  
Chapter IV – The presence of magnesium ions impairs M1 macrophage polarization: impact on the crosstalk with MSCs 
 210 
Decreased CD86 expression on LPS-activated macrophages exposed to 2.5 mM 
and 10 mM Mg2+  
 
In order to evaluate the effect of increased levels of Mg2+ on macrophage polarization, 
cell surface markers associated to M1 (CD86 and HLA-DR) and M2 phenotypes (CD163 and 
CD206) were assessed at day 13. Results are illustrated in Figure 3A and show the changes 
in the different M1 and M2 markers with the polarization. When results were quantified across 
at least 7 different experiments (Figure 3B,C) we observed that exposure of unstimulated 
macrophages to increased levels of Mg2+ did not lead to significant changes in the cell surface 
expression of these molecules. Remarkably, the up-regulation of CD86 exhibited by M1 
macrophages (LPS-activated cells) was significant decreased in macrophages exposed to 2.5 
mM and 10 mM Mg2+ (Figure 3B). M1 macrophages also presented a tendency for up-
regulation of HLA-DR and down-regulation of CD163, while no significant differences were 
observed for CD206 (Figure 3B,C). IL-10 stimulated macrophages presented a slight increase 
of CD163 expression, which was not affected by the Mg2+ treatment. Moreover, Mg2+ 
supplementation did not lead to important changes in cell surface molecules (CD86, HLA-DR 
and CD206) on M2 macrophages. 
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Figure 3. Magnesium supplementation induced downregulation of CD86 expression. Primary monocytes were isolated and 
cultured for 13 days, exposing cells to increased extracellular Mg2+ levels and different activation stimuli. (A) Dot plots of a 
representative donor, where values in each quadrant represent percentage of cells in that quadrant. (B,C) Mean fluorescence 
intensity (MFI) normalized by the control condition (non-stimulated macrophages/0.4mM Mg2+) of M1 markers CD86 and HLA-DR 
(B) and M2 markers CD163 and CD206 (C). Results of all donors tested are presented (n=7-8). Repeated measures ANOVA with 
Bonferroni Correction was used to analyze data, *: p<0.05; **: p<0.01). 
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Macrophage cytokine production was influenced by the Mg2+ concentration  
 
The soluble mediators produced by macrophage upon polarization were evaluated in cell 
culture supernatants at day 13. In order to minimize the influence of the inherent variability of 
response among donors, percentages of effect were calculated for the factors with detectable 
levels in the control condition (unstimulated macrophages 0.4 mM Mg2+). The results are 
presented in Figure 4 and show that treatment of unstimulated macrophages with 2.5 mM and 
10 mM Mg2+ media did not affect the secretion of the soluble factors tested in this study.  
The production of TGF-b1 was down-regulated in M1 macrophages while increased 
levels of IL-10, IL-8, IL-6, IL-12 and TNF-a were found in the supernatants from those cells 
(Figure 4). The exposure of LPS-activated macrophages (M1) to 10 mM Mg2+-enriched media 
seemed to rescue the secretion of TGF-b1 (p=0.1046) to similar concentration to the 
unstimulated macrophages (Figure 4A,B). Remarkably, the Mg2+ supplementation significantly 
damped the production of IL-8 (Figure 4C,D) induced by the activation with LPS. Similarly, a 
tendency to decreased secreted levels of IL-10 was observed in M1 macrophages exposed 
10 mM Mg2+ (Figure 4E). No significant effect of Mg2+ treatment was registered regarding the 
secretion of IL-6, IL-12 and TNF-a (Figure 4F-H) in M1 macrophages.  
 The analysis of M2 macrophages showed a tendency for higher production of TGF-b1 
in presence of 2.5 mM Mg2+. Overall, this anti-inflammatory phenotype presented a similar 
cytokine profile to the unstimulated macrophages, with exception of the increased levels of IL-
10 observed in those conditions. 
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Figure 4. Cytokine profile was altered in macrophages cultured in 2.5 mM and 10 mM Mg2+ media. (A-B) TGF-b1, (C-D) IL-
8, (E) IL-10, (F) IL-6, (G) IL-12 and (H) TNF-a release were determined by ELISA for, at least, five donors per condition (n=5-8), 
using cell culture supernatants from macrophages at day 13, three days after activation. Percentages of effect were calculated 
for cytokines with positive levels in control condition (non-stimulated macrophages in 0.4 mM Mg2+) - TGF-b1 (B) and IL-8 (D). 
Repeated measures ANOVA with Bonferroni Correction (TGF-b1 and IL-8), or their non-parametric counterpart Friedman test 
with Dunn’s Multiple Comparison test (IL-10, IL-6, IL-12 and TNF-a)were used to analyze data, ***: p<0.001).  
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Soluble factors produced by macrophages modulate MSC osteogenic 
differentiation 
 
To evaluate the functional consequences of macrophage exposure to Mg2+ we 
investigated the potential of the secretome from macrophages exposed to the different 
conditions to promote MSC osteogenic differentiation. Moreover, MSCs were also culture in 
Mg2+-enriched DMEM as control for the potential direct effect of Mg2+ on osteogenesis. MSC 
osteogenic differentiation was assessed in absence of other osteoinductive agents, namely 
ascorbic acid, b-glycerophosphate and dexamethasone. Unstimulated macrophages were 
able to promote ALP up-regulation in MSC while conditioned media (CM) from M1 
macrophages induced a general down-regulation of ALP, RUNX2 and SOX9 (Figure 5A-C). 
Remarkably, the treatment of both unstimulated and M1 macrophages with 2.5 mM and 10 
mM Mg2+ led to CM that increased mRNA levels of ALP on MSC. However, the quantification 
of ALP-stained areas showed that CM from non-stimulated macrophages led to an increased 
production of ALP in comparison to basal, being more intense for CM 0.4 mM Mg2+ and 
decreasing as the Mg2+ concentration increases (Figure 5D-I). A slight recovery of ALP staining 
was registered for MSCs cultured with CM from LPS-activated macrophages at 2.5 mM and 
10 mM Mg2+ when compared to analogous condition at 0.4 mM Mg2+. 
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Figure 5. Conditioned media (CM) from macrophage culture promote the expression of key osteogenic markers. (A-C) 
ALP, RUNX2 and SOX9 mRNA levels were measured by qRT-PCR at day 7 for the following conditions: basal media (-), 
osteogenic media (+), Mg2+-enriched DMEM, and media containing CM from macrophages differentiated in presence of increased 
levels of Mg2+ without [Mac+Mg2+] or with LPS-induced activation [Mac+Mg2++LPS]. b2M gene was used as reference control 
(n=2-5). ALP staining was performed at day 14 of osteogenic differentiation assay. (D) ALP stained areas were quantified using 
Matlab and values were normalized by the basal condition (n=2-6). Representative pictures of ALP staining for the following 
conditions: (E) basal (F) osteogenic (G) 2.5 mM Mg2+ DMEM (H) CM 2.5 mM Mg2+ (I) CM 2.5 mM Mg2+ + LPS. 
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Discussion 
 
In this study, we have found a positive effect of Mg2+ supplementation on macrophage 
behavior, leading to a decreased expression of pro-inflammatory markers. We believe that 
these findings are relevant in exploring the use of certain doses of Mg2+ as immunomodulatory. 
The rational underlying this study was to understand to what extent Mg2+ influenced 
macrophage polarization towards M1 and M2 phenotypes, induced by LPS and IL-10, 
respectively. Moreover, biodegradable magnesium alloys for medical applications have 
gathered raising interest [7; 25]. In this context, the Mg2+ levels released by these biomaterials 
may constitute a promising approach to modulate implant-associated inflammation and 
promote tissue repair/regeneration. 
The use of Mg2+ concentrations ranging from 2.5 mM to 10 mM has been previously 
explored at regulating immune responses involving NK cells [3], T cells [26] and 
monocytes/macrophages [5]. However, the role of those supraphysiological Mg2+ 
concentrations on macrophage polarization remained unclear. Moreover, since crosstalk 
between macrophages and MSCs likely plays a role in healing responses [18; 19; 27], this 
study also addressed the effect of macrophage CM on MSC behavior. Although the pro-
osteogenic effect of Mg2+ in human MSCs has been described [14], little is known about the 
indirect effect of Mg2+ on MSC response, through the action of macrophages. 
 The analysis of cell morphology revealed a clear elongation and cell area reduction of 
the macrophages cultured in Mg2+-enriched media. Morphological changes have been studied 
in the scope of macrophage polarization but controversial results are found in the literature 
[21; 28; 29]. Here, non-activated macrophages presented as a heterogeneous population with 
similar proportions of spindle-shaped fibroblastoid and large flat-round cells, in agreement with 
previous reports [28]. Human M1 macrophages are characterized by their elongate 
morphology while M2 macrophages are typically more round cells [28]. In our study, 
macrophages exposed to 2.5 mM and 10 mM Mg2+ media were predominantly elongated, 
resembling the M1 spindle-shaped fibroblastoid morphology. However, expression of cell 
surface receptors and secreted soluble factors revealed that non-activated macrophages 
treated with different Mg2+ concentrations presented similar profiles.  
Therefore, the effect of Mg2+ is likely related to other mechanisms. Prescott and 
colleagues described Mg2+-specific action on cell cytoskeleton, reporting disassembly of F-
actin stress fibres by increasing intracellular Mg2+ levels with microinjections of 10 mM Mg2+ 
[30]. In a previous study, longer spindle-shaped fibroblasts were observed upon blockage of 
the transient receptor potential (TRPM7) [31], a key ion channel for Mg2+ homeostasis in the 
cell [32]. Considering that Mg2+-enriched media will boost Mg2+ uptake and that intracellular 
Mg2+ levels negatively regulate TRPM7 activity [32], it is likely that the observed cell 
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morphologies are related to the interaction between Mg2+ and TRPM channels. It was 
previously reported the key role of TRPM7 in the differentiation of murine macrophages 
towards M2 phenotype through stimulation with IL-4 [33]. In detail, IL-4 promotes the activity 
of TRPM7 and the blockage of this ion channel led to loss of anti-inflammatory features, 
including the spindle-shaped morphology induced by IL-4 and M-CSF described by several 
authors for murine macrophages [21; 29]. Thus, interspecies difference regarding macrophage 
morphology may exist with murine macrophages presenting inverse morphologies for M1 and 
M2 phenotypes when compared to human cells. 
Our study showed that the exposure to levels of Mg2+ up to 10 mM for 13 days does not 
impair macrophage survival. Moreover, macrophages cultured in 2.5 mM Mg2+ presented 
augmented metabolic activity, which is not associated to cell proliferation. As previously 
described, primary human macrophages have minimal mitotic activity in vitro [34] what is in 
line with the consistent number of cells observed throughout the 13 days of culture. Using cell 
lines, Feyerabend and colleagues [35] reported negative effects on cell viability in 
microenvironments with Mg2+ concentrations above 10-20 mM. Moreover, a prior study 
addressed in vitro the influence of Mg2+ supplementation on human osteoclasts, showing that 
levels of 5 and 10 mM Mg2+ led to increased metabolic activity at day 14 and higher expression 
of TRAP [36]. Taken together, those findings are in accordance to our data, confirming that, in 
certain doses, Mg2+ induces higher cell metabolic activity. 
Magnesium exerts major effects on M1 macrophages induced upon activation with LPS. 
Both tested concentrations damped, at least in part, the pro-inflammatory action of LPS 
especially in the cell surface expression levels of co-stimulatory molecule CD86, and regarding 
the secretion of TGF-b1, IL-8 and IL-10. CD86 is a typical marker of the pro-inflammatory M1 
phenotype, is involved in T cell activation and its highly expressed in response to metal ions 
such as nickel [37-39]. The selective decrease of CD86 expression in human 
monocytes/macrophages has been observed in clinical scenarios of immunotolerance [40; 41]. 
In detail, macrophages in decidual tissue, a region of immunological tolerance at the interface 
between the mother and the fetus, presented lower levels of CD86 in comparison to circulatory 
monocytes while CD80 and HLA-DR showed comparable values [40]. In agreement, 
diminished expression of CD86 was observed on monocytes from critical care patients with 
compensatory anti-inflammatory response syndrome [41]. The effect of Mg2+ supplementation 
on the expression of CD86 in LPS-activated macrophages was not addressed in previous 
studies. Therefore, our data on the profile of surface molecules on macrophages showed that 
Mg2+ seems to have a regulatory role in LPS activation, leading to immunological tolerance.  
An immunoregulatory role has been attributed to Mg2+ mostly due to the up-regulation of 
pro-inflammatory cytokines such as TNF-a, IL-6 and MCP-1 in scenarios of Mg2+ deficiency 
[11]. Furthermore, previous studies reported that magnesium supplementation led to 
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decreased production of pro-inflammatory cytokines including IL-6 [5; 42], TNF-a [5; 10] as 
well as other LPS-induced immune mediators [10]. In overall, Mg2+ seems to promote 
immunoregulatory phenotypes, specially by decreasing IL-8, IL-10, but rescuing the secretion 
of TGF-b1 lost due to LPS activation. 
Our findings showed that 2.5 mM and 10 mM Mg2+-media did not deeply impact the 
behavior of IL-10-induced M2 macrophages. Although a significant increase in TGF-b1 
secretion was observed in macrophages exposed to 2.5 mM Mg2+, the three conditions 
stimulated with IL-10 presented similar expression of both surface molecules and soluble 
factors. So, the role of Mg2+ on the polarization of human macrophages seems to be mostly in 
reducing the M1 response, without inducing major changes in M2 phenotype. 
The potential effect of Mg2+ on osteogenic differentiation through modulation 
macrophage behavior was assessed in this study. We have chosen to test MSC response in 
absence of other osteoinductive molecules to evaluate the capacity of Mg2+ modulate the 
differentiation of MSCs into osteoblasts. Overall, MSCs cultured with supernatants from Mg2+-
treated macrophages presented an up-regulation of ALP, which may be associated to the 
higher concentrations of TGF-b1 detected in the supernatants from those macrophage 
cultures. This finding is in line with a previous in vitro study reporting increased expression of 
ALP in human MSCs upon TGF-b1 supplementation [43]. Moreover, MSCs exposed to media 
with 4 mM Mg2+ revealed higher production of ALP at day 14 while pro-regenerative molecules 
TGF-b1, BMP-2 and SMAD4 were up-regulated in cells cultured for 3 days with Mg extracts 
[17]. Similarly, a study showed that 10 mM Mg2+ induce higher ALP activity in human MSCs 
cultured in osteogenic conditions during 3 weeks [14]. Additionally, the Mg2+ uptake to cell 
through TRPM7 was demonstrated as critical for in vivo biomineralization [44]. At day 7, a 
tendency for a small augment of the expression levels of RUNX2, a key transcription factor 
involved in osteogenic differentiation [45], was registered in CM conditions. Moreover, the 
expression of SOX9 was particularly low in presence of LPS-CM while high mRNA levels of 
SOX9 was registered in non-LPS CM conditions in comparison to osteogenic condition. SOX9 
is a major regulator of chondrogenesis [46] and its expression is known to be strongly impaired 
by classical pro-inflammatory cytokines such as TNF-a [47], which was in high levels in LPS 
CMs. Additionally, the expression of SOX9 is known to be reduced in presence of low levels 
of Mg2+ [12]. Likewise, the ratio between SOX9 and RUNX2 was reported to decrease during 
healthy osteogenic differentiation of MSCs by other authors [45]. Therefore, our results show 
that tested Mg2+ concentrations modulate macrophages behavior to support MSC osteogenic 
differentiation. Those findings are in line with previous studies reporting improved 
chondrogenesis [15] and osteogenesis [48] in presence of Mg2+ levels ranging from 2.5 mM 
and 10 mM.   
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Conclusions 
 
In conclusion, our findings have revealed a regulatory effect of Mg2+ in concentrations of 
2.5 mM and 10 mM on human macrophages. This study suggests the use of Mg2+ to modulate 
macrophage phenotype as a therapeutic strategy, especially in scenarios involving the pro-
inflammatory M1 phenotype and exacerbated expression of CD86 and secretion IL-8. 
Unstimulated and M2 macrophages maintained their phenotypic features when cultured in 
Mg2+-enriched media. The use of concentrations of Mg2+ ranging 2.5 and 10 mM is a feasible 
strategy in clinics to dampen the M1 macrophages responses, without impairing tissue healing. 
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The original proposal for the Doctoral dissertation presented herein was the modulation 
of the immune response induced by implantable biomaterials. This topic reflects the growing 
interest and the shift from inert implants to immunomodulatory biomaterials, ongoing in the 
field [1; 2]. In fact, orthopedic implants fail mostly due to biological factors, highly associated 
to the inability of those biomaterials at promoting tissue healing. In this context, new solutions 
to modulate the biological response to biomaterials are required. 
Although fibrinogen and metal ions have been perceived as exclusive pro-inflammatory 
agents [3; 4], they may exert immunomodulation when applied in controlled doses and/or 
arrangements. Hence, we aimed at exploring new therapies based on fibrinogen and metal 
ions that mitigate the drawbacks presented by the orthopedic devices currently used in clinical 
practice. Our objectives have been to (1) identify key immune cell populations and molecules 
involved in the immune response induced by hip implant, (2) develop a new protein-based 
biomaterial with immunomodulatory properties for bone regeneration, (3) test the regulatory 
effect of magnesium ions on macrophages behavior as a therapeutic application of 
biodegradable magnesium alloys. 
Hip prostheses fail mostly due to aseptic loosening (AL) [5], a pathological bone 
resorption induced by an exacerbated immune response against prosthetic debris. In an effort 
to understand this immune response, the synovial tissues and blood collected from both 
osteoarthritis (OA) and AL patients were analyzed by histological and molecular techniques. 
Artificial hip joints constitute a good clinical model and together with laboratorial studies shed 
light on cellular mechanisms underlying prosthetic debris toxicity and immune response in 
presence of high levels of particles and ions [6; 7]. 
This study revealed that macrophages are the most prevalent immune cell type within a 
foreign body response underlying aseptic loosening. In this clinical scenario, both M1 and M2 
macrophage phenotypes were observed while in OA macrophages were in lower number and 
mostly confined to the synovial membrane. Conversely, the expression of classical immune 
mediators in synovial tissues were found similar in OA and AL patients, which was, at least in 
part, unexpected. According to the literature, the pro-inflammatory cytokines TNF-a, IL-1b and 
IL-6 have been considered the key mediators involved in aseptic loosening [8; 9]. However, 
recent publications report findings in line with our data [10], and have clarified the role of other 
molecules such as IFN-g and TLR4 in aseptic loosening [11]. Our strategy addressed 
molecules previously pointed out as targets by other authors using in vitro assays [8; 9] and 
working with animal models [12]. Although this focused approach likely missed changes in the 
levels of other molecules, which are also important in the assessed pathologies, our work 
provides a different view on the inflammatory status of synovial tissues in both OA and AL. In 
the future, the use of high-throughput technologies may provide valuable insights on biological 
events that have been poorly explored in the context of AL, namely the neuro-immune axis. 
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Additionally, the standardization of synovial tissue retrieval is challenging yet critical for the 
accuracy of the obtained results. The use of samples from OA patients allows to overcome the 
lack of access to healthy synovial tissue. However, the use of OA tissues as control is a 
limitation of the majority of studies because two different immune responses are being 
compared in a pathological context. Due to the number of factors influencing the immune 
response involved in AL, further studies must include more defined populations, by applying 
more strict inclusion criteria, namely regarding the presence of relevant comorbidities with 
impact on the immune system. Additionally, future works should focus more on the ratio 
between mediators than in their absolute level of expression. This has been evident as recently 
described in a study revealing the importance of the relative concentration of IFN-g in the 
pathophysiology of AL [11] while earlier reports did not found significant differences of IFN-g 
levels between AL and control groups [10; 13]. 
The significant changes regarding the expression of TGF-b1 in AL patients led us to 
evaluate the levels of this mediator in the bloodstream. The identification of systemic 
biomarkers of early aseptic loosening and osteolysis has been explored by many research 
groups with the objective of developing new diagnostic tools. However, there is no solid 
evidence that support the use of molecules as biomarkers for early implant failure [14]. In our 
study, both OA and AL groups showed concentrations of TGF-b1 ranging between similar 
intervals, as well as the proportions of monocytes, lymphocytes and neutrophils in circulation. 
Therefore, we believe that in humans the pathological responses occurring at the hip seem to 
be mostly confined to the joint [15]. 
The immune response against particles and ions released by implants has a central role 
in aseptic loosening. While major efforts have been done by manufacturers to reduce the 
amount of prosthetic debris produced over time, the development of therapies to modulate the 
immune response is still limited to research. The promising results obtained by the use of 
immunomodulator drugs such as methotrexate [16], IL-4 [17] and NF-kB decoy oligos [18] in 
treating particle-induced osteolysis support further development of immunomodulatory 
biomaterials to mitigate aseptic loosening. 
Unbalanced immune responses in the context of joint replacement are undesirable and 
the therapeutic alternatives to treat hip failure still lead to poor clinical outcomes [19; 20]. The 
gold standard solution in managing aseptic loosening is revision surgery, which involves the 
replacement of one component, typically the acetabular cup [21], or both faulty implants. 
However, this approach does not aim at solving the ongoing immune response to the released 
prosthetic debris [22]. Additionally, orthopedic surgeons are often challenged with the lack of 
bone tissue at the site of the implant, which impairs implant fixation [20]. Therefore, revision 
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surgeries are technically demanding and, even when bone graft materials are used, 
periprosthetic bone repair and proper implant fixation are difficult to achieve [23]. 
Inspired in these challenges faced by orthopedic surgeons, we proposed the 
development of an immunomodulatory biomaterial capable of promoting bone 
repair/regeneration. Implants made of pure fibrinogen (Fg-3D) were prepared and stabilized 
without the use of enzymes, and then implanted in a femoral critical bone defect. This 
innovative biomimetic approach aimed to establish a pro-regenerative environment by 
modulating the inflammatory response. Fg-3D presented a structure somewhat similar to the 
blood clot formed during the first days of bone healing response. Fg-3D implantation led to 
accelerated formation of granulation tissue at the injury site, visible 6 days post-implantation. 
Locally, Fg-3D did not potentiate the inflammatory response induced by bone injury but 
promoted significant changes in the proportions of key immune cell populations at systemic 
level. Bone healing with periosteal repair was observed in animals implanted with Fg-3D at 8 
weeks post-implantation. The reduction of Mac-1 receptor (CD11b/CD18)-expressing cells 
systemically lead us to speculate that those cells may be found locally, but this could not be 
confirmed either by histology or gene expression analysis. Although Fg has been classically 
perceived as a pro-inflammatory molecule [3; 24], the rearrangement of the molecule in a 3D 
structure (Fg-3D) induces molecular changes with impact upon the biological response. In 
detail, a recent study demonstrated a distinct macrophage response to fibrin and soluble Fg, 
with fibrin gels promoting an M2-like phenotype [25]. Earlier studies had also shown differential 
responses when human monocytes and dendritic cells were exposed to soluble or adsorbed 
Fg [24; 26]. Our group has been exploring different ways of presenting Fg, namely adsorbed 
to Ch substrates. We previously reported that human monocytes interact with the Fg adsorbed 
on Ch surfaces through TLR4, inducing increased expression of BMP-2 [27]. In presence of 
same substrates, macrophages increased production of pro-healing factors, such as BMP-7, 
platelet-derived growth factor, TGF-b3, IGF and VEGF [28]. 
Our study is one the first reports showing the systemic nature of the response to bone 
injury and the implantation of biomaterials. Recently, another group has promoted the repair 
of muscle tissue by modulating the host adaptive immune system after applying an 
immunomodulatory biomaterial [29]. Increasing efforts have been applied in the development 
of new biomaterials engineered for immunomodulation and tissue regeneration [30]. The Fg-
3D scaffolds presented in this Thesis offer several advantages in comparison to other materials 
already used in the clinical arena. The porous structure of Fg-3D turns cell migration and 
proliferation within the biomaterial easier than in the hydrogel-structure of fibrin sealants, which 
have been tested for tissue engineering purposes [31; 32]. Moreover, Fg-3D provides a 
biomimetic matrix to close tissue defects providing pro-regenerative signals along the healing 
response. As a biodegradable biomaterial, Fg-3D avoids foreign body response in the long 
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term and improves integration and promote tissue regeneration. Therefore, we envisage that 
Fg-3D may be used as an immunomodulatory biomaterial, as a delivery system or even as a 
coating for conventional biomaterials in order to improve their early biological response. 
Fibrinogen-based systems integrate the orthobiologic strategies, an emerging field that 
includes protein therapeutics, cell-based regenerative therapies and biomimetic matrixes. 
Although promising, orthobiologics are still in their infancy but novel products will likely emerge 
from exploring the new cellular and molecular targets, that result from the increasing 
knowledge on osteoimmunology. Furthermore, the combination of orthobiologic tools with 
conventional biomaterials might mitigate some of the drawbacks related to their soft 
mechanical properties. The fibrinogen biomimetic material presented in this Thesis constitutes 
a promising approach to modulate host biological response but its application in Orthopedics 
in limited to confined and relative small bone defects. Although the mechanical properties of 
Fg-3D may be reinforced by its combination with metals and ceramics, the application of these 
immunomodulatory biomaterials could be explored in other contexts such as soft tissue 
lesions. Moreover, Fg-3D may have a role in cancer immunotherapy due to its systemic 
reduction of Mac-1+ myeloid cells, which was previously show to improve tumor response to 
radiotherapy [33]. 
Also in the context of this Thesis, we proposed to explore the use of metal ions to 
modulate macrophage response. In this context, magnesium ions (Mg2+) may constitute an 
interesting tool due to its immunomodulatory and pro-regenerative effects. Certain doses of 
Mg2+ have been associated to regulatory effects on some immune populations [34] but the role 
of Mg2+ in macrophage polarization remained unclear. Therefore, the differentiation of human 
macrophages was assessed in presence of extracellular levels of Mg2+ up to 10 mM. Our 
findings showed that Mg2+ has an anti-inflammatory effect, particularly in presence of M1 
polarizing stimuli, such as LPS, leading to decreased cell surface expression of CD86 and 
secretion of IL-8, IL-10 and secretion of higher levels of TGF-b1. Unstimulated and IL-10-
activated macrophages did not present significant changes in Mg2+-enriched media. This study 
clarified the immunoregulatory effect of Mg2+ upon macrophages supporting its use in clinical 
scenarios of exacerbated M1 macrophages response. 
Although few reports have addressed the effect of Mg2+ on macrophages, the existing 
literature seems to corroborate, at least in part, the behavior observed by us for this immune 
cell population. Sugimoto and colleagues reported anti-inflammatory effects of 2.5 mM Mg2+ 
on primary human macrophages with decreased production of TNF-a and IL-6. These findings 
contrast with the secreted levels of TNF-a and IL-6 observed by us for M1 macrophages 
exposed to basal (0.4 mM), 2.5 mM or even 10 mM Mg2+. While we measured TNF-a and IL-
6 concentrations by ELISA, Sugimoto determined the percentage of positive cells after 
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intracellular staining for those targets and measured their expression at mRNA level 2-4 hours 
after stimulating the cells with LPS. We believe that the differences between the two 
approaches, perhaps allied to the inherent differences among individuals and populations, may 
account for the dissimilarities to the results previously reported. Moreover, in line with 
Sugimoto’s report, levels of Mg2+ between 2 and 3 mM Mg2+ reduced the placental secretion 
of IL-6 in pre-eclampsia [35]. However, other cell populations may be responding to Mg2+ 
treatment. Our major findings upon macrophage secretome were a dampening effect of Mg2+ 
on IL-8 and IL-10 secretion. A similar reduction of IL-8 was previously reported for decidual 
cells [36] while the decrease of IL-10 levels may be related to the up-regulation induced by 
LPS activation. Overall, Mg2+ has an immunomodulatory role on macrophages but further 
studies, combining laboratorial and clinical observations, are required to clarify the complete 
effects of this ion. 
Magnesium is currently used in clinical practice in different ways. In Obstetrics, 
magnesium sulfate up to 3 mM is administrated in preeclamptic women to control seizures and 
inflammation, protecting the fetus from neurological damage. Conversely, in Orthopedics 
biodegradable magnesium alloys are applied in bone fracture fixation. However, the 
application of controlled levels of Mg2+ for modulating the response of immune cells to 
biomaterials remains widely unexplored. Although fundamental studies on the influence of 
Mg2+ on various cell populations are lacking, new therapies may be envisaged taking profit 
from the immunoregulatory effects of Mg2+. In this context, this Thesis supports the use of a 
patch made from Fg, for example, to deliver controlled concentration of Mg2+ into soft tissue 
lesions or attached to orthopedic prostheses. 
The lessons learned from conventional implants highlighted the instrumental role of the 
immune system in the well-functioning of medical devices. Thus, a next generation of 
implantable medical devices should provide adequate biological signals to the host, benefiting 
from new biomaterials engineered to modulate immune responses and healing processes. In 
this sense, this Doctoral thesis clarified the macrophage-driven response underlying hip 
prosthesis failure and proposed two strategies, which can be combined for immunomodulation 
using fibrinogen and metal ions. 
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